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Abstract 
Telomeres are nucleoprotein complexes located at the end of chromosomes. 
They have an essential role in protecting chromosome ends. Telomerase or ALT 
(alternative lengthening of telomeres) mechanisms maintain telomeres by 
compensating natural telomeric loss. 
We have set up a flow-FISH method and using mouse lymphoma cell lines we 
identified unexpectedly the presence of subpopulations of cells with different telomere 
lengths. Subpopulations of cells with different telomere lengths were also observed in a 
human ALT and non-ALT cell line. Differences in telomere length between 
subpopulations of cells were significant and we term this phenomenon TELEFLUCS 
(TElomere LEngth FLUctuations in Cell Subpopulations). 
By applying flow-FISH we could successfully measure telomere lengths during 
replicative senescence in human primary fibroblasts with different genetic defects that 
confer sensitivity to ionising radiation (IR). The results from this study, based on flow- 
FISH and Southern hybridisation measurements, revealed an accelerated rate of 
telomere shortening in radiosensitive fibroblasts. We also observed accelerated 
telomere shortening in murine BRCA1 deficient cells, another defect conferring 
radiosensitivity, in comparison with a BRCA1 proficient cell line. We transiently 
depleted BRCA1 by siRNAs in two human mammary epithelial cell lines but could not 
find changes in telomere length in comparison with control cells. Cytological evidence 
of telomere dysfunction was observed in all radiosensitive cell lines. These results 
suggest that mechanisms that confer sensitivity to IR may be linked with mechanisms 
that cause telomere dysfunction. Furthermore, we have been able to show that human 
ALT positive cell lines show dysfunctional telomeres as detected by either the presence 
of DSBs at their telomeres or cytogenetic analysis and usually cells with dysfunctional 
telomeres are sensitive to IR. 
Finally, we assessed hTERT mRNA splicing variants and telomerase activity in 
brain tumours, which exhibit considerable chromosome instability suggesting that DNA 
repair mechanisms may be impaired. We demonstrated that high levels of hTERT 
mRNAs and telomerase activity correlate with proliferation rate. The presence of 
hTERT splice variants did not strictly correlate with absence of telomerase activity but 
hTERT spliced transcripts were observed in some telomerase negative brain tumours 
suggesting that hTERT splicing may contribute to activation of ALT mechanisms 
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Foreword 
Early in the nineties, when I was an instrument engineer in process automation 
for the chemical industry, I took a sabbatical year and embarked on a world trip to visit 
treasures of nature. It revived the passion that I had for biology when I was only a boy 
and so I decided to go back studying again. When I finished my master's degree in 
Zoology in 1997 at the University of Ghent, Belgium my scientific research career 
started with a detailed anatomical study of the craniomorphology of the clariid catfish 
Gymnallabes typus. A comparison of this species with their less anguilliform relatives 
revealed an evolutionary trend in the reduction of the osteocranium and a spectacular 
enlargement of the jaw muscles. This work was done in collaboration with the Institute 
of Zoology, Ghent University and the Ichthyology department of the Royal Museum for 
Central Africa, Tervuren, Belgium and I have published this in the Journal of 
Morphology (Cabuy et al., 1999). 
Shortly afterwards, I created the first three-dimensional reconstruction of an ant 
organ, the spermatheca of an Odontomachus ant queen, using Surfdriver software and 
ray-tracing rendered in Asymetrix 3D F/X at the Zoological Institute of the University of 
Leuven, Belgium. 
In April 1999,1 started working as a research fellow and teaching assistant at 
the University of Ghent, Faculty of Medicine, Belgium. My research was focused on 
telomerase and alternative splicing of hTERT mRNA in benign versus malignant brain 
tumours. I was also involved in two short-term research projects. The first one at the 
University of Bologna, Italy, where I cloned the full coding sequence of the cDNA of 
human ß1,4 N-acetylgalactosaminyl transferase from differentiated human colon 
carcinoma Caco2 cells (Cabuy et al., 2002; EMBL/GenBank/DDBJ databases locus 
AF510036), which led to a publication in the Journal of Biochemistry (Presti LL, Cabuy 
E et al., 2003). This was followed by a project at the International Agency for Research 
on Cancer (IARC), in Lyon, France where I worked on the positional cloning of genes 
responsible for heritable thyroid cancers (NMTC1 and TCO). All these different work 
experiences and the variation of the research subjects were equally important to 
acquire experience and flexibility in different research fields and have been crucial in 
allowing me to complete this thesis. However, the main part of research presented in 
this thesis started later in September 2002, when Dr. Predrag Slijepcevic gave me the 
opportunity to work on telomere maintenance at the Institute of Cancer Genetics and 
Pharmacogenomics, Brunel University. 
This thesis summarises the main results of telomeres and telomerase in cellular 
DNA damage response and in brain tumours. Research in collaboration with Dr. Patrick 
Case (Bristol Implant Research Centre, University of Bristol) and Dr. Andrew Silver 
(Colorectal Cancer Unit, St Marks Hospital, London) research group during the 
fulfilment of this thesis have been omitted in this thesis. 
The content of this thesis have not been presented for the award of a degree at 
this or any other university. The data are the original work of the author except where 
indicated. 
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Chapter 1: Introducution 
CHAPTER 1 
GENERAL INTRODUCTION 
1.1 Introduction 
Eukaryotic cells have intricate networks of mechanisms designed to protect 
chromosomal and genomic stability. These include mechanisms that sense, signal and 
repair DNA damage, mechanisms responsible for cell-cycle checkpoint control and also 
mechanisms that control apoptosis (Shiloh and Lemann, 2004). An appropriate 
collective name for these mechanisms is "DNA damage response". It is becoming 
increasingly clear that telomeres, specialized structures at chromosome ends, play a 
role in DNA damage response either directly or indirectly. Here, we will review telomere 
biology, assess the importance of telomeres in DNA damage response and discuss the 
role of telomerase in brain tumorigenesis. 
1.2 Structure and function of telomeres 
Telomeres are long repetitive nucleotide sequences at the ends of 
chromosomes. In normal human cells, the telomeres contain up to 15kb of tandem 
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repeats of aG rich hexanucleotide TTAGGG. When DNA replicates, one strand is 
replicated by leading-strand DNA synthesis and the other by lagging-strand synthesis. 
Owing to the replication properties of mammalian polymerases it has been thought in 
the past that two strands of telomeric DNA will have different terminal structures 
immediately following replication: the leading-strand telomere will be blunt-ended and 
the lagging-strand telomere will have a 3' overhang (see conventional model in Figure 
1.1. ). The size of this 3' overhang should be equivalent to the size of an RNA primer 
i. e. 8-12 base pairs (bp). The loss of these 8-12 bp, which must occur in each cell 
cycle, is also known as the end replication problem (Olovnikov, 1973). However, 
measurements of telomere length in dividing cells revealed a much greater loss, 50- 
150 bp/cell division (Harley et al., 1990). Therefore, additional mechanisms must be 
responsible for this loss and experimental evidence indicate that an exonucleolytic 
activity will modify telomeric DNA in a way that both strands of newly replicated DNA 
will have single-strand overhangs the size of which is -- 200 bp (Makarov et al., 1997; 
McElligot and Wellinger, 1997; see also revised model in Figure 1.1). 
Telomere erosion is cumulative. It is thought that this telomere shortening 
process ultimately limits the capacity of a cell to divide (Olovnikov, 1973), and acts as a 
powerful tumour suppressor mechanism. It eventually produces an altered telomere 
structure, which either activates a DNA damage response (d'Adda di Fagagna et al., 
2003; Takai et al., 2003), or leads to repair-mediated chromosome rearrangements 
causing dicentric (fused) chromosomes. Therefore, gradual telomere shortening in 
normal human somatic cells during consecutive rounds of replication eventually leads 
to critically short telomeres that induce replicative senescence in vitro and in vivo 
(Harley et al., 1990; Lindsey et al., 1991). 
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Figure 1.1 Schematic overview of the end replication problem during DNA replication 
by DNA-dependent DNA polymerases (adapted from Slijepcevic, 1998). Because an 
RNA primer (R) primes synthesis of the lagging strand, removal of the RNA primer 
leaves a gap of 8-12 bp (conventional model) (Wright et al., 1997). However, 
degradation of the 5' ends by exonuclease activity shortens the strand further 
(Wellinger et al., 1996, Makarov et al., 1997) (revised model). 
The telomeric DNA forms a loop structure, which effectively hides the end of 
chromosomal DNA from DNA damage recognition mechanisms. A G-rich overhang at 
the extreme 3'-end of each DNA strand which is approximately 200 ± 75 nucleotides 
long serves as a substrate for proteins in telomere replication and participates in the 
formation of the t- and D-loop structures (Griffith et al., 1999; Munoz-Jordan et al., 
2001). The G-rich overhang has the ability to fold backwards and bond with one of the 
two duplex telomere strands forming a t-loop and the free 3'-end inserts between the 
two strands, forming a minor D-loop (Figure 1.2). Free 3'-end may be recognised as 
DNA strand breaks that can activate the checkpoints of the DNA repair apparatus, 
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which probably could initiate the process of cellular senescence and apoptosis. Thus, 
the loop structures sequester the free 3'-ends, preventing DNA damage and activation 
of repair signals and therefore provide stability to the chromosome. This structure 
critically depends on a telomere binding protein TRF2, but is maintained by many other 
proteins (see section 1.3). This structure is also thought to be dynamic, as several 
proteins need to access the extreme terminus of linear DNA (Bryan et al., 1997). 
NucleosomE 
TIN2 
Figure 1.2 Model for mammalian telomere structure (adapted from Kanoh and 
Ishikawa, 2003; Niedle and Parkinson, 2003). Human telomeres consist of up to 15 kbp 
of double-stranded DNA, which at the extreme end bends backward to form a loop 
structure (t-loop). The G-strand overhang invades part of its upstream sequence to 
form a D-loop. Most of the telomere is packaged into nucleosomes, but at the extreme 
end a few 100 bp of telomeric DNA is associated with TRF1 and TRF2. TRF1 forms 
complexes with two other telomeric proteins, TIN2 and Tankyrase. TRF2 recruits 
RAP1. In addition to the Ku proteins shown here, the MRE1 1 -RAD50-NBS1 complex 
that are involved in double-stranded DNA repair is also localised at telomeres (Rhodes 
et al., 2002). The single stranded G-rich overhang binds POT1. 
The primary role of telomeres is to protect chromosome ends from aberrant 
chromosomal recombination, end-to-end fusions, and DNA degradation (Blackburn, 
1991). They protect chromosome ends from accidental chromosome breakage that 
would otherwise trigger DNA damage response mechanisms and promote cell-cycle 
arrest and DNA repair. In addition to the physical protection of chromosome ends, 
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eukaryotic telomeres have important roles in cellular processes including chromatin 
organisation and control of cell proliferation (Hackett et al., 2001). 
1.3 Telomere binding proteins 
An important aspect of telomere structure and function is the interaction of the 
repeat sequences with specific binding proteins and associated factors, which are 
essential for both the regulation of telomere length and the capping function of 
telomeres. These specific binding proteins form a putative cap structure that protects 
the chromosome end from degradation or from unintended DNA repair. Many proteins 
are associated with eukaryotic telomeric DNA (Muniyappa and Kironmai, 1998; Kanoh 
and Ishikawa, 2003). In mammals, at least 3 different factors (TRF1, TRF2 [Telomere 
Repeat Factor] and POT1 [Protection of Telomere]) have been shown to interact 
directly with the telomeric DNA sequences (Liu et al., 2004) (Figure 1.2). TRF2 is 
involved in the t-loop establishment (Griffith et al., 1999) whereas TRF1 is involved in 
the control of telomere length homeostasis (van Steensel and de Lange, 1997). Four 
additional telomere-associated proteins (TIN2 [TRF1-Interacting Nuclear protein 2], 
RAP1 [Repressor Activator Protein 1], TANK1 and TANK2 [TANKyrase]) are also 
localised at telomeres but through their binding with above mentioned three proteins 
(Ye and de Lange, 2004). Other proteins, involved in DNA repair including the MRE11- 
RAD50-NBS1 (MRN) complex or the DNA-dependent protein kinase complex 
composed of Ku (DNA end binding subunit) and DNA-PKcs (catalytic subunit) are also 
present at telomeres (Song et al., 2000; Wu et al., 2000; Zhu et al., 2000; reviewed in 
Bailey and Goodwin, 2004). Some of these proteins have effects on telomere length, 
the structure of G-rich overhangs and can affect other cell phenotypes. Other genes 
involved in telomere maintenance include genes encoding telomerase associated 
proteins (hTERT and hTERC) and other DNA repair proteins RAD54, RAD51 D, 
ERCC1/XPF (for recent reviews see Chan and Blackburn, 2002; Wei et al., 2002; 
Blasco & Hahn. 2003; Slijepcevic, 2004). 
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Expression of truncated forms of TRF1 and its interacting factor TIN2 induce 
inappropriate telomere elongation in telomerase-positive cells (van Steensel and de 
Lange, 1997; Kim et al., 1999; Smogorzewska et al., 2000). Inhibition of TRF2 in 
cultured cells results in "deprotection" of chromosome ends and covalently fused 
telomeres (van Steensel et al., 1998). Additionally, loss of TRF2 function can lead to 
growth arrest and ATM/p53 mediated apoptosis (van Steensel et al., 1998; Karlseder et 
al., 1999). Both TRF1 and TRF2 are characterised as negative regulators of telomere 
length i. e. overexpression of either results in gradual length decline (van Steensel and 
de Lange, 1997; Smogorzewska et al., 2000). Telomere binding proteins are therefore 
critical regulators of telomere length and essential components of the protective 
structures that are formed at the chromosome ends. 
1.4 Telomere maintenance by telomerase 
In most organisms complete replication of telomeres is accomplished by 
telomerase, a specialised reverse transcriptase that was first isolated from the ciliate 
Tetrahymena (Greider and Blackburn, 1985). Telomerase, or telomere terminal 
transferase, is a ribonucleoprotein that adds telomeric repeats onto chromosomal ends 
by using the RNA template complementary to the (TTAGGG)n repeats (Blackburn, 
1991; Feng et al., 1995). Its occurrence is widely conserved in eukaryotes, as revealed 
by phylogenetic comparison. For many years it was assumed since the first report on 
telomerase activity in cancer (Kim et al., 1994) that normal human somatic cells lack 
telomerase activity. However, a recent study suggested that normal human somatic 
cells such as fibroblasts may show low telomerase activity as revealed by 
immunological detection of telomerase catalytic component in these cells (Masutomi et 
al., 2003; see also Chapter 6). In contrast, high telomerase activity has been detected 
in most human cancers (Kim and Wu, 1997; Meeker and Coffey, 1997; reviewed in 
Dhaene et al., 2000), suggesting a role for telomerase in providing a proliferative 
capacity to cells, which is a requirement for progression towards malignancy. 
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Telomerase is also detected in stem cells, during embryonic development (Ulaner and 
Guidice, 1997; Ulaner et al., 1998), and in adult germ-line tissues (Wright et al., 1996). 
It has been hypothesized that cell senescence can be overcome by upregulation of 
telomerase (Blackburn, 1991; Feng et al., 1995; Kim and Wu, 1997). Experiments by 
Bodnar et al. (1998) confirmed that this is the case. 
The length of telomeres and G-rich overhangs and the levels of the telomerase 
subunits are indirect indicators of the enzyme function that can be assessed in various 
samples. Telomeres are thought to control the expression of subtelomeric genes, a 
phenomenon known as telomere position effect (Baur et al., 2001), and therefore 
paradoxically this might affect the expression of telomerase itself, which is located at 
the extreme end of chromosome 5p in humans (Meyerson 'et al., 1997; Kilian et al., 
1997). Most studies have implicated telomerase in the maintenance of stable telomere 
length although telomere length can, in some cases, be maintained in the absence of 
telomerase by mechanisms referred to as alternative lengthening of telomeres (ALT), 
which is discussed in section 1.5. 
1.4.1 Telomerase components 
Telomerase is a large complex, with an estimated molecular mass of over 1000 
kDa (Schnapp et al., 1998). In vitro, 2 components are absolutely essential for the 
telomerase activity: hTERT (hTERCT, hEST) the human reverse transcriptase (Kilian 
et al., 1997, Nakayama et al., 1998) and hTERC (TER, hTR), the RNA template (Feng 
et al., 1995; Weinrich et al., 1997). However, telomerase has been found to have 
several additional components, including two heat shock proteins (HSP90 and HSP23) 
and the telomerase-associated protein hTEP1 that assists in the function of telomerase 
(Harrington et al., 1997). HSP90 functions as an activator of telomerase catalytic 
activity, but the precise function of hTEP1 is unclear. While hTEP1 is not required for 
telomerase activity, it is thought to function as a structure component, contributing to 
the stability of the telomerase protein-RNA complex (Kickhoefer et al., 2001). In normal 
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cells hTERC is constitutively expressed but hTERT was found to be absent or low in 
many studies (Meyerson et al., 1997; Kanaya et al., 1998; Ramakrishnan et al., 1998; 
Kyo et al., 1999; Takakura et al., 1998 Dhaene et al., 2000). However, a recent study 
suggests that a good-quality antibody can detect hTERT in human primary fibroblasts 
(Masutomi et al., 2003). In most tumours over-expression of hTERT is accompanied by 
an increase in telomerase activity. hTERC and hTERT are indispensable for 
telomerase activity, and expression of these subunits in vitro leads to the formation of a 
functional telomerase enzyme (Counter et al., 1992; Weinrich et al., 1997; Nakayama 
et al., 1998). 
1.4.1.1 hTERC (human TElomerase RNA Component) 
hTERC, the RNA component of the telomerase complex, acts as the template 
for telomere elongation. In in vitro reconstitution experiments, hTERC RNA was one of 
the 2 components essential in obtaining telomerase activity (Weinrich et al., 1997). The 
hTERC gene was cloned and was located on human chromosome 3q26.3 (Feng et al., 
1995). This single-copy gene does not contain any introns. 
Expression of hTERC RNA, as analysed by RT-PCR, showed that this 
component is widely expressed in both tumour and non-tumour tissues (Feng et al., 
1995; Yi et al., 2001). Thus, it was concluded that hTERC was not essential for 
telomerase reactivation. However, using in situ hybridisation, other investigators 
observed that hTERC expression is up-regulated in tumour tissues (Heine et al., 1998; 
Soder et al., 1998). A weak expression in some normal renal parenchymal cells, gastric 
mucosa epithelial cells, smooth muscle cells, Schwann cells of peripheral nerves and 
activated lymphocytes was occasionally detected (Heine et al., 1998; Paradis et al., 
1999; Hiyama et al., 1999). However, RT-PCR for hTERC is error prone, as the 
absence of introns make it impossible to distinguish the cDNA-based PCR product 
from the genomic DNA-based product. It is therefore necessary to perform a DNase I 
digestion of RNA preparations to overcome this problem. Using this technique, hTERC 
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expression was found to be correlated with telomerase activity in colorectal cancer 
(Yan et al., 2001), indicating that this gene might play a role during the process of 
telomerase reactivation. 
In humans, the mature hTERC transcript is 451 nucleotides long and lacks a 
polyA tail. The RNA contains a template region of 11 nucleotides 5'-CUAACCCUAAC- 
3' located in the 5' extremity. Although hTERC RNA sequences are phylogenetically 
divergent, their secondary structures have been found to be similar from ciliates to 
vertebrates (Chen et al., 2000). Recent studies reported the presence of a classical 
small nucleolar RNA (snoRNA) structure called H/ACA box (Mitchell et al., 1999). This 
motif consists of a hairpin-hinge-hairpin-ACA-tail. The H/ACA structure is essential for 
accumulation of hTERC RNA in vivo (Mitchell and Collins, 2000). Several proteins, 
including dyskerin or snoRNP recognise this sequence and may be involved in the 
RNA stability. This role can be provided by a heterologous H/ACA domain when 
substituting hTERC H/ACA domain (Mitchell et al., 1999). Moreover, the H/ACA motif is 
also crucial for telomerase activity in vivo, a role which can not be replaced by a 
heterologous domain. Furthermore, 2 other elements in the H/ACA 5' neighbour hairpin 
(HS1 also called CR4-CR5) are also required for the hTERT-hTERC interaction in vivo 
(Mitchell and Collins., 2000; Bachand et al., 2001; Chen et al., 2002). Finally, a 
pseudoknot has been also found to play a role in hTERC RNA stability (Gilley and 
Blackburn, 1999). 
1.4.1.2 hTERT (human TElomerase Reverse Transcriptase) 
hTERT is the catalytic subunit of telomerase and harbours the reverse 
transcriptase activity. Presence of this subunit was first suggested in 1989 in crude 
nuclear HeLa fractions in which the activity of the human telomerase was identified 
(Morin, 1989). Using sequences derived from Saccharomyces cerevisiae and Euplotes 
aediculatus catalytic subunits, the corresponding human cDNA was isolated in 1997 
(Kilian et al., 1997; Meyerson et al., 1997). However, the genomic sequence and the 
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gene organisation were only characterised in 1999 by several groups (Cong et al., 
1999; Horikawa et al., 1999; Takakura et al., 1999; Wick et al., 1999). The single-copy 
hTERT gene is composed of 16 exons and 15 introns spanning more than 40 kb. Using 
fluorescence in situ hybridisation (FISH), the hTERT gene was localised on human 
chromosome 5p15.33, very close to the telomere (Meyerson et al., 1997; Bryce et al., 
2000). The hTERT gene encodes a 127 kDa protein of 1132 amino acids (Meyerson et 
al., 1997). This protein is almost exclusively localised in the nucleus (Harrington et al., 
1997). hTERT protein presents a telomerase-specific motif (T), followed by 7 
conserved RT (Reverse Transcriptase) motifs (1 and 2, A-E) , 
forming a finger-palm- 
thumb structure (Lingner et al., 1997; Nakamura et al., 1997). 
Phylogenetic studies showed that the reverse transcriptase subunit is very well 
conserved from protozoa to humans, including plants. The RT motifs are also shared 
by viruses and retroelements, indicating that the use of telomerase to maintain 
telomere length might be ancient (Nakamura and Cech, 1998). RT motifs are very 
important for the reverse transcriptase activity as mutations in amino acids in these 
motifs prevented telomerase activity (Harrington et al., 1997; Weinrich et al., 1997; 
Nakayama et al., 1998). Through these motifs, hTERT protein recognises the RNA 
template and reversibly transcribes the telomeric motif, which leads to telomere 
elongation. In the basic mechanism, the telomerase complex is located at the 3' 
extremity of the leading strand. hTERC is correctly positioned through its sequences 
adjacent to the template region. Elongation is then performed by the catalytic subunit 
hTERT, until the end of the template region. Following this step, the complex is 
translocated and repositioned on the newly synthesised DNA, in order to continue 
telomere elongation. Finally, the lagging strand is replicated by DNA polymerases. The 
region containing the RT motifs has also been shown to bind hTP1 protein, 
independent of the hTERC binding (Beattie et al., 2000). 
Telomerase adds telomeric repeats on to the ends of chromosomes, thus 
maintaining their length despite continued cell division. It is postulated that, at crisis, 
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critical telomere shortening results in end-to-end fusions and chromosome breakage- 
fusion cycles that cause marked chromosomal abnormalities and apoptosis (Londono- 
Vallejo, 2004). Expression of telomerase would avoid this catastrophic series of events. 
This model is supported by the demonstration that forced expression of telomerase 
allows maintenance of telomere length and increases the replicative lifespan of some 
cell types without a crisis period (Zhu et al., 1999). However, events additional to 
forced hTERT expression might be required to gain full telomerase activity and cell 
immortalisation. Nevertheless, telomerase expression might be a critical step in the 
immortalisation process during oncogenesis. In telomerase-null yeast, increased 
mutation rates and genomic instability were observed, suggesting that telomerase can 
prevent chromosomal instability (Hackett et al., 2001). Lack of telomerase in mouse 
leads to chromosomal instability (Blasco et al., 1997). 
1.4.2 Regulation of telomerase activity 
The current picture of telomerase regulation is complex. Enzyme activity is likely 
to be controlled at several levels, with multiple pathways converging to modulate the 
functional activity of the holoenzyme. Although the story is far from complete, several 
regulatory pathways have already been implicated in the normal and aberrant activity 
of telomerase in human cells. Extensive evidence from expression studies suggests 
that hTERC and hTERT are regulated on a transcriptional level and that this regulation 
is a major deterministic factor governing the activation of telomerase activity in normal 
and cancer cells. Although much remains to be clarified, cloning of the promoter 
regions for the genes encoding hTERC and hTERT has enabled the identification of 
several positive and negative regulators of telomerase transcription (Ducrest et al., 
2002). 
Telomerase activity can be reconstituted in vitro from its two essential subunits, 
hTERC and hTERT, although the enzyme exists in its active form at the telomere as a 
highly ordered multi-subunit complex. The structure of the holoenzyme therefore 
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represents another level at which telomerase activity is likely to be regulated. Some of 
the constituent proteins that contribute to the complex have intrinsic regulatory 
functions, such as the poly (ADP-ribose)polymerase (PARP) domain of tankyrase, a 
protein identified as interacting with the telomeric-repeat-binding factor TRF1 at the 
telomere. PARP activity is a major mechanism for post-translational regulation of 
nuclear proteins involved in a variety of cellular functions such as the DNA damage 
response. It is now clear that these other post-translational signalling events acting 
directly on hTERT or on other proteins involved in the complex play a role in regulation 
of telomerase activity. The phosphorylation status of hTERT is also involved in 
modulation of the catalytic activity of telomerase: both protein phosphatase 2A and the 
c-Abl tyrosine kinase act as negative regulators of telomerase function, whereas 
protein kinase C (PKC) and the Akt protein kinase upregulate activity. Previous studies 
have shown that c-Myc stimulates hTERT transcription through the binding sites 
located on the hTERT promoter (Zhou and Liu, 2003; Wang and Zhu, 2004). Recently, 
evidence has been provided that the BRCA1 protein binds to the c-Myc protein, turns 
off the transcription of hTERT, and prevents incidental cellular immortalisation (Li et al., 
2002; Xiong et al., 2003; Zhou and Liu, 2003). 
Transcription of eukaryotic genes produces mRNA precursors, which must be 
processed by RNA splicing, precisely removing the introns and joining together the 
exons, before the spliced mRNA is exported to the cytoplasm for translation. Splicing of 
mRNA precursors is carried out by complex particles called spliceosomes, which are 
assembled from several small nuclear ribonucleoprotein components (snoRNPs) and 
contain about 100 different proteins. These post-transcriptional mechanisms could play 
a role in regulating telomerase activity. Kilian et al. (1997) identified several splice 
variants of the hTERT transcript that are expected to be inactive due to truncations or 
mutations in domains essential for catalytic activity. The hTERT alternative splicing 
transcripts include a deletion variant lacking conserved residues from the catalytic core 
component of the protein (Kilian et al., 1997). This hTERT splice variant, termed 
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hTERT a, has been identified as a dominant negative inhibitor of telomerase activity 
(Colgin et al., 2000; Yi et al., 2000). It is expressed in normal and developing tissues 
(Ulaner et al., 1997) and it appears conceivable that it may be expressed in some ALT 
cell lines or tumour tissues. Repetitive hTERT a- inhibits telomerase activities in 
telomerase-positive cells, which results in telomere shortening and chromosome end- 
to-end fusions (Colgin et al., 2000). These results suggest a possible role for hTERT 
splice variants in the regulation of telomerase activity. The function of the remaining 
splice variants of hTERT is still unclear; it is generally accepted that these cannot play 
a role in the activation of telomerase, since they lack key reverse transcriptase or C- 
terminal sequences as a result of open reading frame shifts and premature stop 
codons (Wick et al., 1999). It might be of much interest to examine more precisely the 
role that alternative splicing might play in the regulation of telomerase activity, 
particularly in ALT cell lines. 
1.5 Alternative lengthening of telomeres 
Several distinct strategies for telomere length maintenance have evolved in 
eukaryotes. As we have seen, telomeres can be elongated independently of the rest of 
the genome by telomerase. Although telomerase appears responsible for telomere 
maintenance in most cases, telomerase activity is not detected by the standard TRAP 
(telomeric repeat amplification protocol) assay in - 5-10% of human cancers (Kim et 
al., 1994) and the mechanism by which these cells acquire telomere elongation is not 
fully understood. Therefore, telomerase cannot be the only mechanism of telomere 
maintenance. 
Drosophila melanogaster and related dipterans employ retrotransposons in 
telomere maintenance instead of telomerase (Mason and Biessmann, 1995). 
Homologous recombination (see section 1.6.2) is used for telomere elongation in the 
mosquito Anopheles gambiae (Roth et al., 1997). In the case of telomerase-defective 
yeast, rare survivors are able to elongate their telomeres via recombination events that 
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are dependent on the DNA double-strand break repair gene RAD52 (Lundblad and 
Blackburn, 1993; Teng and Zakian, 1999). Similarly, homologous recombination was 
proposed in humans as a mechanism to elongate telomeres by the formation of 
intertelomeric, T-loop (to allow the 3' extremity to copy itself), and rolling circle and 
integration of extrachromosomal telomeric repeats (Yeager et al., 1999; Reddel et al., 
2001; Henson et al., 2002; Tomaska et al., 2004). Homologous recombination is also a 
leading candidate mechanism for telomere lengthening (Henson et al., 2002) known as 
ALT (Bryan et al., 1995; 1997). 
Telomere morphology and function in ALT cells appear to differ significantly 
from cells with telomerase activity (Ford et al., 2001; Perrem et al., 2001; Scheel et al., 
2001). The existence of ALT has been deduced from the observation of heterogeneous 
and elongated telomeres in the absence of detectable telomerase (Murane et al., 
1994). ALT tumours and some in vitro immortalised cell lines have telomeres that are 
highly heterogeneous in length, ranging from 3 kb to 50 kb (Bryan et al., 1997; 
Grobelny et al., 2000), a range notably higher than the maximum length in non- 
neoplastic somatic tissues (-10-15 kb in humans). Analysis using Q-FISH revealed 
strong telomeric signals in some chromosomes and its complete absence in other 
chromosomes (Ford et al., 2001; Lansdorp et al., 1997; Perrem et al., 2001; Scheel et 
al., 2001). The occurrence of elongated and shortened telomeres and signal-free 
chromosome ends could give rise to chromosomal end-to-end associations and 
breakage-fusion-bridge cycles, resulting in an increased number of complex non- 
reciprocal chromosomal rearrangements (McClintock, 1941). 
Another potential useful morphological marker of ALT is ALT-associated PML 
(promyelocytic leukaemia) bodies (APBs) (Yeager et al., 1999). APBs are unique 
because of their association with telomeric DNA in ALT cells as revealed by 
fluorescence in situ hybridisation (FISH) or the immunological detection of TRF1 and 
TRF2. APBs contain PML, MRE1 1, NBS1, RAD50, and BLM that normally exist in PML 
bodies. In promyelocytic leukaemia, the PML protein forms a fusion protein with retinoic 
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acid receptor a (RAR(x) due to a chromosome 15; 17 translocation, which disrupts PML 
bodies (de The et al., 1991). In addition, APBs contain the telomere-associating protein 
RAP1 and the recombination proteins RAD51, RAD52, and BRCA1, which are not 
normally present in PML bodies (Yeager et al., 1999; Naka et al., 2002; Wu et al., 
2000; 2003). Nabetani et al. (2004) reported that hRAD9, hHUS1, hRAD1, and 
hRAD17 are also constitutive components of APBs. Furthermore, 5-bromo- 
2'deoxyuridine (BrdU) incorporation was detected at the NBS1 foci in a small fraction of 
growing ALT cells, suggesting that DNA is synthesised at APBs (Wu et al., 2000). 
These nuclear bodies probably function in the process of telomere lengthening through 
recombination, because they appear at exactly the same time as the activation of the 
ALT mechanism during cell immortalisation, and because these nuclear bodies include 
RPA, RAD51, and RAD52 (Yeager et al., 1999). APB bodies can be found in 5% of 
interphase nuclei and it would therefore appear feasible to detect them by 
immunohistochemistry. Evidence of APBs is provided by co-localisation of PML with 
either TRF1 and/or TRF2 (Yeager et al., 1999). 
ALT has been found in a subset of in vitro immortalised and tumour-derived cell 
lines as well as in spontaneous human tumours (Reddel et al., 2001). The types of 
tumours and tumour cell lines in which ALT has been observed include, ovarian 
epithelium (Grobelny et al., 2000), osteosarcoma (Scheel et al., 2001), glioblastoma 
(Hakin-Smith et al., 2003), and renal cell carcinoma (Mehle et al., 1996). Although it 
was not mentioned by the authors, ALT was probably also present in one case of 
malignant meningiomas (case 30) showing no telomerase activity and telomere length 
greater than 25kbp (Chen et al., 2000). Genetic changes known to promote ALT 
activation include transformation of cells with SV-40 or human papillomavirus (HPV) 
oncogenes and spontaneous loss of the tumour suppressors p53 and p16INK4a (Bryan 
et al., 1995). 
Notably, not all tumours without telomerase activity have ALT-like telomeres 
(Bryan et al.. 1997). Perhaps some of these findings reflect tumours that presented 
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clinically before immortalisation. Therefore, not all of the approximately 10% 
telomerase-negative tumours display the telomere morphology characteristic of ALT. 
However, the possibility that there are other mechanisms independent of telomerase 
and that do not exhibit the ALT pattern of telomere morphology cannot be excluded. 
Some telomerase-positive tumours were shown to have elongated and heterogeneous 
telomeres, which could indicate a coexistence of ALT and telomerase activity (Bryan et 
al., 1997; Reddel et al., 2001). Coexistence of ALT and telomerase has been described 
in three recent studies (Cerone et al., 2001; Grobelny et al., 2001; Perrem et al., 2001). 
So far, no extensive surveys for ALT in human tumours have been carried out, but a 
variety of malignant human tumours may exhibit ALT (Bryan et at., 1997; Mehle et al., 
1996; Scheel et al., 2001). Cell lines with ALT phenotype are being used in an ongoing 
study of which the first results are described in Chapter 6. 
1.6 Telomeres and DNA damage response 
The evidence is accumulating that telomeres may be involved in DNA damage 
response. For example, mice lacking functional telomerase, the enzyme that 
synthesizes telomeric DNA, are radiosensitive (Wong et al., 2000, Goytisolo et al., 
2000). In addition, ataxia telangiectasia patients, characterized by altered DNA damage 
response, show altered telomere maintenance (Metcalfe et al., 1996). Similarly, several 
genetically deficient strains of mice including Ku , PARP' and scid 
(severe combined 
immunodeficiency) mice show defective DNA damage response and altered telomere 
maintenance (Hande et al., 1999; d'Adda di Faggagna et al.; 1999, Samper et al., 
2000). Also yeast and Caenorhabditis elegans mutants with altered telomeres have 
defective DNA damage responses (Boulton and Jackson 1996, Ahmed and Hodgkin 
2000). Taken together these results argue that telomere maintenance is a part of the 
DNA damage response machinery. This possibility is strengthened by recent studies 
showing an inverse correlation between chromosomal radiosensitivity and telomere 
length in a group of 29 breast cancer patients (Mcllrath et al., 2001) or a larger group of 
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different cancer patients (Wu et al., 2003). In this section we will review the role of 
telomeres in DNA damage response, especially how the cell's response to DNA 
breakage is linked with telomere maintenance. 
1.6.1 Telomeres and repair of DNA double strand breaks (DSBs) 
DNA double strand breaks (DSBs) are the most lethal form of DNA damage. 
They occur in response to ionising radiation (IR), to chemotherapeutic or radiomimetic 
agents (e. g. bleomycin, mitomycin C, cisplatinum, methylmethanesulfonate), as well as 
to endogenous free radicals, the by-products of oxidative metabolism. DSBs also arise 
as a consequence of natural processes, such as V(D)J recombination (a lymphoid 
specific process required for gene rearrangement and maturation of T and B cells), and 
as a consequence of normal cellular metabolism. If not repaired prior to DNA 
replication or mitosis, DSBs can induce cell death. If misrepaired, DSBs have the 
potential to lead to chromosome translocations, genomic instability and cancer 
predisposition. The mechanisms responding to DSBs include pathways of DNA repair, 
cell cycle checkpoint arrest and apoptosis (Jeggo and Concannon, 2001). Cell cycle 
checkpoint controls may serve to prevent cells from initiating critical steps, such as 
DNA replication and mitosis in the presence of DSBs. There are two major pathways 
for the repair of DSBs in mammalian cells, namely homologous recombination (HR) 
and non-homologous end joining (NHEJ). Telomere maintenance is linked with both 
pathways as indicated by telomere dysfunction and changes in telomere length 
regulation in the absence of proteins involved in HR and NHEJ (see below). 
1.6.2 Homologous recombination (HR) 
HR repairs a DSB in one DNA molecule by using a second, homologous 
molecule as a template for DNA synthesis and repair, thereby enabling coding 
information lost at the site of the break to be retrieved (Figure 1.3). HR, therefore, has 
the potential to be a highly accurate and efficient pathway for repairing DSBs. HR is 
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important during and following DNA replication, when a sister chromatid is present as a 
template for repair. 
In the early steps of HR processing (Figure 1.3), the MRE11-RAD50-NBS1 
(MRN) heterotrimeric complex will initially process the DSB. The MRN complex, which 
has exonuclease and endonuclease functions, acts to produce and expose single 
stranded tailed DNA (Rattray and Symington, 1995). 
PROTEINS 
DSB formation 
MAIN STEPS 
--------ý 
XRCC3 Ligation and Holliday 
junction resolution 
E 
Figure 1.3 Schematic representation of homologous recombination repair of DNA 
double-strand break adapted from Thacker (2004). (A) DSB recognition and the ends 
are nucleolytically processed by the MRN complex. (B) 3' Single-stranded tails are 
formed by resection of break ends and are coated with RAD51. (C) Displacement of 
single-stranded binding protein RPA (replication protein A) with the assistance of 
RAD52 and RAD51 like proteins. A 3' end molecule (grey) invades an unbroken (black) 
molecule, displacing a strand (D-loop) that acts as a repair template. (D) RAD54 has 
both pre- and post-invasion roles to facilitate the opening up of DNA. (E) The cross 
stranded structures are ; esolved by XRCC3 and a RAD51 like heterodimer. 
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This complex is also involved in non-homologous end joining (NHEJ) (see next section) 
(Petrini, 1999). In the next step of HR processing RAD51 with the aid of BRCA2 and 
RAD54 will bind the exposed single stranded DNA and invade the broken DNA into the 
adjacent sister chromatid to search for homologous sequences (Yang et al., 2002). 
This invasion displaces the non-complementary intact strand, forming a D-loop, which 
enlarges as new DNA synthesis progresses across the break site. Once the adjacent 
DNA strands are paired at the homologous sequence, DNA polymerases will enter to 
fill the damaged gap, and the resulting Holliday junctions will be resolved to complete 
the process (Thompson and Schild, 2002; Symington, 2002). BRCA1 has been shown 
to co-localise with RAD51 in response to IR (Scully et al., 1997) and might also be 
involved in the HR pathway. 
In higher eukaryotes, HR does not appear to play a major role in the repair of 
radiation induced DSBs since mammalian mutants defective in HR display at most, 
only mild radiosensitivity. However, such mutants do show genomic instability and 
marked sensitivity to DNA cross-linking agents. These and additional findings have 
lead to the commonly held view that in higher organisms, HR uses only a sister 
chromatid as a template for repair, and therefore functions primarily in late S/G2 phase 
to repair DSBs arising at the replication fork (Takata et al., 1998; Johnson and Jasin, 
2001). The sensitivity of HR defective mammalian cell lines to DNA cross-linking 
agents is therefore probably due to the generation of DSBs at the replication fork 
following attempts to replicate past DNA cross-links. 
1.6.3 Non-homologous end joining (NHEJ) 
The potentially more significant pathway for repair of radiation-induced DSBs in 
mammalian cells is DNA non-homologous end-joining (NHEJ) (for a review see Lieber 
et al., 2004). This type of end-joining does not require homologies between the two 
recombining molecules and is distinct from the well-characterised homologous 
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recombination pathway (Figure 1.4). NHEJ is active throughout the cell cycle, including 
late S and G2 of the cell cycle (Takata et al., 1998). 
Five core proteins have been identified that function in NHEJ in higher 
organisms (Pasta and Blasiak, 2003). Three of these constitute a complex termed DNA 
dependent protein kinase (DNA-PK), namely the two subunits of the heterodimeric Ku 
protein (Ku70 and Ku80) and a large catalytic subunit, termed DNA-dependent protein 
kinase subunit (DNA-PKcs). 
PROTEINS MAIN STEPS 
A 
MRN complex DNA break 
BRCA1? 
B 
Ku70/80 END BINDING by Ku 
DNA-PKcs 
4, 
SYNAPSIS by DNA-PKcs 
C 
Artemis: DNA-PKcs 
I 
0 
1 
END PROCESSING: removal of 5' 
and trimming of long 3' overhangs 
END PROCESSING: template- 
dependent fill-in synthesis 
E 
XRCC4 
DNA Ligase IV LIGATION 
F 
Figure 1.4 The steps and proteins in the non-homologous end-joining pathway 
(adapted from Lieber et al., 2004). (A) When a double-stranded DNA break occurs, 
MRE11 processes the DNA ends by 3'-5' endonucleolytic activity enhanced by the 
presence of RAD50 and NBS1. Next, Ku binds to the DNA ends. (B) The second step 
is the recruitment of the nuclease DNA PKcs, which holds the ends in proximity to 
permit subsequent repair to proceed and to align the two ends. (C) This step can be 
referred to as synapsis. (D) For complex DNA ends, as would be generated by ionising 
radiation, there is often need for nucleolytic processing. If so, Artemis: DNA-PKcs are 
likely to carry out processing. (E) The next step is to fill in the gaps by polymerases. (F) 
Ligation is the final step and is done by the XRCC4: DNA ligase IV complex. 
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Ku has strong affinity for double stranded DNA ends, and when DNA bound, Ku 
recruits and activates DNA-PKcs. The remaining two proteins, XRCC4 and DNA ligase 
IV are required for the subsequent rejoining step. They co-associate strongly but are 
not associated with DNA-PK in undamaged cells (Lees-Miller and Meek, 2003). They 
are also defective in their ability to undergo V(D)J recombination demonstrating that 
NHEJ also functions during this process. 
In eukaryotic cells, some fraction of the DNA-PKcs population of molecules is 
bound to the Artemis protein in a very stable complex (Ma et al., 2002). Ku is 
presumably also able to recruit this Artemis: DNA-PKcs complex (Lieber et al., 2004). 
Once bound to a DNA end, DNA-PKcs phosphorylates itself and Artemis (Ma et al., 
2002). One of these two phosphorylation targets permits the Artemis: DNA-PKcs 
complex to function as an endonuclease, allowing it to cleave both 5' and 3' overhangs 
of any length. 
Several studies provide evidence for the involvement of BRCA1 in NHEJ 
(Zhong et al., 2002; Baldeyron et al., 2002). However, the precise biochemical function 
of BRCA1 in NHEJ is unknown. This function is likely mediated through its interaction 
with RAD50 of the MRN complex (Zhong et al., 1999). BRCA1 may also act like DNA- 
PKcs to bridge adjacent DNA molecules (Paull et al., 2001). It also inhibits the 
nucleolytic processing ability of the MRN complex (Paull et al., 2001), suggesting that 
BRCA1 regulates the function of the MRN complex to prevent extensive DNA end 
processing. 
1.7 DSB repair and telomere maintenance 
As shown in section 1.6.2 RAD54 is a RAD51-interacting DNA-dependent 
ATPase involved in homologous DNA pairing (Mazin et al., 2003). By using RAD54- 
defective mice Jaco et al. (2003) provided evidence for the role of this gene product in 
telomere length maintenance and telomere capping. RAD54 deficiency in mice resulted 
in a significant loss of telomeric sequences, suggesting that RAD54 is important for 
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telomere length maintenance in mice (Jaco et al., 2003). This result suggests that HR 
participates in telomere length maintenance or that RAD54 has a role in telomere 
protection. An increase in end-to-end fusions in RAD54 deficient cells is consistent with 
a role for this protein in telomere capping (Jaco et al., 2003). Tarsounas et al. (2004) 
reported that RAD51d, a paralog of RAD51 and a key component in HR (Baumann et 
al., 1996), is also involved in telomere maintenance. Using telomerase positive 
RAD51 d"- TRF'- primary mouse embryonic fibroblasts (MEFs) they demonstrated 
telomere shortening and elevated levels of end-to-end chromosome fusions, a 
signature of telomere dysfunction, compared with wild type MEFs. 
Proteins involved in DNA DSB repair by NHEJ include Ku70, Ku80 and DNA- 
PKcs (Pasta and Blasiak, 2003) as shown in section 1.6.3. Knockout mutations in any 
of these three genes in mice cause spontaneous end-to-end fusions of chromosomes, 
an indication of impaired telomere capping function (Bailey et al., 1999; Goytisolo et al., 
2001). It was also demonstrated that inactivation of Ku in mice causes either telomere 
elongation (Samper et al., 2000) or telomere shortening in primary MEFs (d'Adda di 
Fagagna et al., 2001). Furthermore, inactivation of one allele of the gene encoding 
Ku80 in human cells resulted in telomere shortening (Myung et al., 2004). However, 
inactivation of DNA-PKcs in mice did not cause any effect on telomere length but it did 
affect telomere capping function (Goytisolo et al., 2001). In scid mice, which are natural 
DNA-PKcs mutants, telomeres are abnormally elongated and also lack the capping 
function (Hande et al., 1999). The use of a DNA-PKcs kinase inhibitor induced 
chromosomal end-to-end fusions demonstrating that the telomere end-protection role 
of DNA-PK requires its kinase activity (Bailey et al., 2004). These results establish that 
Ku and DNA-PK, including its kinase activity, play a critical role in telomere capping in 
mammalian cells. 
Taken together, above results suggest that DSB repair proteins are required to 
prevent end-to-end chromosome fusions. In addition, telomere fusions resulting from 
inhibition of TRF2 are generated by DNA ligase IV-mediated NHEJ (Smogorzewska et 
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al., 2002) suggesting further that DSB repair proteins actively participate in 
chromosome stability maintenance through their interplay with telomeres. In line with 
these observations, it has been speculated that dysfunctional telomeres will behave as 
DNA DSBs. The experimental evidence for this possibility was recently obtained in two 
independent studies (d'Adda di Fagagna et al., 2003; Takai et al., 2003). It is clear from 
these studies that telomere dysfunction generated either by cell-senescence 
associated telomere shortening (Bakkenist et al., 2004) or TRF2 defect (Takai et al., 
2003) cause DNA damage response that resemble the cell response to external agents 
that cause DSBs. For example, a protein that specifically detects the sites of DSBs, -y- 
H2AX, co-localises with dysfunctional telomeres (Takai et al., 2003; Bakkenist et al., 
2004) thus formally proving that indeed dysfunctional telomeres are interpreted by the 
cell DNA damage response machinery as DSBs. 
There is another line of evidence supporting the view that DSB repair 
mechanisms and processing of DSBs, particularly through NHEJ, are inextricably 
linked. One way for cells to respond to telomere dysfunction is through end-to-end 
chromosome fusions i. e. these fusions will eliminate DSBs. Chromosome fusion 
junctions from cells with dysfunctional telomeres have been isolated from S. cerevisiae 
(Hackett et al., 2001) and mice (Hemann et al., 2001). The structures of these fusion 
junctions are strikingly similar, suggesting the possibility of a common mechanism for 
their formation in yeast and mammals. Fusion junctions from both organisms contain 0- 
10 bp of microhomology, characteristic of a non-homologous end-joining mechanism. 
These fusions involve the loss of all telomeric and some subtelomeric sequences. The 
loss of sequence suggests that the mechanism of fusion might be an error-prone DNA 
repair pathway i. e. NHEJ. 
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1.8 Telomere maintenance in disorders that are associated with defective DNA 
damage responses 
Chromosome aberrations, genomic instability and cancer predisposition are the 
hallmarks of a number of syndromes in which the defective genes play an important 
role in recognising, signalling and/or repairing DNA damage, DNA processing, cell 
cycle regulation, apoptosis and/or telomeric maintenance (Klapper et al., 2001; 
Surralles et al., 2004). Defects in any of these genes can lead to cancer predisposition 
and to a number of clinical defects. These syndromes share various features at the 
clinical and cellular level that can be explained in most cases by interactions and 
molecular links among them, creating a network of pathways involved in DNA damage 
response. 
Some of the telomere binding proteins are very important for their dual function 
as they also participate in different DNA damage response pathways that altogether 
cross-talk in a complex network of tumour suppressor pathways (Surralles et al., 2004). 
A deficiency in any of these proteins leads to serious disorders of genetic instability 
ultimately leading to cancer predisposition. Syndromes with DNA damage response 
defects that also affect telomere maintenance are briefly discussed below. Primary 
fibroblast cell lines originating from patients with DNA damage response syndromes 
were used in this study (see Chapter 4). 
1.8.1 The role of ATM in telomere maintenance 
Ataxia-telangiectasia (AT) is a rare, autosomal-recessive inherited disorder 
characterised by neurological deterioration, immunodeficiency, spontaneous 
chromosomal instability, hypersensitivity to IR, predisposition to cancer, particularly T 
cell leukaemia and lymphoma, and premature ageing (Metcalfe et al., 1996). The gene 
responsible for AT is ATM (ataxia-telangiectasia mutated). ATM activates a number of 
pathways, which involve either DNA repair or cell cycle checkpoint control (Kastan and 
Lim, 2000). The fact that ATM is associated with phosphorylated H2AX foci (7-H2AX) is 
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consistent with a major role for ATM in the early detection of DSBs and subsequent 
induction of cellular responses (Fernandez-Capetillo et al., 2004). 
Shorter telomeres and higher frequency of chromosome end fusions were found 
in patients suffering from AT (Pandita et al., 1995; 1996). This was confirmed by 
Metcalfe et al. (1996) and Hande et al. (2001). In addition, it has also been reported 
that the ATM protein interacts with TRF1, one of the telomere binding proteins (Kishi et 
al., 2001). However, there is still no evidence that ATM is directly involved in telomere 
maintenance. The defective telomere metabolism in AT cells is most likely the result of 
mechanisms that indirectly affect telomere maintenance. This has been illustrated by 
mild chronic oxidative stress induced by hydrogen peroxide, which increased the rate 
of telomere shortening in AT cells (Tchirkov and Lansdorp, 2003). ATM deficient mice 
show high incidence of extra-chromosomal telomeric fragments (Hande et al., 2001). 
1.8.2 The role of FA genes in telomere maintenance 
Fanconi anemia (FA) also belongs to a group of chromosome instability 
diseases. FA is an autosomal recessive disease of childhood characterised by 
progressive bone marrow failure that often evolves towards acute leukaemia. FA can 
be caused by mutations in at least eight different genes (Tischkowitz and Hodgson, 
2003; Seal et al., 2003). These FA genes correspond to subtypes FA-A, B, C, D1, D2, 
E, FA, and G (reviewed in Joenje and Patel, 2001). Data strongly suggest that the gene 
causing FA-D1 is BRCA2 (Seal et al., 2003). Interaction pathways have been 
established, both between the FA proteins and other proteins involved in DNA damage 
repair, such as ATM, BRCA1 and BRCA2, thereby providing a link with other disorders 
in which defective DNA damage repair is a feature (Tischkowitz and Hodgson, 2003). 
Accelerated telomere shortening in peripheral blood mononuclear cells was 
found in FA patients (Ball et al., 1998; Leteurtre et al., 1999; Hanson et al., 2001; 
Callen et al., 2002). Adelfalk et al. (2001) demonstrated that telomeric DNA is 
continuously lost at a higher rate in FA fibroblasts compared to healthy controls. 
25 
Chapter 1: Introducution 
Accelerated shortening of telomeres could be explained by a hematopoietic stem cell 
undergoing a higher than normal number of cell divisions to generate mature end cells, 
but a recent study has shown that, in addition to replicative shortening, there is also a 
higher rate of breakage at telomeric sequences in FA cells, suggesting a defect in 
telomere maintenance (Callen et al., 2002). The molecular mechanisms leading to 
telomere shortening in FA cells, however, are still unknown. Consistent with telomere 
breakage as an alternative mechanism of telomere shortening, recent investigations 
have shown accumulation of breaks at telomeres after oxidative stress in human 
fibroblasts in vitro (Oikawa and Kawanishi, 1999; von Zglinicki et al., 2000; von 
Zglinicki, 2002) and DNA repair at telomeres is defective (Lansdorp, 2000). It is known 
that FA cells are highly impaired in their response to oxidative stress (Joenje and Patel, 
2001). 
1.8.3 The role of NBS1 in telomere maintenance 
Nijmegen breakage syndrome (NBS) is a rare human disease displaying 
chromosome instability, radiosensitivity, cancer predisposition, immunodeficiency, and 
other defects (Weemaes et al., 1981; van der Burgt et al., 1996; lijima et al., 2004). 
Cells established from patients are defective in their responses to DSBs induced by IR, 
thus showing an increased frequency of chromosomal aberrations (Weemaes et al., 
1994). NBS is caused by a mutation or a defectiveness in the NBS1 gene and the 
majority of the patients are homozygous for the same mutation in exon 6 of the NBS1 
gene, resulting in premature truncation of the protein (Varon et al., 1998). The gene 
that is affected in these patients, NBS1, encodes a protein called nibrin or p95 (Girard 
et al., 2000). Nibrin is a key regulator of the MRE1 1 and RAD50 protein complex, the 
so called MRN complex, involved in the repair and processing of double-strand breaks 
(DSBs) (Carney et al., 1998; Petrini, 1999; lijima et al., 2004). NBS1 is also localised to 
telomere ends in association with the telomere-binding proteins TRF1 and TRF2 (Zhu 
et al., 2000; Wu et al., 2000). Ranganathan et al. (2001) have shown that blood cells 
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from NBS patients have shorter telomeres in comparison to normal individuals. 
Likewise, they observed shortened telomeres in cultured NBS fibroblasts that exhibit a 
premature growth cessation. Ranganathan et al. (2001) suggested that NBS1 might 
contribute to telomere elongation by showing that co-expression of intact NBS1 and 
hTERT in two NBS fibroblast strains resulted in increased telomere lengths compared 
with the parental populations. However, Siwicki et al. (2003) provided evidence that 
telomere length maintenance is possible in the absence of a full-length NBS1 protein in 
human T lymphocytes with high telomerase activity. 
NBS1 is also included in the APBs (Wu et al., 2000; Naka et al., 2002). In ALT 
cells, clear NBS1 foci can be observed in the nucleus from G, -G2-phase, and they co- 
localise with the PML bodies (lijima et al., 2004). However, the PML bodies co-localise 
with telomeres only during G2-phase, suggesting that the APBs might be formed only 
when they act during telomere maintenance. The NBS1 complex, localises at ALT- 
independent PML nuclear bodies and could be a reservoir of repair-related proteins, 
which then translocate to a damaged DNA site in response to DSBs (Iijima et al., 
2004). Thus, these nuclear bodies could not only be involved in telomere maintenance 
when they are located on telomeres, but function also in response to DNA damage. 
1.9 Telomerase activity in benign versus malignant brain tumours 
A large body of evidence accumulated over the last 15 years clearly implicates 
telomeres and telomerase in carcinogenesis. One of our interests is how telomerase is 
regulated in malignant brain tumours in comparison with their benign counterparts. 
Brain tumours are diverse in terms of their malignancy and can originate in all different 
places of the brain determining their phenotypic and genotypic outcome. Brain tumours 
exhibit considerable chromosome instability (EI-Zein et al., 1999; Hui et al. 2001; 
Sawyer et al., 2003), suggesting that DNA repair mechanisms are impaired or that 
genetic susceptibility may lead to defects in DNA damage response pathways. In this 
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section the meningiomas as generally benign and the glioblastomas as highly 
malignant tumours of the brain are briefly discussed. 
Meningiomas are generally slow growing tumours attached to the dura mater 
and composed of neoplastic meningothelial cells. These tumours arise from arachnoid 
cells that form the middle layer of the meninges, the arachnoid mater (Whittle et al., 
2004) (Figure 1.5). 
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Figure 1.5 Meningiomas. Schematic overview of meninges and arachnoid granulations 
(A) (drawing adapted from Clinical Anatomy for Medical Students, Lippincott William 
and Wilkins, 7th Edition); Detail from a histological slide showing a cross section of an 
archnoid granulation (1) and arachnoid cap cells (2) (meninges provided by Prof. Dr. 
Katharina D'Herde, University Ghent) (B); Sagittal image of a MR acquisition showing a 
meningioma attached to the dura mater (case 25, Table 2.3) (C). 
Microscopically, meningiomas have a varied but characteristic histopathologic 
appearance, the diversity of which forms the basis for the pathologic classification of 
meningiomas (for a review see Whittle et al., 2004). Most meningiomas are benign in 
nature. In atypical meningiomas, certain features that may be seen by light microscopy 
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show an increased tumour aggressiveness and increased likelihood for recurrence. 
Loss of architectural pattern, high cellularity, increased mitotic figures, necrosis. 
prominent nucleoli, and nuclear pleomorphism are identified as histologic parameters. 
In general, cellular proliferation increases from benign to atypical to anaplastic 
(malignant) meningioma. Meningiomas are known to be induced by even a low dose of 
IR (Kleinschmidt and Lillehei, 1995). Radiation-induced meningiomas are more 
commonly atypical or aggressive, and multifocal, show higher proliferation indices 
(Musa et al., 1995). Flow cytometric studies have demonstrated approximately equal 
numbers of diploid and aneuploid cells in meningioma tumours, and have shown 
significant correlations between aneuploid tumours and features such as recurrence, 
pleomorphism, high cellular density, mitotic activity and infiltration of brain and soft 
tissue (Cruz et al., 1993). Previous studies of meningiomas showed contradicting 
results with regards to telomerase activity (Carroll et al., 1999; DeMasters et al., 1997; 
Falchetti et al., 1999, Hiraga et al., 1998, Sano et al., 1998; Langford et al., 1997; 
Simon et al., 2000; Boldrini et al., 2003; Pistolesi et al., 2004). In general a correlation 
exists between telomerase activity and tumour grading, since enzymatic activity is 
detectable in anaplastic/malignant meningiomas (Falchetti et al., 2002; Boldrini et al., 
2003; Leuraud et al., 2004; Pistolesi et al., 2004). However, telomerase was also 
detected in benign meningiomas (Langford et al., 1997; Simon et al., 2000; Falchetti et 
al., 2002). 
Glioblastoma multiforme (GBM) is the most common malignant tumour of 
neuroepithelial origin in the human brain. This neoplasm is highly proliferative. 
Glioblastoma is composed of poorly differentiated neoplastic astrocytes. 
Histopathological features include cellular polymorphism, nuclear atypia, brisk mitotic 
activity, vascular thrombosis, microvascular proliferation and necrosis. They have an 
abnormal DNA content determined by flow cytometry, which could reflect aneuploidy 
(Ehemann et al., 1999). Gene amplification occurs frequently in glioblastomas (Fischer 
'I et al., 2002). They may develop from diffuse astrocytomas WHO grade II (World Health 
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Organisation classification; Kleihues and Cavenee, 2000) or anaplastic astrocytomas, 
but more frequently, they manifest after a short clinical history de novo, without 
evidence of a less malignant precursor lesion. In malignant gliomas, telomerase activity 
is very often detected (Langford et al., 1997; DeMasters et al., 1997; Sallinen et al., 
1997; Sano et al., 1998; Falchefti et al., 1999; Kleinschmidt-DeMasters et al., 2000; 
Harada et al., 2000). In malignant gliomas, telomerase is positive in 10 to 100% of 
anaplastic astrocytomas and in 26 to 100% of glioblastoma. Although the ratio of 
telomerase-positive cells in gliomas varies, most of the reports show that the incidence 
of telomerase expression is closely correlated with malignancy. By contrast, neither 
normal brain tissues (DeMasters et al., 1997; Huang et al., 1999; Harada et al., 2000; 
Cabuy and de Ridder, 2001), nor the meninges (Cabuy and de Ridder, 2001) express 
telomerase activity. 
1.10 The aim and outline of the PhD project 
The first task of the PhD project was to set-up a flow-FISH technique for 
telomere length measurement in our laboratory and verify its accuracy on a new 
Beckman coulter EPICS XL cytometer. This is a relatively new, accurate and fast 
technique with a good potential for further improvements towards a multicolour FISH 
(Baerlocher and Lansdorp, 2003). During these studies we discovered the 
phenomenon we termed TELEFLUCS (TElomere LEngth FLUctuations in Cell 
Subpopulations) and demonstrated the importance of flow-FISH in telomere analysis 
(Chapter 3). 
The next aim was to assess whether flow-FISH could be used to measure 
telomere length in radiosensitive fibroblast cell lines (Chapter 4). So far, flow-FISH was 
used almost exclusively in cells of hematopoietic origin (Scheding et al., 2003; Van 
Ziffle et al., 2003; Rigolin et al., 2004). Given a potential link between telomere 
maintenance and radiosensitivity (Slijepcevic, 2004) and the role of telomeres in DSB 
repair (Mills et al., 1999; Martin et al., 1999) we hypothesized that telomere shortening 
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may be a consequence of radiosensitivity (Mcllrath et al., 2001). Since the cellular 
capacity to respond to IR is proportional to their ability to repair DSBs we investigated 
telomere maintenance in mouse cell lines deficient in DSB repair. This part of the 
project is relevant for elucidating the genetic basis of radiosensitivity. 
Since many genes involved in DNA damage response also affect telomere 
maintenance we wanted to test whether the BRCA1 (breast cancer 1, early onset) 
gene may participate, directly or indirectly, in telomere maintenance (Chapter 5). This 
hypothesis stems from two recent studies implicating BRCA1 in telomerase regulation 
(Xiong et al., 2003) and in ALT cell telomere maintenance (Wu et al., 2003). To 
investigate this we used small interfering RNA (siRNA) oligonucleotides in two 
mammary epithelial cell lines and assessed DNA damage indicators, chromosome 
abnormalities and telomere lengths up to 11 days post-transfection. We also analysed 
telomere maintenance and interactions of BRCA 1 with some other DNA damage 
response factors (y-H2AX) in a panel of 4 human ALT cell lines. 
Finally, we evaluated hTERT mRNA expression and telomerase activity in 
benign versus malignant brain tumours (Chapter 6). Brain tumours exhibit considerable 
chromosome instability (EI-Zein et al., 1999; Sawyer et at., 2003), suggesting that also 
DNA repair mechanisms might be impaired in brain tumours and telomere dysfunction. 
This part of the project was focused on the relationship between alternative splicing of 
hTERT mRNA, telomerase activity and cell proliferation in brain tumours. 
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CHAPTER 2 
MATERIALS AND METHODS 
2.1 Cell lines and tissue culture conditions 
2.1.1 Human cell lines 
2.1.1.1 Human primary fibroblast cell lines 
Primary fibroblast cell lines (Table 2.1) derived from 9 patients with defects in 
various DNA damage response pathways were provided by Dr. P. A. Jeggo, University 
of Sussex, Brighton. Normal fibroblasts were purchased from the Coriell Cell 
Repository, Camden, USA. Human fibroblast cell lines were cultured in Dulbecco's 
Modified Eagle Medium (D-MEM) supplemented with 100 U/mL of penicillin and 0.1 
mg/mL of streptomycin, 2 mM L-glutamine, 0.1 mM non essential amino acids and 15% 
foetal bovine serum (FBS) at 37°C under 5% CO2 (all reagents were from Gibco, 
Invitrogen, NY, USA). Cells were subcultured 1: 3 by gentle trypsinisation and medium 
was changed twice a week until cells failed to double within two weeks. 
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2.1.1.2 Human lymphoblastoid cell lines 
Normal human lymphoblastoid cell lines and lymphoblastoid cell lines derived 
from carriers of BRCA1+L and BRCA7 mutations (Table 2.2) were purchased from the 
Coriell Cell Repository, Camden, USA. The cells were grown as a suspension culture 
in RPMI 1640 medium containing 10% FBS, 100 U/mL of penicillin and 0.1 mg/mL of 
streptomycin. Lymphoblastoid cells were subcultured depending on the cell culture 
density. 
MOLT-4 cells (T lymphoblast) were purchased from American Type Culture 
Collection (ATCC) Cat. No. CRL-1582 (Rockville, MD). The MOLT-4 cell line was 
grown in RPMI 1640 medium supplemented with 10% FBS, 2 mM L-glutamine, 1.5 g/L 
sodium bicarbonate, and 10 mM HEPES at 37 °C in a humidified atmosphere of 5% 
C02 and 95% air at cell densities between 5x 104 and 2x 106/mL. Cultures were 
maintained by addition or replacement of fresh medium. Viable cells were counted by 
0.2% trypan blue exclusion method with a Neubauer hemocytometer. 
Macrophages from blood samples (kindly donated by Prof. Dr. Ann Vral, Ghent 
University, Belgium) were used as negative controls in immunocytochemistry hTERT 
assays. 
2.1.1.3 Human epithelial cell lines 
Human Hela cells (cervix epithelial adenocarcinoma) were purchased from 
ATCC (Cat. No. CCL-2, Rockville, MD) and grown in Eagle Minimum Essential Medium 
(EMEM) with 2mM L-glutamine, 1.5 g/L sodium bicarbonate, 0.1 mM non-essential 
amino acids, and 1.0 mM sodium pyruvate, and 10 % FBS in a humidified atmosphere 
of 5% CO2 at 37°C. 
The breast epithelial cell line MCF10A was obtained from the ATCC (Cat. No. 
CRL-10317, Rockville, MD). These cells are not tumorigenic in immunosuppressed 
mice, but form colonies in semisolid medium. MCF10A human breast epithelial cells 
were cultured in mammary epithelial basal medium (MEBM) supplemented with 0.4% 
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bovine pituitary extract, 0.5 µg/mL hydrocortisone, 5 µg/mL insulin, 20 ng/mL EGF 
(Cambrex Co, NJ, USA). Antibiotics and cholera toxin were omitted. Cells were 
incubated at 37 °C with 5% CO2 and passaged if they reach no more than 80% 
confluence. Routine trypsinisation of cells was achieved by aspirating the medium and 
rinsing the cell monolayer with 30mM Hepes Buffered Saline Solution (HBSS) and 
addingl mL of Trypsin-EDTA (0.025% - 0.01 %) to 25cm2 culture flasks. The flasks 
were kept at 37 °C until the cells had dispersed (-15 min) and the cells centrifuged at 
900 xg for 4 minutes. Trypsin was neutralized by the addition of 1 mL of Trypsin 
Neutralising Solution (TNS) (all products from Clonetics, Cambrex, Wakersville, USA). 
The resulting cell pellet was resuspended in the appropriate volume of complete 
medium and seeded in a tissue culture flask. Cells were cryopreserved in culture 
medium containing 7.5% DMSO. 
The breast adenocarcinoma cell line MCF7 obtained from the European 
Collection of Cell Cultures (ECACC, Cat No. 86012803) was grown in EMEM (Sigma- 
Aldrich) supplemented with 2mM Glutamine, 1% non-essential amino acids, 10% FBS 
and 5 pg/mL insulin. Cells were cryopreserved in 90% FBS and 10% DMSO. 
The breast cancer cell line HCC1937, which has a truncated, non-functional 
BRCA1 and which has defective IR-induced S-phase and G2-M checkpoints, was 
cultured in RPMI 1640 (Gibco/BRL) supplemented with 15% FBS at 37°C in a 
humidified atmosphere containing 5% CO2. This cell line is heterozygous for the 
BRCA1 5382C mutation, whereas the primary tumour cell line is homozygous for the 
same mutation. The cell line was a gift from Dr M. Zdzienicka, University of Leiden. 
Primary human mammary epithelial cell line (HMEC) Bre-80 (kindly donated by 
Prof. Rob Newbold) was used in control experiments. The cells were maintained in 
MEBM, supplemented with 10 ug/mL EGF in a buffered bovine serum albumin (BSA) 
solution, 5 pg/mL bovine insulin, 0.5 pg/mL hydrocortisone, and 5% bovine pituitary 
extract. Cells were incubated at 37 °C with 5% CO2. Cells were passed prior to 
confluence using 0.05% trypsin/EDTA solution (Life Technologies). 
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The breast cancer line 21 NT pBabe hTERT was used as a positive control for 
BRCA1 and hTERT in RT-PCR experiments. The cells were cultured in MEM alfa 
medium supplemented with 10 % FBS, 0.5 µg/ml- hydrocortisone, 1 µg/ml- insulin, and 
12.5 ng/mL EGF (Cambrex Co, NJ, USA). Cells were passaged prior to confluence 
using 0.05% trypsin/EDTA solution (Life Technologies). 
The prostate adenocarcinoma cell line PC-3 (ATCC, Cat. No. CRL-1435) was 
cultured in Ham's F12K medium with 2 mM L-glutamine adjusted to contain 1.5 g/L 
sodium bicarbonate and 10% FBS in an atmosphere with 5% CO2. Proteins from this 
cell line were used to set up a calibration curve for the real-time PCR TRAP assay. 
2.1.1.4 Human ALT cell lines 
The lung fibroblast cell line WI-38 (ECACC, Cat. No. 90020107) and WI-38 
VA13/2RA (ECACC, Cat. No. 85062512), derived from the SV40-transformed WI-38, 
and the lung adenocarcinoma SK-LU-1 cell line (ECACC, Cat. No. 93120835) were 
grown in EMEM (Sigma-Aldrich) supplemented with 2mM Glutamine, 1% non-essential 
amino acids, and 10% FBS. The derivative WI-38 VA13/2RA+hTERT was obtained 
from Dr. Silvia Baccetti, McMaster University, Canada and grown in the same culture 
conditions. 
The human osteosarcoma cell line U2-OS (ECACC, Cat. No. 92022711) and G- 
292 (ECACC Cat. No. 90110522) were grown in McCoy's 5a culture medium 
supplemented with 1.5mM Glutamine and 10% FBS. 
All cells were cryopreserved in 90% FBS and 10% DMSO. 
2.1.2 Mouse cell lines 
2.1.2.1 Mouse embryonic stem cells 
Mouse embryonic stem (ES) cells (wild type and mutant BRCA 1- - obtained from 
B. Koller, University of North Carolina at Chapel Hill) were propagated and maintained 
as described previously (Snouwaert et al., 1999). Undifferentiated ES cells were 
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cultured at 37°C in an atmosphere with 5% C02, on gelatine-coated dishes in 
KnockOut D-MEM medium supplemented with 20% KnockOut serum replacement, 2 
mM L-glutamine, 0.001% ß-mercaptoethanol (Sigma-Aldrich, MO, USA), 1000 U/mL 
ESGRO (Chemicon, CA, USA), 10 U/mL penicillin, and 10 pg/mL streptomycin (all 
purchased, except were stated, from Gibco, Invitrogen, NY, USA). Medium was 
changed every 3 days and cells subcultured initially at the ratio 1: 2 and the ratio 
progressively increased up to 1: 8. 
2.1.2.2 Mouse lymphoma cells 
Mouse lymphoma LY-R (radio-resistant) and LY-S (radio-sensitive) cells were 
grown in suspension under standard tissue culture conditions using RPMI 1640 
medium and 10% FBS supplemented with 100 U/mL of penicillin and 0.1 mg/mL of 
streptomycin. Cells were subcultured at the ratio 1: 10 every 2-3 days. Mouse 
lymphoma LY-R and LY-S cells were used as a reference to extrapolate the telomere 
fluorescence values from fibroblasts into kb. LY-R and LY-S showed previously to have 
telomere lengths of 48 and 7kb, respectively (Mcllrath et al., 2001). 
2.1.2.3 Irradiation of mouse lymphoma cells 
Mouse lymphoma cells were grown to about 60% confluence in RPMI before 
irradiation. LY-R/S cells were irradiated with 2.0 and 5.0 Gy of y rays using a 60Co 
source with a dose rate of 0.25 Gy/min. After irradiation the cells were immediately 
transferred to an incubator to recover for 2h before harvesting for flow-FISH analysis. 
2.1.3 Brain tumour samples and handling 
2.1.3.1 Brain tumour biopsies 
Multiple tissue samples, when possible from different locations in brain tumours, 
were collected by the author during open brain surgery of 32 patients. Table 2.3 shows 
the clinical data and histopathological diagnosis. The group consisted of 21 female 
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patients and 11 male patients, with ages ranging from 1.5 to 88 years. All cases under 
study came from total surgical removal of tumours from between 2000-2001. No 
chemotherapy or radiotherapy was administered before surgery. Prior therapeutic 
embolisation, which can cause extensive necrosis, was carried out on the tumours of 
two patients (case no. 25 and 28). Informed consent was obtained for the use of brain 
tissue and for access to medical records for research purposes. 
Table 2.3 Clinical data and histopathological diagnosis of 32 brain tumours. 
a All samples were frozen immediately except for *, which were frozen 2-4 h after 
tumour resection; b oedematous brain tissue present in samples from *; M: male; F: 
female. 
Case No. a Age Sex Diagnosis b Recurrence 
1 72 F meningothelial meningioma 
2 28 F meningothelial meningioma 
3* 88 F transitional meningioma 
4 75 F transitional meningioma 
5 62 F angiomatous meningioma 
6 64 F meningiothelial meningioma 
7 44 F meningiothelial meningioma 
8 74 M meningiothelial meningioma 
9 34 M acoustic schwannoma 
10 37 F pituitary adenoma 
11 3 F medulloblastoma 
12 33 F astrocytoma 2nd 
13 52 F glioblastoma multiforme 
14* 1.5 M ependymoma 
15* 41 F glioblastoma multiforme* 
16* 30 F astrocytoma* 
17 69 M atypical meningioma 
18 77 M meningothelial meningioma 
19 70 F meningiothelial meningioma 
20 73 F meningiothelial meningioma 
21 56 F meningiothelial meningioma 
22 69 F meningiothelial meningioma 
23* 9 F medulloblastoma* 2nd 
24 58 M glioblastoma multiforme 
25 70 M transitional meningioma 
26 64 F fibrous meningioma 
27 80 F atypical meningiomas 3th 
28 46 F transitional meningioma 
29* 64 M glioblastoma multiforme 
30 46 M psammomatous meningioma 
31 40 M transitional meningioma 
32 75 M glioblastoma multiforme 
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The tumours were classified according to WHO criteria (Kleiheus and Cavenee, 2000) 
by neuropathologists at the University Hospital and the St Lucas Hospital (Ghent, 
Belgium). The tumours comprised 20 meningiomas, 18 of which were benign and two 
atypical, one acoustic schwannoma, one pituitary adenoma, eight gliomas, and two 
medulloblastomas. All biopsies were divided into approximately 125 mm3 pieces and a 
total of 121 samples were immediately frozen and stored separately in liquid nitrogen 
under RNase-free conditions. This procedure was carried within half an hour after 
surgery, except for six samples (case no. 3,14-16,23 and 29), which were frozen in 
liquid nitrogen 2-4 hours after surgery. Dura mater and arachnoid tissue could also be 
obtained from case 2 for in vitro cell culture. The histological identity of multiple 
formalin fixed specimens of each tumour was checked by microscopy of serial sections 
stained with hematoxylin-eosin and Masson trichrome. 
2.1.3.2 Brain tumour derived cell cultures 
Twenty-one primary cell cultures derived from collected brain tumour tissues 
were grown in Hanks modification of Eagles medium (HMEM) supplemented with 10% 
FBS and 50 µg/mL streptomycin, 50 U/mL penicillin and Fungizone. Subconfluent cells 
grown on 13 mm diameter Thermanox coverslips (Nunc) in medium were washed with 
PBS and then fixed with 4°C acetone for 3 min. 
The human glioblastoma cell line U251 was established from a glioblastoma 
multiforme tumour and grown in DMEM supplemented with 10% FBS and 4mM 
glutamine, 50 U/mL penicillin, and 50 pg/mL streptomycin. This cell line was used as a 
positive control in experimental TRAP assay and RT-PCR. 
2.1.4 Mycoplasma 
All cell lines were tested negative for Mycoplasma contamination as detected by 
PCR ELISA (Roche Diagnostics, Mannheim, Germany) (see section 2.14). 
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2.1.5 Calculation of population doublings 
When recording the phase of a cell population, age should be expressed as a 
population doubling, rather than passage number. The term "passage" is often used to 
indicate the age of cell cultures. However, it indicates only the number of trypsinisation 
steps performed during the culture period. It is therefore inadequate for describing the 
age of a culture because trypsinisation can be performed at different split ratios. 
Since one population doubling (PD) means doubling the number of cells as a 
group, the relationship between PD and dilution factor is defined as follows: 
2n = dilution factor (where n= PD) 
If the logarithm of both sides is taken and rearranged: 
log 2n = log(dilution factor) 
n (PD) = Iog(dilution factor)/log 2= Iog(dilution factor)/0.301 
This formula was used when for each passage number the dilution factor was known. 
Otherwise the cell PDs were calculated using the following formula: 
PD = (Log N, /Log2) - (LogNo/Log2) 
where No is the cell number at the beginning and N, is the cell number at the end of the 
cell culture period. In order to determine the concentration of the cells, a Neubauer 
haemocytometer was used. 
2.2 Reverse transcription-PCR (RT-PCR) 
2.2.1 RT-PCR analysis of BRCA1 and hTERT 
2.2.1.1 RNA isolation and reverse transcription 
Total cell RNA was extracted from monolayers using NucleoSpin RNA 11 
(Macherey-Nagel GmbH & Co., Düren, Germany), according to the manufacturer's 
instructions. Briefly, cells were lysed by incubation in a solution containing large 
amounts of chaotropic ions. This lysis buffer immediately inactivates RNases and 
adsorbs RNA to a silica membrane. Contaminating DNA, which is also bound to the 
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silica membrane, is removed by a DNase I solution. Simple washing steps with two 
different buffers remove salts, metabolites and macromolecular cellular components. 
Pure RNA is finally eluted under low ionic strength conditions with RNase-free water. 
The RNA concentration was determined by A260 using an Eppendorf BioPhotometer. 
Aliquots of 1 µg RNA were reverse transcribed using M-MLV reverse transcriptase 
(Promega) at 10,000 units/mL. Aliquots of cDNA corresponding to 0.5 ug of original 
RNA were used for PCR amplification. RNA integrity was initially checked on a 1% 
agarose gel by judging the presence of the 18S and 28S ribosomal RNA bands (Figure 
2.1). 
1234 
28s rRNA Vow 40ko 
18s rRNA 
56 
Figure 2.1 Extracted RNA quality control of brain tumours and mammary epithelial 
cells. Lane 1: meningioma; Lane 2: glioblastoma; Lane 3: medulloblastoma; Lane 4: 
astrocytoma; Lane 5: MCF10A and Lane 6: MCF7 
2.2.1.2 PCR 
The cDNA samples were amplified in a 20 µL reaction mixture containing buffer 
(10mM Tris-HCI, 50mM KCI, and 0.1 % Triton), 200 µM dNTP's, 1U of Taq polymerase, 
and 0.2 µM of primers. 
The 285bp segment amplified from BRCA1 is located from positions 5239 to 
5524 in the published cDNA sequence (GenBank accession number U15595, 
submitted by Mike et al., 1994). DNA was first denatured for 1.5 min at 94°C, then 
amplified using cycles of 1 min at 94°C, 45 sec at 50°C and 1 min at 72°C, with a final 
7 min incubation at 72°C. 
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Primers for hTERT were used to amplify a region including the specific T-motif 
of hTERT to generate a 145 bp fragment. DNA was first denatured for 1.5 min at 94°C, 
then amplified using cycles of 30 sec at 94°C, 35 sec at 58°C and 30 sec at 72°C, with 
a final 7 min incubation at 72°C. 
ß-actin was amplified as a control, resulting in a 764bp product located from 
positions 265-1028. The cycle number was adjusted so that all reactions fell within the 
linear range of product amplification. 
The sense and antisense PCR primer pairs (5' to 3' direction) and expected 
product sizes are listed in Table 2.4. PCR products were analysed by electrophoresis 
through 1.5% agarose gels containing 0.1 mg/mL ethidium bromide and gels were 
photographed under UV light. The mRNA expression levels were quantified by 
densitometry of the cDNA bands and expressed relative to the control gene (ß-actin) by 
using the ImageQuant Software 5.2 (Amersham Biosciences, USA). 
2.2.2 RT-PCR analysis of telomerase transcripts in brain tumours 
2.2.2.1 RNA isolation and reverse transcription 
Total RNA was obtained from 72 frozen brain tumour samples using Tri-reagent 
(Sigma-Aldrich), in accordance with the manufacturer's protocol. During dissection care 
was taken (macroscopically) to avoid areas with necrosis and excessive blood 
infiltration. Brain tissues were homogenised in 200-500 pl Tri-reagent in microtubes 
and matching disposable pestles. This product, a mixture of guanidine thiocyanate and 
phenol in a mono-phase solution, effectively dissolves DNA, RNA, and protein on 
homogenisation or lysis of tissue samples. After adding chloroform and centrifuging, 
the mixture separates into 3 phases: an aqueous phase containing the RNA, the 
interphase containing DNA and an organic phase containing the proteins. The RNA in 
the supernatant was precipitated with isopropanol, washed with 75% ethanol, allowed 
to air dry for 30 min, and dissolved in double distilled water at 4°C. The RNA 
concentration was determined by A260 using an Eppendorf BioPhotometer. RNA 
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integrity was initially checked on a1% agarose gel by judging the presence of the 18S 
and 28S ribosomal RNA bands (Figure 2.1). 
First-strand synthesis (reverse transcription, RT) was carried out from total RNA in a 
volume of 20 µL at 37°C for 1h with MMLV-reverse transcriptase using random 
hexamers, followed by inactivation of the MMLV enzyme by incubation at 95°C for 5 
min (all reagents from Promega). The RNA yield ranged between 0.4 and 1.2pg/pl and 
approximately 1 pg RNA was processed for RT. 
2.2.2.2 PCR 
The cDNA samples were amplified in a 20 µL reaction mixture containing buffer 
(10mM Tris-HCI, 50mM KCI, and 0.1% Triton), 50 µM dNTP's, 1U of Taq polymerase, 
and 0.2 µM of primers. We used a nested PCR approach with primers according to the 
cDNA sequences as reported by Kilian et al. (1997) and Ulaner and colleagues (Ulaner 
et al., 1998; 2000) (see also Figure 6.1; Table 2.4). 
Table 2.4 Overview of primer sequences used in this study. 
Gene Forward Primer Reverse Primer Product 
size (bp) 
BRCA 1 
BRCA 1 
BRCA 1 
TERT 
TERT 
TERT 
TERT 
TERC 
TS/PS 
3-actin 
O-actin 
5'-GATTTGACGGAAACATCTTAC-3' 
5'-TTGCGGGAGGAAAATGGGTAGTTA-3' 
5'-ATGCTGAATGAG-CAT-GATTTT-3' 
5'-TTCCTGCACTGGCTGATGA-3' 
5'-CGGAAGAGTGTCTGGAGCAA-3' 
5'-AGTTCCTGCACTGGCTGATGAGT-3' 
5'-GCCTGAGCTGTACTTTGTCAA-3') 
5'-CTAACCCTAACTGAGAAGGGCGTAG-3' 
5'-AATCCGTCGAGCAGAGTT-3' 
5'-CCAGCATCAGTAGTATGA-3' 
5'-TGTGCCAAGGGTGAATGATGAAA-3' 
5'-AGAGTGCTACACTGTCCAAC-3' 
5'-GTGTCTGGAGCAAGTTGCAA-3' 
5'-GGATGAAGCGGAGTCTGGA-3' 
5'- CTCGGCCCTCTTTTCTCTGCG -3' 
5'-CGCAAACAGCTTGTTCTCCATGTC-3' 
5'-GAAGGCGGCAGGCCGAGGCTTTTCC-3' 
5'-GCGCGG [CTTACC]3 CTAACC-3' 
5'-GGAAGCTTATCAAAGTCCTCGGCCACA-3' 
236 
285 
351 
126 
146 
5'-GGGAATTCAAAACTGGAACGGTGAAGG-3' 
5'-CAGGTCATCACCATTGGCAATGAGC-3' 
328 
457 
103 
TRAP 
98 
5'-CGGATGTCCACGTCACACTTCATGA-3' 135 
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Primers hTERT-1784S (5'-CGGAAGAGTGTCTGGAGCAA-3') and hTERT- 
1928A (5'-GGATGAAGCGGAGTCTGGA-3') were used to amplify a region including 
the specific T-motif of hTERT to generate a 145 bp fragment. The reaction mixtures 
were heated at 94°C for 30 sec, followed by 33 cycles of 94°C for 20 sec, 68°C for 40 
sec and 72°C for 30 sec. Primers 774 (5'-GGGAATTCAAAACTGGAACGGTGAAGG- 
3') and 775 (5'-GGAAGCTTATCAAAGTCCTCGGCCACA-3') were added at 72°C of 
cycle 13 for ß-actin internal control. 
Primers hTERT-2164S (5'-GCCTGAGCTGTACTTTGTCAA-3') and hTERT- 
2620A (5'-CGCAAACAGCTTGTTCTCCATGTC-3') were used to amplify a sequence 
between the two reverse transcriptase motifs A and B' of hTERT, to generate a 457 bp 
fragment. The reaction mixtures were heated at 94°C for 30 sec, followed by 35 cycles 
of 94°C for 25 sec, 68°C for 50 sec and 72 °C for 50 sec. Primers 774 and 775 were 
added at 72°C of cycle 15 for ß-actin internal control. 
Primers hTERC-46S (5'-CTAACCCTAACTGAGAAGGGCGTAG-3') and 
hTERC-148A (5'-GAAGGCGGCAGGCCGAGGCTTTTCC-3') were used to amplify a 
hTERC region to generate a 103 bp fragment. The reaction mixtures were heated at 
94°C for 30 sec, followed by 28 cycles of 94°C for 20 sec, 68°C for 40 sec and 72°C for 
30 sec. Primers 5899 (5'-CAGGTCATCACCATTGGCAATGAGC-3') and 5900 (5'- 
CGGATGTCCACGTCACACTTCATGA-3') were added at 72°C of cycle 9 for ß-actin 
internal control. 
Amplified products were electrophoresed on 4-20% polyacrylamide gels 
(Novex, Belgium) and visualized with SYBR-Green I nucleic acid gel stain by use of an 
UV-transilluminator. Double-checks were performed on most samples. Amplification of 
ß-actin cDNA was used to confirm cDNA synthesis and integrity in each sample and 
the leukaemia cell line Molt-4 was used as a positive control. Some confluent, slow 
growing cell cultures of meningiomas (cases 5,7,9,17, and 20) were also tested for 
telomerase expression. 
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2.3 Telomere length measurement 
2.3.1 Terminal restriction fragment (TRF) telomere length analysis 
Telomeric hexanucleotide repeats (TTAGGG), in humans and some sub- 
telomeric DNA sequence, do not contain restriction sites. Digestion of genomic DNA 
with restriction enzymes such as Hinfl, reduces the majority of genomic DNA to small 
fragments, whilst the terminal chromosome fragment remains whole. This fragment, 
containing an undisclosed length of sub telomeric DNA in addition to the terminal 
section of hexameric repeats, is termed the terminal restriction fragment (TRF). The 
average size of the TRF, when separated by agarose gel electrophoresis, can be 
measured by Southern blotting and hybridisation to an isotope end labelled telomeric 
oligonucleotide primer, (TTAGGG)4, and detected by autoradiography or 
Phosphorimager. Telomeric DNA, which is constantly eroded during DNA replication, 
appears as a smear when analysed, indicating the characteristically heterogeneous 
telomere population. This technique is commonly used to determine variation in 
telomere length. 
2.3.1.1 Telomere amount length assay 
2.3.1.1.1 Extraction of DNA 
Exponentially growing monolayer cells were collected by scraping with a rubber 
policeman, washed two times with PBS and frozen at -80°C upon retrieval. Genomic 
DNA from frozen fibroblasts was extracted as described by Sambrook et al. (1989). In 
brief, cells were lysed by incubating at 37°C for 30 min in 10 mM Tris-HCI, pH 8.0,20 
mM EDTA, 0.5% SDS, 20 pg/mL DNase free RNase. Poteinase K (100 pg/mL) (Sigma, 
St. Louis, MO) was then added and the mixture was incubated at 48°C overnight. The 
mixture was extracted with 1 volume of phenol, chloroform/isoamyl alcohol. The 
genomic DNA in the supernatant was precipitated with 2 volumes 100% ethanol/0.1 
volume of 3M sodium acetate (pH 5.2), washed with 70% ethanol, allowed to air dry 
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for 30 min, and dissolved in double distilled water overnight at 4°C. The DNA 
concentration was determined by A260 using an Eppendorf BioPhotometer. 
2.3.1.1.2 Preparation of 32P-labelled telomere probe 
The telomere probe (TTAGGG)4 (Sigma-Genosys) was end-labelled with 32P. 
Briefly, 75 ng of (TTAGGG)4 oligonucleotide was incubated with the forward reaction 
buffer (Gibco BRL), 35 NCi 7-32P-ATP (Pharmacia Biotech) and 10 units Polynucleotide 
T4 Kinase (Gibco BRL) for 30 min at 37°C. The labelled probe was purified using 
QlAquick Nucleotide Removal kit (QIAGEN). 
2.3.1.1.3 Telomere amount and length assay (TALA) 
Aliquots (2.5 pg) of DNA were digested with the restriction enzymes, i. e., 10 
units each of Hinf I, Hha I, Hae III in ReACT2 buffer (all from Gibco BRL), overnight at 
37°C. Complete cutting was confirmed by electrophoresis of 5pl of DNA digests on 1% 
agarose gels. The digested DNA was mixed with 1.5ng 32P-labeled probe in the ReACT 
2 buffer. The mixture was denatured at 98°C for 6 min, hybridised at 55°C for 40 min, 
and further cooled to 4°C for at least 5 min. The unhybridised excess probe and 
digested non-telomeric DNA fragments were separated from the hybridised telomeres 
by gel electrophoresis on a 0.7% agarose gel for 6h at 90 volts in 1X TBE. The gel 
was then dried in a heater. The dried gel was transferred on a filter, covered with 
plastic wrap film and exposed to a phosphorimager screen for at least 6 h. The 
resulting autoradiograph was captured using a phosphorimager, and the intensity of the 
signal was determined using lmageQuantNT software (Molecular Dynamics, Sunyvale, 
CA). The average signal was calculated as the average of the signal found in the 
background areas. The telomere amount was calculated as total intensity of the 
telomeric signal using the area under curve method minus the background signal. The 
mean telomere length was defined as length corresponding to the position where 50% 
of the total signal occurred. Data calculation and statistical analysis were performed 
46 
Chapter 2: Materials and Methods 
using the Microsoft Excel program. This method was executed successfully but the 
next non-isotopic method was preferred to eliminate safety issues associated with the 
handling of radioactive isotopes as the telomeric probe is labelled with digoxigenin 
(DIG) (see below). 
2.3.1.2 Non-radioactive chemiluminescent assay to determine telomere length 
2.3.1.2.1 Extraction of DNA and enzyme digestion 
Exponentially growing monolayer cells were collected by scraping with a rubber 
policeman, washed two times with PBS and frozen at -80°C until required. Genomic 
DNA from frozen fibroblasts was extracted as described by Sambrook et al. (1989). In 
brief, cells were lysed by incubating at 37°C for 30 min in 10 mM Tris-HCI, pH 8.0,20 
mM EDTA, 0.5% SDS, 20 pg/mL DNase free RNase. Poteinase K (100 pg/mL) (Sigma, 
St. Louis, MO) was then added and the mixture was incubated at 48°C overnight. The 
mixture was extracted with 1 volume of phenol, chloroform/isoamyl alcohol. The 
genomic DNA in the supernatant was precipitated with 2 volumes 100% ethanol/0.1 
volume of 3M sodium acetate (pH 5.2), washed with 70% ethanol, allowed to air dry 
for 30 min, and dissolved in double distilled water overnight at 4°C. The DNA 
concentration was determined by A260 using an Eppendorf BioPhotometer. A6 pg 
sample of genomic DNA from each cell culture was digested overnight with a Rsal/Hinfl 
restriction enzyme mixture (Roche Diagnostics, Mannheim, Germany) at 37°C. 
2.3.1.2.2 Electrophoresis and hybridisation of digested DNA 
Digested DNA was subjected to 0.8% agarose gel electrophoresis in 1x TAE 
buffer. The gels were stained with ethidium bromide prior to hybridisation to indicate 
that the samples were loaded evenly. Two digoxigenin (DIG) size markers were run on 
each gel to test uniformity of DNA migration rate across the gel. The gel was then 
depurinated for 5-10 min in 0.25M HCI, denatured for 30 min in 0.5 M NaOH, 1.5 M 
NaCl, and neutralized for 30 min in 0.5 M Tris-HCI, 3M NaCl (pH 7.5). Upward 
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capillary transfer was used to transfer the DNA from the gel to a positively charged 
nylon membrane and fixed with UV. Hybridisation was carried out with a 3'-end DIG- 
labelled d(TAGGG)4 at 42°C for 3h. Stringency washes were carried out by washing 
membranes two times in 2xSSC/0.1 % SDS and in 0.2xSSC/0.1 % SDS at room 
temperature. Chemiluminescent detection was performed by virtue of alkaline 
metabolising CDP-Star as recommended by the manufacturer (Roche Diagnostics, 
Mannheim, Germany). 
2.3.1.2.3 Computing densitometry 
Exposure of a chemiluminiscent detection film (Roche) to the membrane 
revealed telomere lengths as smears ranging from 2 to more than 21 kb. The films 
were scanned with a densitometer and using ImageQuant software 5.2 (Amersham 
Biosciences, USA) the telomere signal in each lane was quantified in a grid object, 
defined as a single column with 30 rows (see Figure 2.2). This grid was placed over the 
lanes corresponding to the molecular size markers and telomere lane, and recorded. 
These data were transferred to a spreadsheet Excel (Microsoft) and quantitation was 
performed by integrating volume. Interpolating molecular sizes for each row were 
determined by plotting the row number, 1- 30, against the log10(molecular size) for 
the molecular size ladder, and fitting a best (least squares) line. The average labelled 
TRF length in each lane was calculated in Excel as the mean of the optical density 
above background using the formula L=E(OD; )/E(OD; L; ), where OD; and L; are the 
signal intensity and TRF length (in base pairs; bp) respectively at position i on the gel 
image. The samples underwent one to three replicate experiments, and the 
experimental errors were found to be within 5%. 
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Figure 2.2 Image of a typical gel used to measure telomere lengths. The lane on the 
left side shows the molecular size marker. Gel profiles were read in a densitometer and 
collected in a grid, data were transferred to Excel spreadsheet for analysis. Telomeric 
sizes are then calculated as described in the text. 
2.3.2 Telomere length determination by flow-FISH 
The average telomere length in cells was measured by flow cytometry as 
described previously with minor modifications (Rufer et al., 1998). Cells were washed 
in phosphate-buffered saline (PBS), centrifuged, the supernatant discarded and 5x105 
cells were resuspended in 500 pl of hybridisation mixture containing 70% deionised 
formamide, 20mM Tris buffer pH 7,1% BSA and 0.3 µg/mL FITC conjugated (C3TA2)3 
peptide nucleic acid (PNA) probe (Applied Biosystems, MA, USA). 
PNA probes contain an uncharged glycine backbone rather than the charged 
phosphate-ribose/deoxyribose backbone of traditional oligonucleotide probes. The PNA 
probe hybridises to complementary DNA in low ionic strength solutions that do favour 
reannealing of the target strands. PNA-DNA interactions are more stable than DNA- 
DNA or RNA-RNA interactions under hybridisation conditions. This property yields 
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more reproducible results and a stronger fluorescent signal than can be obtained with 
conventional DNA oligonucleotides. 
Samples were heat-denatured for 10 min at 80°C and left to hybridise for 2h in 
the dark at room temperature. Samples without PNA probe were used as negative 
control. Excess probe was then washed away twice in a wash solution containing 70% 
formamide, 10 mM Tris buffer (pH 7), 0.1 % BSA and 0.1 % Tween-20, centrifuged for 5 
min at RT at 3000 rpm and again washed twice in PBS, 0.1 % BSA and 0.1 % Tween-20 
and centrifuged for 5 min at RT at 2000 rpm. The cells were then incubated in 500 µl 
PBS, 0.1 % BSA, 10 µg/mL RNAse A and 0.1 µg/mL propidium iodide (PI) for 1h at 4°C 
prior to the analysis. All samples were stored on ice until analysis by flow cytometry. 
Flow cytometric analysis was performed on fresh and frozen samples using a Beckman 
coulter EPICS XL equipped with a single laser and a4 colour (FITC, PE, ECD/PI and 
PeCy5) detection system (Becton Dickinson, USA). The size and internal granularity 
were described by the forward scatter and side scatter, respectively. The FITC signal 
was detected in the FL1 channel and the propidium iodide fluorescence in the FL3 
channel with no compensation set on the instrument. Polyploid cells were eliminated 
prior to cell cycle analysis because they were recorded next to the G2/M peak position. 
Apoptotic and necrotic cells were identified and measured on the PI fluorescence 
histogram as a hypodiploid peak, as described previously (Nicoletti et al., 1991). 
List mode data from 20,000 un-gated events were collected in each experiment 
and evaluated using Expo32 ADC Analysis software (Coulter corporation, USA). In 
order to obtain the best CV (coefficient of variation), the flow rate was kept below 150 
events/sec. Mean telomere fluorescence intensity (TFI) was calculated as the 
difference between the mean fluorescence FL1 channel of electronically gated Go/G, 
cells and the control samples. The performance of the instrument was monitored 
before analysis by using Flow-Check fluorospheres (Beckman Coulter). 
The conversion of TFI units into bp was performed using the formula y=4.13x 
+ 2.56 (R2=1). This formula was obtained following telomere length correlation analysis 
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in LY-R and LY-S cells, which have telomere lengths of 49 and 7 kb, respectively 
(Mcllrath et al., 2001), by two independent methods, flow-FISH and Q-FISH 
(quantitative-FISH). This formula was validated using telomere length values from six 
established human lymphoblastoid cell lines determined by Southern blot and flow- 
FISH. 
2.4 Telomeric repeat amplification protocol (TRAP) assay 
The PCR based TRAP (telomeric repeat amplification protocol) assay for 
telomerase activity was performed essentially as described (Kim et al., 1994) except 
that there is no incorporation of radioactive nucleotides, use of wax barrier nor end- 
labelling of primers. Cell lysates were prepared using the CHAPS detergent lysis 
method and 0.7 pg of total protein was used in each assay. The protein concentration 
of lysates was measured using Bio-Rad protein assay kit. Amplification products were 
separated on a 10% non-denaturing polyacrylamide gel, stained with SYBR-green I 
(Molecular Probes) and visualized using a UV-transilluminator. 
2.4.1 Assay for telomerase activity 
The TRAP assay measures enzymatic activity of telomerase if it is present. In 
the first step of the reaction, telomerase adds a number of telomeric repeats 
(GGTTAG) onto the 3' end of a substrate oligonucleotide (TS). In the second step, the 
extracted products are amplified by PCR using the TS and ACX (reverse) primers. 
Following the PCR amplification the reactions are electrophoresed on an acrylamide 
gel, and if telomerase products are present, they are visible as a6 bp ladder of 
products with 6 base increments starting at 50 nucleotides: 50,56,62,68 etc. upon 
staining of the gel with a fluorescent dye. Additionally, each reaction mixture contains a 
primer (K1) and a template (TSK1) for amplification of a 36 bp internal standard. 
Incorporation of this internal positive control makes it possible to quantify telomerase 
activity more accurately and to identify false-negative samples that contain Taq 
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polymerase inhibitors. Since telomerase is a ribonucleoprotein, precautions against 
contamination with RNases were always taken, as well as conventional precautions 
against contamination with PCR products. 
2.4.2 Lysis of cells and tissues 
Frozen brain tumour samples were homogenized in 200-600 µL ice-cold 
extraction buffer [10 mM Tris-HCI (pH 7.5), 1 mM MgCI2i 1 mM EGTA, 0.1 mM 
benzamidine, 0.5% CHAPS, 5 mM ß-mercaptoethanol, 10% glycerol], depending on 
the size of the tumour sample. After 30 minutes of incubation on ice, lysates were 
centrifuged at 12,000 g for 20 minutes at 4°C, and 40-200 µL of each supernatant was 
collected. 
2.4.3 Measurement of protein concentration 
Protein content in each lysate was measured by the Bradford assay (Bio-Rad 
laboratories) by using BSA as a standard (y=0.612 + 0.014; R2=0.99) and adjusted to 2 
µg/µL. The OD595 of samples were measured on an Eppendorf BioPhotometer. Aliquots 
of 40 µL protein extracts were frozen in liquid nitrogen, which were used only once. 
2.4.4 Telomerase and PCR reaction 
Telomerase enzymatic activity was determined in 49 samples using the TRAP 
protocol of the TRAPeze Telomerase Detection Kit (Intergen) with minor modifications. 
Briefly, 0.7 µg of protein extract was incubated in 20 µL of reaction mixture containing 
1x TRAP reaction buffer, 50 µM dNTPs, 0.45 µL TS primer (5'-AATCCGTCGAGCAGA 
GTT-3'), 0.45 µL Primer Mix (RP primer 5'-GCGCGG [CTTACC]3CTAACC-3' 
(manufacturer's communication), K1 primer and TSK1 template for internal control), 
and 1U of Taq DNA Polymerase at 300C for 30 min for telomerase-mediated extension 
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of the TS primers. Reaction mixtures were subjected to 33 cycles using the following 
conditions: 94°C for 40 sec, 59°C for 30 sec, and 72°C for 30 sec. 
2.4.5 Electrophoresis 
Ten microlitres of each PCR reaction was analysed by electrophoresis on 10% 
polyacrylamide-urea gels (Novex) and visualized with SYBR-Green I nucleic acid gel 
stain by means of an UV-transilluminator. High telomerase activity is defined as more 
than six incremental TRAP products. All samples were repeated twice to validate our 
findings. 
2.4.6 Internal PCR standard for TRAP assay 
The inclusion of an internal control, a synthetic DNA construct added to all 
samples and which is amplified with the TS and RP primers to generate a 36-bp 
product, aided the detection of false-negatives which can result from the presence of 
PCR inhibitors in the extracts. The immortal cell lines Hela (human cervix carcinoma), 
U251 (human glioblastoma) and Molt-4 (human T lymphoblastic leukaemia) showed 
telomerase activity and expressed all alternative splice products of hTERT mRNA. In 
all further experiments Molt-4 was ultimately used as a positive control, because of 
ease of cell culture production. As a negative control, cDNA was replaced by lysis 
buffer. 
2.5 Real-Time Quantitative TRAP assay (RTQ-TRAP) 
2.5.1 Assay for telomerase activity 
A real-time quantitative TRAP (RTQ-TRAP) system has been developed (Hou 
et al., 2001; Wege et al., 2003) by combining a real-time PCR technique with the 
conventional TRAP method. RTQ-PCR, designed to avoid the deficiencies of 
conventional PCR, uses the ABI PRISM 7900HT Sequence Detection System (PE 
Applied Biosystems). The fluorescent dye SYBR Green is capable of binding to the 
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double-stranded amplicons and generating fluorescence signals in a PCR reaction. 
This allows the amount of PCR products to be determined based on fluorescence 
produced during the extension step of each cycle in a closed tube. 
2.5.2 Protein extraction 
Cells (1-2 x 106) were lysed in 50 pI of CHAPS buffer containing RNase inhibitor 
and incubated at 4°C for 30 min. The lysate was then centrifuged at 12,000 g for 30 
min at 4°C, and the supernatant was collected. The protein concentration was 
measured using the Coomassie (Bradford) Protein Assay (Pierce Biotechnology, USA) 
by using BSA as a standard (y=0.007x + 0.7126; R2=0.897) and adjusted to 250 ng/µL. 
The OD595 of samples were measured on an Eppendorf BioPhotometer. 
2.5.3 RTQ-TRAP assay 
The total volume of the reaction mixture was 25 pl and contained 1x SYBR 
Green PCR master mix (P/N 4309155, PE Applied Biosystems), 0.1 pg of primer TS (5'- 
AATCCGTCGAGCAGAGTT-3') and 0.05 pg of primer ACX (5'-GCGCGG(CTTACC)3 
CTAACC-3'). The PCR was performed in a 96 well microtiter plate on an ABI PRISM 
7900HT Sequence Detector System. The reaction mixture was first incubated at 25°C 
for 20 min to allow the telomerase in the protein extracts to elongate the TS primer by 
adding TTAGGG repeat sequences. The PCR was then started at 95°C for 10 min, 
followed by a 35-cycle amplification (95°C for 20s, 60°C for 30s, and 72°C for 90s). 
SYBR Green, a fluorescence dye, is known to bind double-stranded DNA. When new 
amplicons were produced, SYBR Green bound to them at once and generated 
fluorescence signals, which were collected and analysed with the Sequence Detector 
software (Version 2.1; PE Applied Biosystems) during the late step of each cycle. The 
fluorescence threshold was calculated as 10 SD of the baseline fluorescence intensity 
at the default setting of 3-15 cycles. Quantification of telomerase activity in unknown 
samples is extrapolated from the standard curve and threshold cycle Ct. PC3 cells 
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(prostate adenocarcinoma cell line) were used to set up a standard calibration curve. 
All samples were run in triplicates, TSR8 oligonucleotide template and MCF10 cells 
were used as a positive control and the lysis buffer was used as a negative control. 
2.6 Transfection of human cells with small interfering RNAs 
2.6.1 Principles of siRNA interference 
RNA interference (RNAi) is a sequence-specific posttranscriptional gene 
silencing mechanism, which is triggered by double-stranded RNA and causes 
degradation of mRNAs homologous in sequence to the dsRNA. Although RNAi has 
been observed in a wide range of eukaryotes, including plants, protist, filamentous 
fungi, and vertebrate animals, it has only recently become possible to silence human 
genes in cultured somatic cells. The detection of RNAi in somatic mammalian cells has 
been hampered by the presence of a number of dsRNA-triggered pathways that 
mediate non-specific suppression of gene expression. dsRNA is a potent inducer of 
type I interferon (IFN) synthesis and is the activator of two clases of IFN-induced 
enzymes: PKR, the dsRNA-dependent protein kinase, and 2', 5'-oligoadenylate 
synthetases, whose products activate the latent ribonuclease RNase L. These non- 
specific responses to dsRNA are not triggered by dsRNA shorter than 30 bp including 
siRNA duplexes that resemble in length and structure the natural processing products 
from long dsRNAs. The most predominant processing products are duplexes of 21- 
and 22nt RNAs with symmetric 2-nt 3' overhangs, which are also the most efficient 
mediators of mRNA degradation. 
2.6.2 Procedure of siRNA interference 
The small interfering RNAs (siRNA) target sequence of BRCA1 used is: AAG 
GAA CCU GUC UCC ACA AAG UU (Bruun et al., 2003). The siSTABLE siRNA duplex 
was synthesized by Dharmacon Research and provided as a purified and annealed 
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duplex (Technical Bulletin, Dharmacon Research). Transfection was carried out using 
Oligofectamine (Invitrogen) following the protocol recommended by Invitrogen. 
Briefly, MCF10A and MCF7 cells were grown in T25 flasks until they reached -- 
70% confluence and 4 hours before transfection cells were given fresh culture medium. 
For each T25 flask, 10 µl of 75 µM stock of siSTABLE siRNA duplex was mixed with 
500 µl of Opti-MEM (Invitrogen) while in a separate tube 25 µI of oligofectamine was 
mixed with 500 µl of Opti-MEM and incubated at room temperature for 5 min. The 
lipofectamine solution was mixed with the diluted siSTABLE siRNA duplex and 
incubated at room temperature for 20 min. The lipofectamine-siRNA complex was 
added drop wise to the cells in 4mL culture medium including serum and incubated at 
37°C. 
MCF1OA and MCF7 cells were also grown on Thermanox coverslips in 24 well 
plates. For each coverslip, 1 µl of 75 µM stock of siSTABLE siRNA duplex was mixed 
with 50 µl of Opti-MEM (Invitrogen) while in a separate tube 2 µl of oligofectamine was 
mixed with 50 . il of Opti-MEM. The two solutions were then gently combined and added 
to cells in 500 pI culture medium including serum. Cells without siRNA were mock- 
transfected with lipofectamine. The medium was changed after 48h and cells were 
harvested after 0-11 days. 
2.7 Western blotting 
2.7.1 Protein isolation 
Cells were scraped from flasks (MCF10A) and petri-dishes (MCF7), centrifuged 
and washed with ice-cold PBS then lysed on ice for 15 min in lysis buffer. The aim was 
to find a method that would solubilise all the target antigen (hTERT and BRCA1) in a 
form that is immunoreactive and undegraded. Therefore, different lysis buffers were 
examined e. g. single detergent lysis buffers based on Triton XP-100 or Igepal CA-630 
(formerly called NP-40) and the triple detergent RIPA lysis buffer, which contains three 
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detergents. The RIPA lysis buffer was finally chosen to extract proteins: 50mM Tris-HCI 
pH 8,150mM NaCl, 1% Igepal CA-630,0.5% sodiumdeoxycholate, 0.1% SDS 
supplemented with protease inhibitor mix (Roche, Mannheim, Germany) and 1 mM 
PMSF (phenyl methylsulfonylfIuoride). Cell debris was removed from extracts by 
centrifugation at 13,000 g for 5 min. The protease inhibitor from Roche inhibits a broad 
spectrum of serine, cysteine and metalloproteases as well as calpains. PMSF is an 
irreversible protease inhibitor of trypsin-like serine proteases. It causes sulfonylation of 
the active-site serine residues. 
2.7.2 Protein concentration measurement 
Concentrations of proteins were determined by using the Bio-Rad DC protein 
assay. This is a colorimetric assay based on the reaction of protein with an alkaline 
copper tartrate solution and Folin reagent. This assay was applied because 
compounds like SDS, Triton X-100, or 2% Igepal, which were used in testing several 
protein lysis buffers, are compatible with the Bio-Rad DC Protein Assay. A standard 
curve of optical density against increasing protein concentration was established for 
each protein sample using serial dilutions of bovine gamma globulin and a Coomassie 
blue-based dye reagent (Biorad). The protein absorbance was measured on a Hitachi 
U-1100 spectrophotometer set at 750 nm (located in students teaching laboratory). 
2.7.3 SDS-PAGE electrophoresis 
hTERT and BRCA1 protein expression levels were determined in MCF cells 
transfected with siRNA BRCA1, as explained above, and harvested at different times 
(0-11 days). Aliquots of protein (50 µg/lane) stored at -20°C were mixed with 
denaturing 5x SDS-PAGE sample buffer (0.25MTris-HCL pH 6.8,8% SDS, 30% 
glycerol, 0.2% Bromophenol blue, 5% ß-mercaptoethanol) and denatured by heating at 
90 CC for 4 min. A 30% acrylamide/methylene bisacrylamide solution was used to 
prepare a 6°0 running gel and a 5% stacking gel (6 and 5%, respectively for BRCA1; 
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10 and 5%, respectively for hTERT) prepared with standard Laemmli solutions. 
Hundred micrograms of protein per lane was loaded onto the gel and SDS-PAGE was 
carried out using a Biorad Mini-Protein II electrophoresis cell for 30 min at 100 V and 
then for 45 min at 150 V at 4 °C. In each experiment, equal aliquots of total cellular 
protein were electrophoresed. A high range molecular weight marker (Biorad) was run 
on each gel. 
2.7.4 Immunoblotting 
Proteins were transferred to Hybond-P membranes (Amersham Biosciences) in 
a mini trans-blot electrophoresis transfer cell (BioRad) for 1h at 180 mA at 4 °C and 
blocked for 1 hour in 5% non-fat dry milk, 0.1 % Tween-TBS. 
All antibodies used in this study are shown in Table 2.5. To detect BRCA1 and 
hTERT proteins, blots were incubated overnight at 4°C. BRCA1 was detected using a 
mouse monoclonal antibody Ab-4 (Oncogene) at a concentration of 2µg/ml- or a rabbit 
polyclonal antibody C-20 (Santa Cruz Biotechnology, CA, USA) at a dilution of 1: 200. 
hTERT was detected using L-20 (Santa Cruz). This antibody is an affinity purified goat 
polyclonal antibody, mapping near the amino terminus of TERT of mouse origin 
The blots were then rinsed in TBS with 0.1 % Tween for 2x10 min and incubated 
at RT for 1 hour with a secondary peroxidase (BRCA1: goat anti-mouse IgG at a 
dilution of 0.2 pg/mL or with a secondary peroxidase goat anti-rabbit IgG at a dilution of 
1: 5000; hTERT: chicken/donkey anti-goat IgG at a dilution of 1: 5000). The 
immunoblots were rinsed for 3x10 min with 0.1 % T-TBS. 
Blotted proteins were visualized using the enhanced chemiluminiscence 
(ECL+PIus) detection reagents (Amersham Biosciences). A monoclonal anti ß-actin 
AC-15 (Sigma, MI. USA) at a dilution of 1: 5000 was used to confirm siRNA BRCA1 
transfection efficiency and equal protein loading to each well. A dual colour marker (Cat 
No. 161-0374, BioRad) was used as a molecular size standard. The blotted membrane 
was exposed to Lumi-Film Chemiluminiscent detection film (Roche). The protein bands 
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were quantitated by densitometry using the ImageTool Software 3.0 (The University of 
Texas Health Science Center, San Antonino, USA) and the values were expressed 
relative to ß-actin as a control. The total protein content on the membrane was checked 
by Coomassie blue staining. 
Table 2.5 Overview of antibodies used for Western blotting (WB) and 
immunocytochemistry (IHC). M: monoclonal; P: polyclonal 
Antibody Cat. No. Type Source Application 
BRCA1 (Ab-1) OP92 M Oncogene IHC 
BRCA1 (Ab-4) OP107 M Oncogene WB 
BRCA1 (C-20) sc-642 P Santa Cruz WB 
y-H2A. X (Ser139) 05-636 M Upstate Biotechnology IHC 
Ki-67 NCL-K167-MM1 M Novocastra IHC 
Ki-67 A0047 P Dako IHC 
PCNA (PC10) sc-56 M Santa Cruz IHC 
Nucleolin - C23 (MS-3) sc-8031 M Santa Cruz IHC 
TERT (L-20) sc-7214 P Santa Cruz WB 
TERT (H-231) sc-7212 P Santa Cruz IHC 
TRF1 (C-19) sc-1977 P Santa Cruz IHC 
TRF2 (N-20) sc-8528 P Santa Cruz IHC 
PML (PG-M3) sc-966 M Santa Cruz IHC 
PML (A-20) sc-9863 P Santa Cruz IHC 
ß-Actin (AC-15) A5441 M Sigma WB 
goat anti-mouse IgG HRP DC02L - Oncogene WB 
goat anti-rabbit IgG HRP sc-2004 - Santa Cruz WB 
donkey anti-goat IgG HRP sc-2020 - Santa Cruz WB 
rabbit anti-goat IgG biotinylated BA-5000 - Vector Laboratories IHC 
goat anti-mouse IgG FITC F5262 - Sigma IHC 
donkey ant-goat IgG FITC sc-2024 - Santa Cruz IHC 
donkey anti-goat IgG TR sc-2783 - Santa Cruz IHC 
donkey ant-goat IgG TRITC sc-2094 - Santa Cruz IHC 
chicken anti-mouse IgG FITC sc-2989 - Santa Cruz IHC 
chicken anti-mouse IgG TR sc-3924 - Santa Cruz IHC 
chicken anti-mouse IgG TRITC sc-2861 - Santa Cruz IHC 
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2.8 Immunocytochemistry 
2.8.1 Single immunofluorescence detection of y-H2AX, BRCA1, PML, and TRF1/2 
Immunofluorescent staining was performed on 1: 1 methanol/acetone-fixed cells 
on Thermanox coverslips or on poly- L-lysine-coated slides (Sigma), fixed for 15 min at 
room temperature in a 4% paraformaldehyde-buffered solution, and permeabilised with 
0.1% Triton X-100 for 10 min at 4°C. For list of antibodies see Table 2.5. Cells were 
blocked in 0.5% BSA in PBS and incubated with 2µg/mL mouse monoclonal anti- 
phospho-histone H2AX (Upstate, NY, USA), 1: 100-500 mouse monoclonal anti-BRCA1 
(Oncogene Research, CA, USA), mouse monoclonal anti-PML, mouse monoclonal 
anti-TRF1 and TRF2 (Santa Cruz) in blocking buffer for 1 hour at room temperature or 
performed overnight at 4°C. Cells were then washed and incubated with a species- 
specific secondary IgG FITC-, TRITC- or Texas Red-conjugated antibody (Sigma and 
Santa Cruz) at 1: 100-500 for 1 hour at room temperature. Cells were then washed in 
PBS several times and covered with Vectashield mounting medium (Vector 
Laboratories, CA, USA) containing 1.5 . ig/mL DAPI. Slides were viewed using a Zeiss 
fluorescence Axioplan2 imaging microscope and digitally scanned. 
2.8.2 Double immunofluorescence detection of TRF2 with PML, yH2AX, and BRCA1 
Cells were spread onto poly-L-lysine-coated slides. For the simultaneous 
visualization of TRF2-PML, TRF2-y-H2AX, and TRF2-BRCA1 foci, cells were fixed as 
mentioned in previous section. Cell preparations were blocked for 1h in 10% FBS/PBS, 
rinsed, and incubated with primary antibodies. Double staining with antibodies was 
performed for 1 hour at room temperature or overnight at 4°C in PBS/1% BSA, 
whereas species-specific FITC-, TRITC-, or Texas Red-conjugated secondary 
antibodies were applied for 1h at room temperature followed by counterstaining for 
5 min at room temperature with 0.5 pg/mL DAPI. Slides were mounted in Vectashield 
(Vector Labs, USA) and analysed by fluorescence microscopy. All primary antibodies 
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were used at 1: 300-600 dilutions, whereas the secondary antibodies were employed 
at a1: 500 dilution. At least 100 nuclei were examined, showing at least one foci, 
which were scored at a magnification of 400x using a fluorescence microscope. Parallel 
samples, incubated either with serum or only with the secondary antibody, confirmed 
that the observed fluorescence pattern was not attributable to artefacts. 
2.8.3 Immunocytochemistry on paraffin embedded brain tumour tissues 
Eighty-five paraffin-embedded tissues of 32 intracranial tumours were used for 
the cell proliferation assessment. Sections of 3 µm thickness, adjacent to H&E and 
Masson trichrome sections, were heated in sodium citrate buffer (10 mM; pH 6.0) for 
10 minutes in a microwave oven for high temperature antigen unmasking. The 
endogenous peroxidase activity was blocked by 3% H202 in Tris-Buffered Saline (TBS) 
buffer, pH 7.6 for 5 min. 
A three-step SABC method was used. Sections were first incubated with the 
monoclonal antibody Ki-67 (Novocastra NCL-Ki-67-MM1) at a dilution of 1: 100. 
Subsequently, sections were incubated with biotinylated rabbit anti-mouse, 1: 200 in 
TBS for 30 min, followed by the third incubation step with streptavidin-biotin-peroxidase 
complex, 1: 200 for 30 min. Visualization of the complex was realized with 
diaminobenzidine (DAB) and sections were counterstained with haematoxylin. 
Epidermis tissue and Molt-4 cells were applied as positive controls, whereas brain 
tissue was used as negative control. Ki-67 labelling indices (LI) were calculated as 
mean percentage values by counting nuclei of tumour cells in three 0.22 mm2 areas of 
a single tumour, each area consisting of 500 to 1800 neoplastic cells depending on the 
tumour type. 
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2.8.4 Immunocytochemistry on brain tumour cell cultures 
2.8.4.1 Immunocytochemistry of Ki-67, hTERT, PCNA and Nucleolin 
Cells were either grown on Thermanox coverslips or fixed and dropped on 
slides. For preparation of droplet slides, T25 cell cultures were trypsinised and 
centrifuged at 900 rpm for 4 min. The cell pellets were resuspended in 10 mL of 
hypotonic buffer (75mM KCI) and placed in a 15 mL tube at RT for 15 min. This was 
followed by fixation (9: 1: 10, formaldehyde: acetic acid: Ringer buffer) for 5 min on ice. 
Cells were centrifuged at 900 rpm for 4 min and resuspended again in 10 mL fixative, 
followed by 5 min incubation on ice and centrifugation. Fixative was changed in 70% 
ethanol. Cells were immediately dropped on slides and processed. Cells on coverslips 
were washed three times with cold PBS then fixed by treatment with acetone at 4°C for 
3 minutes. 
Cells were incubated with primary antibody solutions for 1 hour at room 
temperature with a monoclonal Ki-67 (NCL-Ki-67-MM1, Novocastra), polyclonal Ki-67 
(A 0047, Dako, UK), rabbit polyclonal hTERT antibody (H231 and L-20, Santa Cruz 
Biotechnology), PCNA (PC10, Novocastra, UK), and Nucleolin (C23, Santa Cruz, USA) 
at 1: 100 at room temperature for 1.5 h. After washing three times in PBS, cells were 
incubated with biotinylated secondary antibodies at 1: 200 for 30 minutes at room 
temperature. Cells were then washed three times with PBS and once with water then 
stained with DAB or AEC+ substrate chromogen (Dako), and counterstained with 
Haematoxylin or toluidine mounted onto glass slides in aqueous mounting medium 
(Faramount, Dako). Slides were viewed using a Zeiss Axiolab microscope and digitally 
scanned using a Pixera Professional camera. Images were collected using a 40 or a 
100x oil-immersion lens and were edited in Adobe Photoshop 5.5 and CorelDrawl0. 
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2.8.4.2 Double immunocytochemsitry of Ki-67 with hTERT 
Cells on coverslips were washed three times with PBS then fixed by treatment 
with acetone at 4°C for 3 minutes or with 50% methanol/acetone for 2 min at room 
temperature. Coverslips were blocked in 0.5% BSA/PBS. Co-staining for Ki-67 and 
hTERT was carried out using a 1: 100 dilution of the monoclonal Ki-67 (NCL-Ki-67- 
MM1, Novocastra) and the rabbit polyclonal TERT antibody (L-20, Santa Cruz 
Biotechnology). After washing three times in PBS, cells were incubated in a 1: 100 
dilution of the FITC rabbit anti-mouse IgG (Dako) and the Texas Red goat anti-rabbit 
IgG secondary antibodies. Dilutions were established by preliminary titration. Cells 
were then washed three times with PBS and once with water then mounted onto glass 
slides in 10% DABCO and 1 pg/mL DAPI or propidiumiodide (Pl). Slides were viewed 
with Vectashield mounting medium (Vector) using a Leica DMRB fluorescence 
microscope. Images were collected using a 100x oil-immersion lens and were edited in 
Adobe Photoshop 5.5 and CorelDrawlO. Images were photographed using a Leitz 
orthomat camera or digitally scanned with a Pixera camera. 
2.9 Fluorescence in situ hybridisation (FISH) of telomeres 
In order to obtain metaphases, 0.1 µg/mL colcemid (Demecolcine, Sigma) was 
added 2 hours prior to harvesting to exponentially growing cell cultures. Cells were 
centrifuged at 1200 rpm for 4 min followed by 30 min hypotonic pre-treatment with 
75mM KCI then fixation in 3: 1 methanol: acetic acid solution. Cell suspensions were 
dropped onto clean glass slides and aged at 55°C overnight. The slides were washed 
in PBS and fixed in 4% formaldehyde for 2 minutes. After a second wash in PBS, the 
metaphases were incubated in 1 mg/mL pepsin solution (Sigma) in acidified water (1 
mM hydrochloric acid) at 37°C for 10 min. The slides were then briefly washed in PBS, 
fixed in 4% formaldehyde for 2 min, and dehydrated through 70%, 90%, and 100% 
ethanol. Metaphase spreads were hybridised with a6 pI/mL FITC or Cy3-conjugated 
PNA probe (C3T2A)3 (Applied Biosystems, MA, USA) in 700 pI deionised formamide, 5 
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pI blocking reagent (10% in maleic acid), 50 pl MgCl2 buffer (2.5M MgCl2) 9 mM 
Na2HPO4, pH 7), 10 pI TRIS (1 M, pH 7.2), and 152 pI deionised water, as described in 
Zijlmans et al. (1997). The slides were denatured at 72°C for 2 min and incubated for 2 
h at room temperature in the dark. The slides were washed in 70% formamide (15 min) 
and in PBS, and dehydrated in ethanol before counterstaining with DAPI. Images of 
metaphase and interphase cells were obtained on a Zeiss Axioplan working station 
equipped with a CCD camera (Photometrics) and Smartcapture 2 software (Digital 
Scientific) using fixed time exposure of 0.3 sec and magnification of 400x and 1000x. 
Only the objects on the same planar focus were chosen for analysis. The total telomere 
fluorescence intensity per cell was determined using ImageQuant software (version 5.0 
Molecular Dynamics, USA). The average signal was calculated as a total intensity of 
the telomeric signal using the area under curve method minus the background signal. 
The accuracy of the method was verified by comparing TFI values of LY-R cells 
generated by this method and TFI values of the same cells generated by conventional 
Q-FISH. To test for the presence of cell subpopulations with different telomere lengths 
the following method was applied. TFI of each individual cell was compared with 
remaining 14 cells (a total of 15 cells is typically analysed in Q-FISH measurements) on 
the basis of grouping cells into clusters in which TFI values of individual cells do not 
differ by > 50% from any other cell in the cluster. For example, if TFI of a single cell is 
1,000 any cell that has 50% more or less fluorescence (the range 500-1500) will 
become part of that cell cluster. This method is referred to as cell clustering. The 
presence of two cell clusters with statistically significant differences in the average TFI 
values is consistent with two subpopulations of cells with different telomere lengths. 
2.10 Combined immunofluorescence and FISH (Immuno-FISH) 
Cells were grown, fixed, and permeabilised as described previously. First, 
detection of y-H2AX foci by immunofluorescence was performed. Digital images of cells 
with y-H2AX foci were captured and coordinates were noted. Next, the FISH method, 
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described in previous section, was applied with a Cy3-conjugated PNA probe (C3T2A)3 
(Applied Biosystems, MA, USA), followed by standard formamide and SSC washes. 
Cells were counterstained with DAPI in fluorescence antifade medium. Digital images 
of cells with I-H2AX foci and telomere signals were edited in CorelDraw or layered on 
top of each other by use of Photoshop software. 
2.11 Cytogenetic analysis 
2.11.1 Anaphase bridge analysis 
For anaphase bridge analysis, cells were cultured on Thermanox plastic 
coverslips (Nunc, NY, USA) in 24-well plates or on poly-L-lysine-coated slides in the 
appropriate culture medium. Cells were treated with or without cytochalasin B. 
Cytochalasin B depoplymerise (eliminates) actin and therefore maintains the two 
daughter nuclei in the same cytoplasm by inhibition of cytokinesis which makes it more 
easy to detect anaphase bridges. Fibroblasts were harvested at different passages, 
mammary epithelial cells before and during different stages of BRCA1 siRNA 
transfection and fixed with methanol: acetic acid (3: 1). Slides were stained with 10% 
Giemsa or DAPI and a total of 100-200 cells were scored for the presence of anaphase 
bridges. 
2.11.2 Metaphase chromosome analysis 
Cell monolayers were grown in 25 and 75 cm2 flasks until 80-90% confluency 
and then treated for 2-6 hours at 37°C by addition of 20p1 of demecolcine (colcemid) 
solution (10pg/mL in HBSS, Sigma-Aldrich) to the culture. The culture medium and 
PBS wash were retained during trypsinisation and combined with the harvested cells, 
which were then centrifuged at 400 g in a 50 mL tube for 8 min. The cell pellets were 
resuspended in 10 mL of hypotonic buffer (75mM KCI) and placed in a 15 mL tube at 
37°C for 12 min. This was followed by addition of 1 mL of ice cold fixative (3: 1, 
methanol: acetic acid) and a5 min incubation on ice. Cells were centrifuged again at 
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400 g for 8 min and resuspended twice in 10 mL fixative, followed by 5 min incubation 
on ice and centrifugation. Preparations were stored in 15 mL fixative at -20°C. 
2.12 AgNOR silver staining 
Representative sections of the resected brain tumours were selected for the 
AgNOR silver staining technique. Four-micron unstained sections were obtained from 
these areas to perform the stain. The modified AgNOR silver staining technique 
introduced by Ploton et al. (1982) was used. The tissues were deparaffinised in several 
changes of xylene and descending alcohol concentrations, followed by rehydration in 
several changes of ultrapure distilled water. The tissues were then incubated in acid 
alcohol (3 parts ethanol :2 parts acetic acid) for 5 min and several times rinsed in 
ultrapure distilled water. The sections were then incubated with silver nitrate solution in 
a dark humidified chamber for 30 min. The silver staining solution consisted of two 
parts of a 50% solution of silver nitrate and one part 2% gelatine in 1% formic acid 
solution. The sections were then incubated with a 10% solution of sodium thiosulfate 
solution for 5 min, washed in distilled water, dehydrated in graded alcohol, xylene and 
coverslipped. 
2.13 TUNEL apoptotic cell detection in paraffin-embedded tissues 
In the TUNEL assay, the enzyme terminal deoxynucleotide transferase (TdT) 
adds fIuorescently-labelled dUTP onto broken DNA strands. TUNEL (terminal 
deoxynucleotidyl transferase [TdT]-mediated deoxyuridinetriphosphate [dUTP] nick end 
labelling) assay was performed as described by the manufacturer (Promega, MA, 
USA). Briefly, paraffin embedded tumour tissues (5pm paraffin sections) were 
deparaffinised in toluene, washed in ethanol 100% and then rehydrated by sequentially 
immersing slides through graded ethanol washes for 3 minutes each at room 
temperature. Tissues were permeabilized with 20pg/mL proteinase K for 10 minutes at 
room temperature. The tissue sections were refixed in 4% paraformaldehyde solution 
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in PBS for 5 minutes at room temperature. The sections were equilibrated with 1 00p1 of 
equilibration buffer (200mM potassium cacodylate pH 6.6,25mM Tris-HCL pH 6.6, 
0.2mM DTT, 0.25mg/mL BSA and 2.5mM cobalt chloride) for 10 minutes. Tissues were 
incubated with TdT (Terminal deoxynucleotidyl Transferase) enzyme reaction mixture 
(TdT enzyme, biotinylated nucleotide mix, and equilibration buffer) at 37°C for 1 hour 
inside a humidified chamber to allow end-labelling reaction to occur. The reaction was 
terminated in 2x SSC for 15 minutes and washed in PBS for 2x5 minutes. Immersing 
the slides in 0.3% hydrogen peroxidase for 3 minutes at room temperature blocked 
endogenous peroxidase. Tissue sections were incubated for 30 minutes in streptavidin 
HRP solution at a dilution of 1: 500, washed in PBS and incubated for 10 minutes in 
DAB chromogen solution. Slides were stained with H-E and mounted in Canada 
balsem. 
HL-60 cells were used as a positive control by treating them with DNase I to cause 
DNA fragmentation. For negative controls, sections were incubated without TdT 
enzyme. 
2.14 PCR ELISA for detection of Mycoplasma 
A photometric enzyme immunoassay was used for the detection of PCR- 
amplified DNA of Mycoplasma in cell cultures according to the manufacturer (Roche 
Diagnostics GmbH, Mannheim, Germany). Briefly, cells were centrifuged and lysed in 
an alkaline lysis solution then neutralised. A conserved Mycoplasma-specific region of 
the DNA was amplified in the presence of a digoxigenin-labelled dUTP (DIG-dUTP). 
The DIG-labelled amplicon was denatured by NaOH treatment. The single stranded 
PCR product was hybridised to a biotin labelled capture probe and immobilised on 
streptavidin coated microtiter plate wells. The immobilised amplicon was detected by 
means of an antibody to digoxigenin coupled to horseradish peroxidase (anti-DIG- 
POD) and a sensitive peroxidase substrate. 
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2.15 Statistical Analysis 
The Mann-Whitney U test and the two-tailed Student's t-test were applied to 
compare the mean ± standard error (S. E. ) or standard deviation (S. D. ) values. A P- 
value < 0.05 was considered as statistically significant. Linear regression correlation 
was analysed by the Spearman rank correlation coefficient. 
68 
Chapter 3: Identification of subpopulations of cells with different telomere lengths 
CHAPTER 3 
IDENTIFICATION OF SUBPOPULATIONS OF CELLS WITH DIFFERENT 
TELOMERE LENGTHS IN MOUSE AND HUMAN CELL LINES BY FLOW-FISH 
3.1 Introduction 
Telomeres are specialized protective structures at chromosome ends, which 
undergo dynamic changes in each cell cycle (Blackburn, 2000). Telomere dynamics 
involves mechanisms of telomere degradation, as well as mechanisms of telomere 
renewal. Telomere degradation results from the end replication problem (Olovnikov, 
1973), exonuclease activity (Wellinger et al., 1996) and DNA breakage within telomeric 
sequences due to oxidative damage (von Zglinicki, 2002). Telomere renewal is 
achieved either through the activity of telomerase or recombination mechanisms known 
as the ALT (alternative lengthening of telomeres) pathway (Blackburn, 2000). The 
interplay between opposing mechanisms of degradation and renewal is usually 
mediated by telomere binding proteins (Smogorzewska et al., 2000). These proteins 
regulate telomerase in either a positive or negative fashion on the basis of telomere 
length information (Smogorzewska et al., 2000). Mechanisms that regulate ALT are not 
clear at present. 
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In normal human somatic cells telomere degradation mechanisms are dominant 
and after a limited number of divisions cells will eventually reach telomere-mediated 
senescence, which can be recognized by the formation of nuclear foci comprising 
dysfunctional telomeres and numerous DNA damage response factors (d'Adda di 
Fagagna, 2003). In human immortalized cell lines telomere length is generally stable 
suggesting that in these cells an equilibrium exists between telomere degradation and 
telomere renewal (Blackburn, 2000). 
There is far less information about the status of telomere length in primary 
versus immortalized mouse cell lines. However, results exist for various normal mouse 
strains, which indicate much longer and more heterogeneous telomeres in comparison 
with human cells (Zijlmans et al., 1997). It is noteworthy that in many genetically 
modified mouse strains telomeres are either significantly shorter or longer in 
comparison with wild type animals. For example, telomeres in telomerase deficient 
mice shorten gradually in each successive generation (Blasco et al., 1997). In contrast, 
telomeres in scid (severe combined immunodeficiency) mice, which have defective 
DNA-PK, an enzyme involved in DNA double-strand break repair (see section 1.6.3), 
are abnormally elongated (Hande et al., 1999). Interestingly, mice deficient in Ku, 
another protein involved in DNA double strand break repair (see section 1.6.3), show 
either shorter or elongated telomeres in comparison with wild type animals (d'Adda di 
Fagagna et al., 2001; Samper et al., 2000). Therefore, telomere length in mouse cells 
appears to fluctuate more than telomere length in human cells possibly as a result of 
mouse telomeres being naturally long. 
The assessment of telomere dynamics is critically dependent on telomere 
length measurement techniques. Several techniques are available including Southern 
blot analysis, quantitative fluorescence in situ hybridisation (Q-FISH), flow-FISH, 
hybridisation protection assay (HPA), quantitative PCR and single telomere length 
analysis (STELA). Each technique has advantages and limitations. For example, 
Southern hybridisation and flow-FISH can determine average telomere length whereas 
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Q-FISH provides information about telomere length in individual chromosomes. Unlike 
Southern blot, the HPA quantifies the telomeric repeats and does not include 
subtelomeric regions (Nakamura et al., 1999; Freulet-Marriere et al., 2004). Another 
method to measure average telomere lengths is quantitative PCR (Förstemann et al., 
2000; Cawthon, 2002). Quantitative PCR, which is inherently sensitive and accurate, 
has been hampered by the lack of appropriate primer binding sites (Förstemann et al., 
2000; Cawthon, 2002). In addition to Q-FISH, which can measure the length of 
telomeres from individual chromosomes, a new elegant method called STELA was 
recently developed by Baird et al. (2003). However, in contrast to Q-FISH, which 
measures all telomeres, so far STELA was used to measure telomeres in only XpYp 
chromosome at a time. A distinctive advantage of flow-FISH over other techniques is 
that it can accurately identify sub-populations of cells with different telomere length in a 
given cell population. For example, pioneering flow-FISH experiments revealed that 
different subpopulations of human peripheral blood lymphocytes have different 
telomere lengths (Rufer et al., 1998). 
The first aim of this study was to set up the flow-FISH method in our laboratory 
and assess its accuracy in comparison with other methods in particular Southern blot 
and Q-FISH. We used a pair of mouse lymphoma cell lines with well defined telomere 
lengths as calibration standard for flow-FISH and unexpectedly identified the presence 
of subpopulations of cells with different telomere lengths in several cell lines. Results of 
this analysis are described in detail below. 
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3.2 Results 
3.2.1 Establishment of flow-FISH protocol for telomere length measurement 
The first task in this study was to set up the flow-FISH method in our laboratory. 
Initially, the flow-FISH technique was applied on mouse lymphoma LY-R and LY-S 
cells. These cells have well defined telomere lengths as determined by Q-FISH in one 
of our earlier studies i. e. LY-R cells have, on average, 7-8 times longer telomeres than 
LY-S cells (Mcllrath et al., 2001). Telomeres in LY-S cells are -r 7 kb whereas 
telomeres in LY-R cells are - 50 kb long (Mcllrath et al., 2001). Given that one cell line 
has short telomeres and the other one long telomeres, these cell lines can potentially 
be used as calibration standards for flow-FISH. An example of LY-R cells hybridised 
with a telomeric PNA probe before flow-FISH analysis is shown in Figure 3.1. Our flow- 
FISH measurements of telomere fluorescence intensities (TFIs) indicated a good 
agreement with Q-FISH. For example, in several independent experiments we 
observed Q-FISH-like differences in TFIs between LY-R and LY-S cells (results not 
shown; for flow-FISH profiles of LY-R and LY-S cells see below). This is in line with 
results generated in the laboratory of our collaborator, Dr. Maria Blasco, where LY-R 
and LY-S cells are used routinely as calibration standards for flow-FISH (Samper et al., 
2002; Espejel et al., 2002; Franco et al., 2004). Because results of TFI measurements 
in LY-R and LY-S cells were highly reproducible we generated a calibration curve for 
the conversion of TFI into base pairs (bp) of DNA using published Q-FISH results 
(Mcllrath et al., 2001) and our own flow-FISH measurement in LY-R and LY-S cells 
(Figure 3.2). Therefore, the conversion of TFI values from any cell line into bp of 
telomere length can be carried out using the formula y=4.13 x+2.56 (Figure 3.2 A). 
To test the formula we performed a correlation analysis of telomere length 
measurement between the classical Southern blot method and flow-FISH 
measurements generated for six human lymphoblastoid cell lines. This analysis 
revealed a good correlation with the R2-value of 0.90 (Figure 3.2 B). 
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Figure 3.1 LY-R cells floating in PBS buffer hybridised with a FITC conjugated (C3TA2)3 
PNA probe and the nuclei counterstained with propidium iodide (PI) ready for flow- 
FISH analysis. 
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Figure 3.2 (A) A calibration curve generated using published 0-FISH results (Mcllrath 
et al., 2001) and our own flow-FISH measurements (TFI) in LY-R and LY-S cells. (B) 
Correlation analysis of telomere length using flow-FISH and Southern hybridisation in 
six lymphoblastoid cell lines (for the list of cell lines see table 2.2). 
3.2.2 Telomere length dynamics in mouse lymphoma cell lines 
Above results indicate that the flow-FISH method generates highly reproducible 
results in our hands and that these results are remarkably similar to those produced in 
the laboratory of our collaborator Dr. Maria Blasco. Therefore, we wanted to assess 
telomere dynamics in LY-R and LY-S cells over time using flow-FISH. Assessment of 
telomere dynamics in these cells is interesting for a specific reason described below. 
The mouse lymphoma cell line, LY-S, shows extreme sensitivity to ionising radiation 
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(IR), in contrast to the parental cell line, LY-R, which has normal sensitivity to IR 
(Alexander and Mikulski, 1961). The process of transformation of LY-R cells into LY-S 
cells is spontaneous and occurs after prolonged in vitro culture. Sensitivity of LY-S cells 
to IR results from impaired repair of DNA double strand breaks (DSBs) although many 
known DSB repair components in LY-S cells are normal (Mcllrath et al., 2001). As 
mentioned above LY-R cells have much longer telomeres (- 50 kb) than LY-S cells (- 7 
kb (Mcllrath et al., 2001). This difference in telomere length is not due to differences in 
telomerase activity i. e. both cell lines showed similar levels of telomerase activity as 
was verified by RTQ-TRAP (real-time quantitative telomeric repeat amplification 
protocol) (Figure 3.3). Therefore, the process of spontaneous transformation of LY-R 
cells into LY-S cells must be accompanied by a dramatic loss of telomeric DNA and we 
wanted to investigate whether this loss occurs gradually or in more dramatic episodes. 
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Figure 3.3 Telomerase activity as determined by RTQ-TRAP in LY-S and LY-R cells. 
Pooled results are shown (n=6) indicating telomerase activity as a percentage relative 
to that found in the prostate adenocarcinoma cell line PC-3. NTC: negative control; 
TSR8 oligonucleotide template: positive control. 
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The above two cell lines were grown for -- 80 population doublings (PDs) and 
telomere length was monitored by flow-FISH after, on average, each 9 PDs. LY-R cells 
had expected telomere length and flow-FISH parameters indicated the presence of a 
single cell population up to PD - 20 (Figures 3.4 A and C). However, after - 20 PDs 
two subpopulations of cells were identified within the LY-R cell line, one of which had 
telomere length similar to the original population of LY-R cells, but the remaining 
subpopulation had significantly shortened telomeres in comparison to the original 
population of LY-R cells (Figures 3.4 B and C). We estimated that the subpopulation of 
cells with longer telomeres had average length of 43.0 kb whereas the subpopulation 
with shorter telomeres had average length of 16.6 kb. 
Subpopulations of cells with different telomere lengths were defined by two 
parameters: (i) detection of two or more separate peaks on the FL 1 (FITC) channel 
representing telomere fluorescence in gated Go/G, cells and (ii) two separate 
populations of cells in a FL1 vs. FL3 dot plot (see Figure 3.4 B left panel). Within the 
subpopulation of cells with shorter telomeres two clear peaks were identified on the 
FL1 channel representing telomere fluorescence (Figure 3.4 B, third panel). This 
suggests that the group of cells with shorter telomeres may consist of two overlapping 
subpopulations of cells with different telomere length. However, these two putative 
subpopulations of cells remained indistinguishable by the above criteria until the end of 
the experiment (Figure 3.4 C). 
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Figure 3.4 (A) A typical flow-FISH profile of LY-R cells at the beginning of the 
experiment. A dot-plot profile in the first box represents a combination of FL3 
channel [the DNA content, excluding subG0/G, peaks and polyploid cells, after 
staining nuclei with PI (propidium iodide)] and FL1 channel [the telomere 
fluorescence after FITC (fluorescein isothyocianate) staining]. One single 
population of cells was distinguished at PDs <20 as indicated by the presence of a 
single group of cells in the dot-plot or a single peak on the FL1 channel (FITC). 
Histograms in second and third box show PI and FITC profiles separately. (B) A 
gate (E) was drawn in Go/G, of the cell cycle distribution histogram to obtain a 
histogram of telomere fluorescence for the gated region. Two cell subpopulations 
with different telomere lengths were distinguished at PDs >20 as indicated on FL3 
vs. FL1 dot plot (two groups of cells) and in the FITC histogram (two separate 
peaks). (C) Subpopulations of cells with different telomere lengths at PDs 1-73. A 
dot represents one cell subpopulation. (D) 0-FISH image of LY-R interphase cells. 
Note clear differences in telomere fluorescence intensity between three middle cells 
and cells at the periphery of the image. 
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The 0-FISH technique was used to confirm the existence of two cell 
subpopulations with different telomere lengths. For this analysis, 15 cells (standard 
number for Q-FISH) were randomly selected in post-PD20 cell culture and TFI was 
determined (Figure 3.4 D and Table 3.1). Using the method referred to as cell 
clustering (see Materials and Methods, section 2.9) two cell subpopulations with 
different telomere lengths were identified in the LY-R cell line (Table 3.1). These results 
were remarkably similar to flow-FISH results even though the number of cells analysed 
by Q-FISH was low. For example, the subpopulation of cells with longer telomeres 
comprised 30-60% of LY-R cells as observed by flow-FISH (Figure 3.5), and 0-FISH 
measurements indicated that the subpopulation of cells with longer telomeres 
comprised 40% of LY-R cells (Table 3.1). Differences between mean TFIs of two 
subpopulations were significant by both methods. Therefore, the existence of cell 
subpopulations with different telomere lengths in the LY-R cell line is confirmed by 0- 
FISH. This suggests that the process of telomere loss in LY-R cells during their 
spontaneous transformation into LY-S cells is not gradual but may occur in rapid 
episodes after which telomere length remains stable for a long time (Figure 3.4 C). 
Figure 3.5 Telomere length dynamics in LY-R cells. Percentages are shown for 
subpopulations of cells with average telomere length 43.0 kb (TFI 1) and 16.6 kb (TFI 
2), respectively. 
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Table 3.1 Telomere fluorescence intensity (TFI) in LY-R cells in arbitrary units as 
measured by Q-FISH. A cell cluster represents a group of cells in which TFI values do 
not differ by >50%. For example cell number 8 belongs to the cluster of cells 1-8. Cell 
clusters in bold represent two subpopulations of cells with significantly different 
average telomere lengths (p<0.01, t-test). 
Cell 
Number 
TFI Cell 
cluster 
Mean S. E. 
1 1803 1-4 
2 1875 1-5 
3 2106 1-7 
4 2356 1-7 
5 2788 1-8 2552.6 459.4 
6 2893 1-8 
7 2903 1-8 
8 3697 1-8 
9 6142 2-8 
10 7167 8-14 
11 7822 8-15 
12 8001 9-15 8077.0 226.1 
13 8599 9-15 
14 8941 9-15 
15 9867 9-15 
In contrast to LY-R cells, analysis of telomere fluorescence in LY-S cells by 
flow-FISH showed a single cell population throughout the experiment (Figure 3.6). 
To exclude the possibility that the presence of subpopulations of cells with 
different telomere length in the LY-R cell line was an artefact associated with cell 
culture, LY-R and LY-S cells were obtained from another source (laboratory of M. 
Blasco, Madrid) and telomere length analysed as above. Similarly, this analysis 
revealed presence of two subpopulations of cells with different telomere lengths in LY- 
R cells after - 50 PDs but the lack of multiple subpopulations of cells in the LY-S cell 
line (Figure 3.7). 
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Figure 3.6 A typical flow cytometry profile of LY-S cells (A) and analysis of 
subpopulations of cells with different telomere lengths at PDs 1-73 (B). One single 
population was distinguished on FL3 vs. FL1 dot-plot and in the FL1 (FITC) histogram. 
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Figure 3.7 Two subpopulations of cells at PDs >50 in the LY-R cell line (A) and single 
population in the LY-S cell line (B). LY-R and LY-S cells for this analysis were obtained 
from the laboratory of Dr. Maria Blasco. 
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Since telomeres in some subpopulations of LY-R cells were short and 
potentially comparable in length to LY-S cells (see Figures 3.4 C, 3.6 B and 3.7 A) 
there is a chance that LY-R cells could become "contaminated" with LY-S because 
both cell lines have been maintained simultaneously. Alternatively, the subpopulation of 
cells with shorter telomeres in LY-R cells may arise as a result of spontaneous 
transformation, which eventually results in LY-S cells (Mcllrath et al., 2001). To exclude 
these possibilities, both LY-R and LY-S cells were irradiated with 2.0 and 5.0 Gy 
gamma rays and flow cytometry parameters and telomere length monitored before and 
after irradiation. IR induces cell killing either through apoptosis or necrosis and these 
events can be identified by flow cytometry. Frequencies of apoptotic and necrotic cells 
induced by IR were expected to be higher in radiosensitive LY-S cells than in LY-R 
cells. The dose of 2.0 Gy induced high levels of apoptotic and necrotic cells in the LY-S 
cell line and as a result the frequency of proliferating cells was markedly reduced 
(Figure 3.8 A). However, after approximately 2-3 PDs LY-S cells recovered and 
frequencies of apoptotic, necrotic and proliferating cells returned to almost normal 
levels (Figure 3.8 A). The dose of 5.0 Gy had much greater effect on LY-S cells and 
most cells died after this dose (Figure 3.8 B). Telomere length measurement in LY-S 
cells after irradiation is shown in Figure 3.8 C and D. 
In contrast to LY-S cells, LY-R cells were much more resistant to IR. The dose 
of 2.0 Gy generated only a slight effect in LY-R cells (Figure 3.9 A), whereas the dose 
of 5.0 Gy had a more pronounced effect but LY-R cells recovered almost completely 
after 2-3 PDs (Figure 3.9 B). There was no change in the frequencies of 
subpopulations of cells with different telomere lengths in LY-R cells after IR (Figure 3.9 
C and D) thus excluding the possibility that the observed subpopulations of cells with 
different telomere lengths in LY-R cells may be the result of contamination with LY-S 
cells or that the new subpopulation of cells is sensitive to radiation. Similar results were 
found in the second source (laboratory of Dr. Maria Blasco) of LY-R and LY-S cells 
(Figure 3.10). 
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Figure 3.8 Flow cytometric counts for cycling (proliferating), apoptotic and necrotic 
cells in the LY-S cell line following the dose of 2.0 Gy (A) and 5.0 Gy (B). IR (ionising 
radiation) was administered at day 42 as indicated by arrows. Telomere length 
measurements in LY-S cells (24h, 48h, 96h, and 6 days) after irradiation with 2.0 Gy 
(C) and 5.0 Gy (D). 
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Figure 3.9 Flow cytometric counts for cycling (proliferating), apoptotic and necrotic 
cells in LY-R cells following the dose of 2.0 Gy (A) and 5.0 Gy (B). IR (ionising 
radiation) was administered at day 42 as indicated by arrows. Telomere length 
measurements in LY-R cells (24h, 48h, 96h, and 6 days) after irradiation with 2.0 Gy 
(C) and 5.0 Gy (D). 
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Figure 3.10 Flow cytometric counts for cycling (proliferating), apoptotic and necrotic cells 
in LY-S cells following the dose of 2.0 Gy (A) and 5.0 Gy (B) and in LY-R cells following 
the dose of 2.0 Gy (C) and 5.0 Gy (D). IR (ionising radiation) was administered at day 45 
as indicated by arrows. LY-R and LY-S cells for this experiment were obtained from Dr. 
Maria Blasco's laboratory. 
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Therefore, we conclude that the LY-R cell line contains subpopulations of cells with 
different telomere lengths. This conclusion is in line with published Q-FISH measurements 
of telomere size in LY-R cells, which indicated several-fold differences in the average 
telomere length between individual cells (Wong and Slijepcevic, 2004). 
One way of providing further evidence that two subpopulations of cells exist in 
post-PD20 LY-R cells would be a cloning experiment i. e. analysis of telomere length in 
single cell clones. We attempted to perform such an experiment. However, diluting LY-R 
cells, which grow in suspension, down to a single cell was difficult to verify with the 
methods that we have at our disposal. The best cell dilution that could be verified with a 
high degree of confidence was down to 100 cells. Flow-FISH was then performed on the 
material starting from 100,1000 and 105 and 106 cells and in all cases two subpopulations 
of cells with different telomere lengths were observed with very similar proportions of cells 
with short and long telomeres (Figure 3.11). 
84 
Chapter 3: Identification of subpopulations of cells with different telomere lengths 
0 J 
J 
U- 
10 
102 
0 J 
10 
J 
LL 
I(), 
, 0, 
1o 
0 
0 J 10' 
J 
U- 
I 00 
10, 
10' 
0 
--i 
-, 
i 
O. O ti UýIU 
O 1023 
m_ 
U) 
`- 41 z 
3 
.P 
1023 
I- Z 
Z) 0 U 
i t4 
`F9 
E 
0 023 
'1\ 
;o 
U) I- 
0 0 
E D 
O 
U 
im 
o' 1 
\_ - 01000 
Cc: 8 100000 
911000000 
o 
41 
0 
TH2 
TFI 1 
E 
Figure 3.11 LY-R cells revealed two subpopulations after one week of cell culture 
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3.2.3 Telomere length dynamics in mouse embryonic stem cells 
To investigate if the presence of subpopulations of cells with different telomere 
lengths is more widespread in mouse cell lines, we used a normal mouse embryonic 
stem (ES) cell line, as well as the mouse ES cell line in which both copies of BRCA1 
were disrupted by gene targeting (for details see Snouwaert et al., 1999). These cell 
lines were grown for 25-28 PDs and telomere length monitored at six time intervals. To 
check for the presence of subpopulations of cells with different telomere lengths in 
these two cell lines we applied the same parameters as above, i. e. detection of two or 
more clearly separated peaks on the FL1 channel representing telomere fluorescence 
and two or more populations of cells in the FL1 vs. FL3 dot plot. By applying these 
criteria, only a single population of cells was identified in both cell lines throughout the 
experiment (Figure 3.12). However, on some occasions (e. g. at 21.5 PDs in wild type 
ES cells and at 7.2 PDs in BRCA1 deficient ES cells) we identified two peaks in the 
FL1 telomere fluorescence channel but these were not completely separated from each 
other (Figure 3.12) thus not fulfilling set criteria for detecting subpopulations of cells 
with different telomere length (see above). However, the possibility cannot be excluded 
that these peaks arise as a result of two overlapping subpopulations of cells with 
different telomere lengths, which cannot be clearly detected using the flow-FISH 
method. 
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3.2.4 Telomere length dynamics in human non-ALT cell lines 
To investigate if subpopulations of cells with different telomere lengths exist 
within human cell lines, we investigated telomere length by flow-FISH in six different 
human lymphoblastoid cell lines. Two cell lines were derived from normal individuals, 
two cell lines were from carriers of BRCA1 mutations and remaining two from carriers 
of BRCA2 mutations. By applying the same criteria as above two subpopulations of 
cells with different telomere lengths were observed in the cell line, GM14622, from one 
of the carriers of BRCA2 mutation (Figure 3.13 A). We estimated that the 
subpopulation of cells with longer telomeres had average telomere length of 18.5 kb, 
whereas the subpopulation with shorter telomeres had average length of 6.7 kb. The 
presence of subpopulations of cells with different telomere length in the GM14622 cell 
line was also observed after Southern blot analysis i. e. the bi-modal distribution 
observed in lane 6 (Figure 3.13 B) and was also confirmed by Q-FISH (Figure 3.13 C 
and Table 3.2). Cell subpopulations with different telomere lengths remained stable 
during the observed time (Figure 3.14). 
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Figure 3.13 (A) Flow cytometry parameters in the human lymphoblastoid cell line, 
GM14622, from a BRCA2 carrier. Note the presence of two cell subpopulations on the 
FL1: FL3 dot plot and on a FITC channel. (B) Southern blot analysis of telomere length 
in six different human lymphoblastoid cell lines. Cell lines from Lane 1- Lane 6: 1: 
G M00893; 2: G M01945; 3: 0M14090; 4: GM 13705; 5: GM 14170 and 6: GM 14622. 
MWM: molecular weight marker. * the bulk of telomeric signal was concentrated in a 
narrow smear around 21 kb and in a smear below this point. (C) A FISH image of 
interphase GM14622 cells with clearly identifiable different telomere signal intensities. 
Z 
TFI I I ýI 
TFI1 
FITC 
TFI1 TFI2 
89 
MWM 123456 
Chapter 3: Identification of subpopulations of cells with different telomere lengths 
Table 3.2 Telomere fluorescence intensity (TFI) in GM14622 cells in arbitrary units as 
detected by Q-FISH. Two subpopulations of cells (cell clusters in bold) are defined as 
0245 11 14 
Population doublings 
in Table 3.1 and the difference in mean TFI between two subpopulations is statistically 
significant (p<0.01, t-test). 
Cell 
Number 
TFI Cell 
cluster 
Mean S. E. 
1 1376 1-3 
2 1678 1-3 
3 1987 1-4 
4 2724 1-6 2395.8 348.9 
5 3015 2-6 
6 3595 3-7 
7 5122 4-8 
8 6618 6-14 
9 7858 7-15 8258.3 520.7 
10 8367 7-15 
11 8760 7-15 
12 8766 7-15 
13 8942 7-15 
14 9670 7-15 
15 10222 7-15 
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Figure 3.14 Telomere length dynamics in the human lymphoblastoid cell line 
GM14622. Percentages of cells from two different subpopulations (TFI 1 and TFI 2). 
Average telomere length for TFI 1 was 18.5 kb and for TFI 2 was 6.7 kb. 
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The GM14622 cell line had unusually long telomeres, on average 3 times longer 
than telomeres in the rest of cell lines (data not shown). Examination of telomere length 
by Southern blot analysis confirmed that this cell line had extremely long telomeres and 
the majority of telomeric signal was concentrated in a narrow smear around 21 kb 
(Figure 13 B). This pattern is similar to the pattern usually observed in ALT positive 
cells (Grobelny et al., 2000). However, examination of telomeres in metaphase 
GM14622 cells did not reveal telomere heterogeneity in individual chromosomes typical 
of ALT cells (data not shown). In addition, all six lymphoblastoid cell lines showed 
low/moderate levels of telomerase activity as was detected by RTQ-TRAP (Figure 
3.15) suggesting that the GM14622 cell line is not an ALT cell line i. e. ALT cells usually 
lack detectable telomerase activity. 
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Figure 3.15 Telomerase activity as measured by RTQ-TRAP in normal, BRCA1 and 
BRCA2 deficient lymphoblastoid cell lines. Pooled results are shown (n=6) indicating 
telomerase activity as a percentage of the prostate adenocarcinoma cell line PC-3 
telomerase activity. NTC: negative control; TSR8 oligonucleotide template: positive 
control. 
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We have also analysed telomere length in three normal primary fibroblast cell 
lines and primary fibroblast cell lines from nine patients with different DNA damage 
response defects. We observed only a single population of cells in all analysed 
fibroblast cell lines (Figure 3.16). 
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Figure 3.16 A representative example of a flow cytometry dot-plot and histograms 
obtained by flow-FISH analysis of telomere length in fibroblasts, in this case a normal 
fibroblast cell line (GM09503). One single population was distinguished on FL3 vs. FL1 
dot plot and in the FL1 (FITC) histogram. 
3.2.5 Telomere length dynamics in human ALT cell lines 
The presence of cell subpopulations with different telomere lengths in the 
human cell line GM14622 which has unusually long telomeres and the complete 
absence of cell subpopulations with different telomere lengths in 18 human cell lines 
with a typical average telomere length (12 fibroblast cell lines and 6 lymphoblastoid cell 
lines, see above) suggest that human cell lines with long telomeres may be more 
susceptible to the formation of cell subpopulations with different telomere lengths than 
cell lines with normal telomere length. This possibility can be tested by analysing 
human ALT cell lines. ALT cell lines show great telomere length heterogeneity and 
significantly longer telomeres than human non-ALT cell lines (Henson et al., 2002). For 
this purpose four verified ALT cell lines were used: U2-OS; WI-38 VA13/2RA; SK LU1; 
and G-292 (Henson et al., 2002). By applying the same criteria as above we observed 
three cell subpopulations with different telomere lengths in the U2-OS cell line (Figure 
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3.17). These three subpopulations with average telomere lengths 23.7, 39.8 and 64.3 
kb remained stable for at least 20 PDs (Figure 3.18). Q-FISH analyses confirmed the 
existence of three cell subpopulations with different telomere lengths in this cell line 
(results not shown). We did not observe subpopulations of cells with different telomere 
lengths in the remaining three ALT cell lines (Figure 3.19). Given that 1 out of 4 
analysed ALT cell lines showed multiple cell subpopulations with different telomere 
lengths as opposed to 1 out of 18 non-ALT cells lines this suggest that human cell lines 
with longer than normal telomeres could be more susceptible to the process that 
causes appearance of cell subpopulations with different telomere lengths than cell lines 
with normal telomere length. 
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Figure 3.17 Flow-FISH profiles of human ALT cell lines U2-OS. Note the presence of 
three subpopulations (dot plot and FITC channel) of cells with average telomere 
lengths of 23.7,39.8 and 64.3 kb. PD: population doubling 
93 
Chapter 3: Identification of subpopulations of cells with different telomere lengths 
FL3 LIN 
FL1 LOG 
L 
O) 
C 
N 
0) 
E 
0 
A 
80 
70 
60 
50 
40 
30 
20 
10 
0 
10 -i QTFI1 
QTFI2 
8t .m , zi 
O 
ö ga 
CL 
a OL 
27', 
`ice 
13 
BC 
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Figure 3.19 Flow-FISH profiles of human ALT cell lines: WI-38 VA13/2RA (A), SK LU1 
(B) and G-292 (C). One single population was distinguished on FL3 vs. FL1 dot plot 
and in the FL1 (FITC) histogram. 
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3.3 Discussion 
The initial aim of this study was to set up the flow-FISH method in our 
laboratory. Using a pair of mouse lymphoma cell lines LY-R and LY-S which have well 
defined telomere lengths (Mcllrath et al., 2001) we have been able to show 
reproducibility of TFI measurements by flow-FISH and our results were in good 
agreement with published Q-FISH (Mcilrath et al., 2001; Wong and Slijepcevic, 2004) 
or flow-FISH (Espejel et al., 2002; Samper et al., 2002) results. We have also designed 
a procedure, which allows conversion of TFI values generated by flow-FISH into kbs of 
DNA length and verified this using several human lymphoblastoid cell lines. 
Having verified accuracy and reproducibility of our flow-FISH method we then 
analysed telomere dynamics in several different cell lines. Interestingly, our results 
suggest that at least one out of four analysed mouse cell lines contained two 
subpopulations of cells with different telomere lengths (Figures 3.4 and 3.7). In 
addition, two subpopulations of cells with different telomere lengths were identified in 1 
out of 18 analysed human non-ALT cell lines. Finally, we observed multiple 
subpopulations of cells with different telomere lengths in 1 out of 4 analysed human 
ALT cell lines. Differences in telomere lengths between subpopulations of cells were 
significant in all cases and we name this phenomenon TELEFLUCS (TElomere LEngth 
FLUtuation in Cell Subpopulations). It is possible that TELEFLUCS could be more 
widespread in mouse cell lines as shown by the observations of two distinct but not 
clearly separated peaks representing telomere fluorescence in two mouse ES cell lines 
(Figure 3.12). To clearly show that these peaks are due to the existence of two 
subpopulations of cells with different telomere lengths further improvements in flow- 
FISH methodology are required. One potential improvement of interest is multicolour 
flow-FISH, which allows simultaneous detection of telomeres and subpopulations of 
cells carrying specific markers that can be detected by appropriate antibodies 
(Baerlocher and Lansdorp, 2003). 
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It is also interesting that the only TELEFLUCS positive human non-ALT cell line 
had unusually long telomeres (Figure 3.13). This suggests that cells with long 
telomeres may be potentially more susceptible to TELEFLUCS than cells with short 
telomeres. In line with this possibility, we observed only a single cell population with 
uniform telomere length in the mouse cell line, LY-S, with short telomeres, which are 
comparable in length to human telomeres, whereas mouse cells with expected average 
telomere length were either TELEFLUCS positive, or suspected to be TELEFLUCS 
positive as shown by the observation of two distinct but not clearly separated peaks on 
the FL channel representing telomere fluorescence in two mouse ES cell lines (Figure 
3.12). Also, human cells with expected average telomere length completely lacked 
TELEFLUCS, whereas 1 out of 4 analysed human ALT cell lines, regularly associated 
with long telomeres, showed multiple subpopulations of cells with different telomere 
lengths (see above). It is now of interest to analyse larger number of ALT cell lines by 
flow-FISH and determine the extent of TELEFLUCS in these cell lines. The use of flow- 
FISH could also enable more precise analysis of telomere dynamics in ALT positive 
human cell lines and help elucidating mechanisms underlying ALT. 
It is noteworthy that TELEFLUCS can reliably be detected only by flow-FISH. 
For example, analysis of telomere restriction fragments by Southern hybridisation is 
frequently non-informative in mouse cells. In human cells Southern hybridisation 
cannot identify TELEFLUCS unambiguously. For example, Southern blot analysis in 
the only TELEFLUCS positive human cell line revealed that the bulk of telomeric signal 
was concentrated in the narrow smear around 21 kb (Figure. 4.13 B). However, this 
may also mean that this bulk of telomeric DNA originates from chromosomes with 
exceptionally long telomeres not necessarily from different subpopulations of cells. 
Similarly, TELEFLUCS cannot be always accurately detected by Q-FISH because this 
technique typically relies on the information from 15-20 cells. However, we analysed 
LY-R and GM14622 cells by Q-FISH and confirmed the presence of cell 
subpopulations with different telomere lengths (Tables 3.1 and 3.2). This was possible 
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because two subpopulations of cells with different telomere lengths were approximately 
equal numerically in LY-R and GM14622 cell lines (see above). However, if one 
subpopulation is much smaller than the other then Q-FISH becomes statistically 
unreliable because of low numbers of cells that are typically analysed by this 
technique. Analysing large numbers of cells by Q-FISH is not practical. In contrast, 
flow-FISH analyses large numbers of cells (thousands), provides information on 
proportions of cells with different telomere lengths and as a result it is statistically much 
more reliable. 
Mechanisms of TELEFLUCS are not known. Sudden appearance of new 
subpopulations of cells within the LY-R cell line with shorter telomeres in comparison 
with the original population of cells suggest dramatic loss of telomeric DNA. Dramatic 
loss of telomeric DNA termed TRD (telomere rapid deletion) has been described in 
yeast (Li and Lustig, 1996) and it was proposed that a similar mechanism exists in 
human and mouse cells (Lustig, 2003). In line with this possibility recent studies 
indicate that a more dramatic loss of telomeric DNA could occur through the formation 
of extra-chromosomal telomeric circles (Cesare and Griffith, 2004; Wang et al., 2004). 
It is therefore possible that subpopulations of cells with short telomeres in the LY-R cell 
line may have arisen as a result of these or similar mechanisms. However, 
TELEFLUCS reflects not only a dramatic loss of telomeric DNA but also its dramatic 
gain. For example, flow-FISH analysis of the human non-ALT cell line, GM14622, 
showed two subpopulations of cells, one with telomere length typical of most human 
cell lines and the other subpopulation with unusually long telomeres (Figure 3.13). It 
has been previously shown that individual telomeres in ALT cells can rapidly shorten 
and elongate (Murnane et al., 1994). This is consistent with the role of telomere- 
telomere recombination, which has been shown to occur in GM847 cells (Dunham et 
al., 2000), as the principal mechanism of ALT telomere maintenance as 
recombination/copy switching has the potential to generate such telomere length 
dynamics. Also, a human ALT cell line. U2-OS, showed multiple subpopulations of cells 
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with different telomere lengths (Figure 3.17) and according to our estimate the 
subpopulation with the longest telomeres had an average telomere length of 64 kb. 
Therefore, significant gains of telomeric DNA associated with TELEFLUCS may occur 
by both ALT and non-ALT related mechanisms. Future studies are now required to 
examine mechanisms of TELEFLUCS. 
Based on the above results, as well as published results, we would like to 
propose that flow-FISH should be used as a method of choice for the estimate of 
average telomere length when human blood samples are used as a source of cells for 
telomere length measurement. The arguments for this proposal are summarized in 
Table 3.3, which also contains description of advantages and disadvantages of each 
technique used for this purpose. While some other techniques provide more sensitive 
assessments of telomere length in individual chromosomes (Q-FISH, STELA) or have 
better resolutions (quantitative PCR, HPA) there is no technique which is (i) better in 
detecting subpopulations of cells with different telomere lengths or (ii) faster than flow- 
FISH (see above). While Q-FISH and Southern blot can detect subpopulations of cells 
with different telomere lengths in some cases, the information provided by these two 
techniques is statistically far less reliable than that provided by flow-FISH (see above). 
The importance of using flow-FISH when measuring telomere length in human blood 
samples is supported by following arguments. Peripheral blood is a mixture of different 
cell types among which lymphocytes comprise the largest percentage of cells utilized 
for measurement by any technique described in Table 3.3. Peripheral blood 
lymphocytes are not homogeneous population of cells in terms of telomere length 
(Rufer et al., 1998; 1999; Brummendorf et al., 2000; Batliwalla et al., 2000; Baerlocher 
and Lansdorp, 2003) and a technique that can make distinction between these 
subpopulations can provide qualitatively highly relevant information. For example, 
measurement of telomere length in human blood samples is frequently used to make 
important clinical predictions. 
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Cawthon et al. (2003) discovered that people over the age of 60 with shorter telomeres 
in peripheral blood cells have higher mortality rates than people with longer telomeres 
from the same age group. It is almost certain that this analysis may have been refined 
had flow-FISH been used instead of quantitative PCR analysis i. e. flow-FISH combined 
with antibodies against different lymphocyte subpopulations (there is no limit here in 
terms of the number of subpopulations) would generate a profile of telomere lengths in 
cell subpopulations from each sample which potentially could be a better prognostic 
indicator than a single value of average telomere length from a mixture of cell 
subpopulations. In addition, blood cells are ideal for use in flow-FISH as no significant 
preparatory efforts are required and a chosen subpopulation(s) of lymphocytes can be 
selected to serve as internal control(s) i. e. subpopulation with shortest or longest 
telomeres. The availability of appropriate internal controls is crucial for any telomere 
length measurement technique and no method other than flow-FISH has better 
flexibility or adaptability for this purpose. The only disadvantage of flow-FISH is that 
relatively expensive equipment is required but it is likely that any major laboratory will 
have this equipment. 
In conclusion, we show here that at least 1 out of 4 mouse cell lines, 1 out of 18 
human non-ALT cell lines and 1 out of 4 human ALT cell lines exhibit subpopulations of 
cells with different telomere lengths. These results together with points discussed 
above underscore the importance of flow-FISH in telomere length analysis. 
3.4 Summary 
Telomeres are specialized nucleoprotein structures at chromosome ends that 
undergo dynamic changes after each cell cycle. Understanding the mechanisms of 
telomere dynamics is critically dependent upon the ability to accurately measure 
telomere length in a cell population of interest. Techniques such as Southern 
hybridisation, which measures average telomere length, and quantitative fluorescence 
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in situ hybridisation (0-FISH), which can estimate telomere length in individual 
chromosomes, are limited in their capacity to determine the distribution of cells with 
different telomere lengths in a given cell population. We employed flow-FISH to ask a 
question if mouse and human cell lines exhibit subpopulations of cells with different 
telomere lengths. 
Our analysis revealed that at least one out of four analysed mouse cell lines 
showed multiple subpopulations of cells with different telomere lengths. Differences in 
telomere length between subpopulations of cells were significant and we term this 
phenomenon TELEFLUCS (TElomere LEngth FLUctuations in Cell Subpopulations). 
TELEFLUCS was also observed in 1 out of 18 analysed human non-ALT cell lines and 
in 1 out of 4 analysed human ALT cell lines. The existence of cell subpopulations with 
different telomere lengths was confirmed by Q-FISH. These results underscore the 
importance of flow-FISH in telomere length analysis. 
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CHAPTER 4 
ACCELERATED TELOMERE SHORTENING AND TELOMERE DYSFUNCTION IN 
CELLS WITH DEFECTIVE DNA DAMAGE RESPONSE 
4.1 Introduction 
Results presented in the previous chapter indicate that we can use flow-FISH to 
reliably measure average telomere length in human and mouse cell lines. The main 
advantage of flow-FISH over other common methods for telomere length 
measurement, such as Southern blot and Q-FISH, includes the ability to identify 
subpopulations of cells with different telomere lengths. In addition, flow-FISH is a much 
faster and less time-consuming method than Southern blot and Q-FISH and it is ideal 
for analysing large number of samples in a short period of time. We have also 
proposed that flow-FISH should be the method of choice for determining the average 
telomere length in human lymphocytes, especially in combination with immunological 
detection of lymphocyte subpopulations (multi-colour flow-FISH) (Rufer et al., 1998; 
Baerlocher et al., 2003). 
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However, flow-FISH has not been used to analyse telomere length in non- 
hematopoietic cells such as cell lines of fibroblast or of epithelial origin, which are more 
common in many laboratories than lymphocytes. Potential problems with applying flow- 
FISH on fibroblast or epithelial cells include auto-fluorescence. This particularly applies 
to primary cells such as human fibroblasts which senesce in culture i. e. senescent cells 
show increased auto-fluorescence intensities (personal observation). Our preliminary 
results on telomere length measurements by flow-FISH in 11 different human fibroblast 
cell lines indicate that flow-FISH can work in these cells as well (see previous chapter). 
However, it is not known if flow-FISH is sensitive enough to detect telomere shortening 
in human fibroblast/epithelial cell lines during replicative senescence. To test for this 
possibility we used 12 human primary fibroblast cell lines, cultured them for 20-40 PDs 
and measured telomere length by flow-FISH at multiple intervals during this period. As 
a control in this experiment we used telomere length measurement by Southern blot 
analysis. To the best of our knowledge this is the first successful attempt (see below) to 
determine the rate of telomere shortening during replicative senescence of human 
fibroblasts by flow-FISH. 
Primary fibroblast cell lines selected for this study reflect our interest in the role 
of telomeres in DNA damage response. Apart from three cell lines established from 
normal individuals, all other cell lines have been established from patients with genetic 
defects that confer sensitivity to ionising radiation (IR), i. e. these defects cause altered 
DNA damage responses (for the list of cell lines see Table 2.1). Previous studies 
including our own have shown that short telomeres correlate with increased sensitivity 
to IR in lymphocytes from breast, head and neck, kidney, bladder and lung cancer 
patients, as well as in mice lacking mTERC, a gene encoding the RNA component of 
telomerase (Goytisolo et al., 2000; Wong et al., 2000; Mcllrath et al., 2001; Wu et al., 
2003). Another striking example of the correlation between radiosensitivity and short 
telomeres are the LY-R and LY-S cell lines described in the previous chapter. LY-S 
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cells have exceptionally short telomeres and are more sensitive to IR than parental LY- 
R cells (Figures 3.8 and 3.9). 
Alterations in telomere maintenance have been observed in several human 
diseases characterized by defects in DNA damage responses that confer either a high 
sensitivity to IR e. g. ataxia telangiectasia (AT) (Metcalfe et al., 1996; Smilenov et al., 
1997; Pandita and Dhar, 2000; Hande et al., 2001; Tchirkov and Lansdorp, 2003) and 
Nijmegen breakage syndrome (NBS) (Ranganathan et al., 2001) or a minor sensitivity 
to IR e. g. Fanconi anemia (FA) (Metcalfe et al., 1996; Adelfalk et al., 2001). 
Furthermore, proteins involved in the repair of DNA double strand breaks (DSBs), Ku 
and DNA-PKcs, are located at telomeres and their deficiencies cause both telomere 
dysfunction and IR sensitivity (Samper et al., 2000; Goytisolo et al., 2001). Taken 
together above observations argue that mechanisms involved in telomere maintenance 
may be linked with mechanisms that confer sensitivity to IR (Slijepcevic, 2004). 
Although the primary aim of this study was to test whether flow-FISH can be 
used for measuring rates of telomere shortening in human primary fibroblasts during 
replicative senescence, we reasoned that if this approach is successful we can then 
test whether the observed link between telomere maintenance and DNA damage 
response exist in the above cell lines. We also examined telomere maintenance in 
mouse embryonic stem (ES) cells deficient in BRCA1 and human lymphoblastoid cell 
lines established from carriers of BRCA1 and BRCA2 mutations (Table 2.2). BRCA1 
participates in the repair of DNA double strand breaks (DSBs) through homologous 
recombination (see Chapter 1) and lack of functional BRCA1 causes sensitivity to IR 
(Abott et al., 1999; Foray et al., 1999). Also BRCA2 is involved in homologous repair of 
DSBs (Yang et al., 2002). We compared telomere maintenance between mouse ES 
cells in which both copies of BRCA 1 were disrupted by gene targeting (Snouwaert et 
al., 1999) and matching BRCA1+'+ ES cells and telomere length dynamics in 
lymphoblastoid cells heterozygous for BRCA1 and BRCA2 mutations and their 
corresponding controls. 
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4.2 Results 
4.2.1 Telomere length analysis by flow-FISH in human primary fibroblast cell lines 
Having verified the accuracy of flow-FISH measurements in several different 
human and mouse cell lines (see previous chapter) we wanted to examine whether 
flow-FISH can be used to measure the rates of telomere shortening in primary human 
fibroblasts during replicative senescence. The panel of cell lines used in this study is 
shown in Table 2.1. Our panel included cell lines from nine patients with different DNA 
damage response defects and from three normal individuals (Table 2.1). We used 
primary cell lines from patients with AT, NBS, FA, Xeroderma pigmentosum (XP), 
Ligase IV syndrome, a patient with defective Ligase I, a patient with an unknown 
mutation (2BN) and a patient with an Artemis defect. As a result of these defects all 
patients were clinically sensitive to IR (for references see Table 2.1). However, in one 
case sensitivity to IR was absent in vitro and these cells, isolated from a FA patient, 
showed sensitivity to mitomycin C an alkylating agent which induces interstrand and/or 
intrastrand DNA crosslinks that inhibit DNA synthesis. The XP patient from 
complementation group C (XP-C) was also sensitive to IR suggesting that this patient 
may have an additional mutation conferring IR sensitivity i. e. XP patients are only 
sensitive to UV radiation but not to IR (Rogers et al., 2000). 
Telomere maintenance was not examined before in ligase I deficient cells or in 
cells defective in Artemis, a protein involved in DSB repair (Jeggo and O'Neill, 2002; 
Lees-Miller and Meek, 2003). Telomere maintenance was not examined before in cells 
from the above XP-C patient. Also, telomere maintenance was not examined before in 
cells from an immuno-deficient patient characterised by impaired DSB repair and 
extreme IR sensitivity (cell line 2BN, Table 2.1). All known DSB repair components are 
normal in 2BN cells suggesting that an additional factor, defective in these cells, may 
be required for DSB repair (Dai et al., 2003). 
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Previous results indicated that cells sensitive to IR in many cases also showed 
alterations in telomere maintenance (see above). Most cell lines were grown for 
between 20 and 40 PDs and telomere length was measured at multiple points during 
the period of cell culture by flow-FISH but also by classical Southern hybridisation. 
Our preliminary experiments with fibroblast cell lines (see previous chapter) 
indicated higher levels of FITC fluorescence intensity in non-hybridised pre-senescent 
cells (results not shown). These high fluorescence intensity values are probably due to 
the presence of cytoplasmic and nuclear bodies, specific for fibroblasts, which are 
highly auto-fluorescent. The same phenomenon is observed when 
immunocytochemistry-based techniques are applied on fibroblasts (personal 
observation). Therefore, the high level of auto-fluorescence could be the major problem 
for using flow-FISH in senescing fibroblast cells and it does not occur, for example, in 
cells of hematopoietic origin such as lymphocytes or lymphoblastoid cell lines. We 
noticed that auto-fluorescence in fibroblasts increases with the cell passage number 
(see below). 
To avoid the problem of auto-fluorescence our flow-FISH method adapted for 
fibroblasts included subtracting fluorescence intensity values due to FITC 
(fluorochrome used to detect telomeres in our flow-FISH set-up) observed in non- 
hybridised control cells from telomere fluorescence intensity (TFI) values observed in 
cells hybridised with the telomeric PNA probe. Results of our analysis are presented in 
Figure 4.1 (please note that an example of flow-FISH profile in fibroblast cell lines can 
be seen in Figure 3.16). The portions of bars in grey represent TFI in non-hybridised 
cells (Figure 4.1). Interestingly, particularly high fluorescence intensity values in non- 
hybridised cells were measured when cells reached a pre-senescent state in almost all 
DNA damage response defective cell lines in contrast to control lines. We also noticed, 
based on flow cytometry parameters, that pre-senescent cells had a tendency to stick 
to each other more frequently than younger cells and this contributed to the reduction 
of cells analysable by flow-FISH in higher passage cell samples. In parallel to flow- 
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FISH we have also performed Southern blot analysis (see below) for which high 
numbers of cells were required. Given all factors that contributed to the reduction of 
cells available for analysis by flow-FISH we measured TFI values only at 3-5 time 
points during the in vitro culture period (several months) in most cell lines (Figure 4.1). 
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Figure 4.1 Histograms showing fluorescence due to FITC originating from hybridised 
telomeric PNA (open bars) or FITC originating from non-hybridised (grey bars) 
fluorescence (auto-fluorescence) at successive PDs in different cell lines. Telomere 
fluorescence was calculated by subtracting fluorescence intensity values observed in 
control cells not used for hybridisation from telomere fluorescence values after 
hybridisation of cells with telomeric PNA. Note that the non-hybridised fluorescence 
intensities generally increase with PDs. 
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However, in two cell lines we were able to measure telomere length by flow-FISH on 
two occasions only (Figure 4.1). The level of apoptotic cells was low in all cell lines as 
indicated by flow cytometry parameters (data not shown) suggesting that telomere 
shortening observed, results from normal cell proliferation and not apoptosis. In 
addition, we carefully monitored growth rates for each cell line by cell counting and 
analysing flow cytometry parameters, such as proportions of cells in each phase of the 
cell cycle and counting necrotic and apoptotic cells. This analysis indicated 
approximately similar growth rates in all cell lines (with the exception of 2BN cells; 
results not shown) thus excluding increased cell turnover as a potential cause of 
differences in the rates of telomere shortening. Taken together, our results indicate that 
TFI values in all 11 cell lines declined with passage number, as measured by flow-FISH 
(Figure 4.1), suggesting that flow-FISH can detect subtle differences in telomere length 
and has a potential to be used for estimating rates of telomere shortening in fibroblast 
cell lines. 
To directly test this possibility, we generated telomere shortening curves for all 
cell lines (Figures 4.2 A and B) and used mathematical formulas that describe the 
slopes of telomere shortening curves to estimate rates of telomere shortening in each 
cell line in bp/PD (Table 4.1). Conversion of TFI into bp was performed as described in 
the previous chapter. Our results indicated that the rates of telomere shortening varied 
between 120 and 230 bp/PD (Figure 4.2 C), which is in good agreement with published 
results (Metcalfe et al., 1996; Smilenov et al., 1997; Adelfalk et al., 2001; Ranganathan 
et al., 2001; Tchirkov and Lansdorp, 2003). 
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Table 4.1 Calculation of telomere shortening in bp/PD by use of flow-FISH and 
Southern blot hybridis ation methods. Data from 2BN obtained by flow-FISH was 
excluded from the analysis because the telomere shortening rate was u nusually high. 
f low-FISH Southern hybridisation 
Phenotype Cell line PD TFI bp bp/PD PD TRF (bp) bp/PD 
normal (NFB 1) GM09503 0 1.7 9581 60.1 0 9.9 89.7 
3.2 1.4 8342 20.5 9.0 
6.3 1.3 7029 37.9 6.5 
41.2 1.1 7103 - - 
normal (NFB 2) GM08399 0 1.2 7516 93.4 0 10.1 97.7 
3.2 1.0 6690 7.9 7.5 
6.3 0.9 6277 17.4 8.4 
11.1 1.0 6690 - - 
12.7 0.8 5864 - - 
22.1 0.7 5451 - - 
normal (NFB 3) GM04505 - - - - 0 6.6 34.5 
6.3 6.3 
- - - 17.4 6.0 
Artemis CJ179 0 1.6 9168 162.6 0,0 7.7 113.1 
6.3 1.3 7929 7.9 5.8 
7.9 0.7 5451 22.1 5.2 
25.4 0.6 5038 - - 
AT AT1 BR 0 1.4 8342 122.4 0 10.2 177.9 
20.6 1.0 6690 14.2 5.9 
27.0 0.6 5038 25.3 5.7 
AT variant AT6BR 0 1.1 7103 142.4 0,0 8.1 182.8 
17.4 0.5 4625 6.3 7.0 
- - - 12.6 5.7 
- - - 14.2 5.5 
FA 425BR 1.6 1.0 6690 160.4 0 7.8 147.7 
20.6 0.2 3386 7.9 6.5 
- - - 12.6 5.9 
- - - 14.2 5.7 
Unknown mutation 2BN 0 1.0 6690 774.4 0 6.2 142.4 
4.8 0.1 2973 1.6 5.5 
- - - 3.2 5.4 
- - - 6.3 5.3 
DNA ligase I 46BR 3.2 1.3 7929 204.6 0 7.2 120.8 
22.2 0.2 3386 12.6 6.6 
- - - 17.4 5.1 
DNA ligase IV 180BR 0 1.2 7516 237.4 0 7.1 180.8 
9.5 0.8 5864 7.9 5.6 
17.4 0.2 3386 11.1 5.1 
NBS 347BR 0 1.3 7929 138.8 0 8.3 145.6 
8.0 0.8 5864 9.5 6.9 
23.8 0.5 4625 15.8 6.0 
XP-C XP14BR 0 0.9 6277 130.7 0 5.7 51.7 
3.2 0.6 5038 6.3 4.9 
15.8 0.4 4212 17.4 4.8 
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Figure 4.2 A and B. Telomere shortening curves constructed on the basis of flow-FISH 
results in human primary fibroblast cell lines presented in Figure 4.1 and Table 4.1. 
Curves are presented in two separate panels to avoid overlaps, which may create 
difficulties in identifying points used for curve fitting. C. Rates of telomere shortening in 
primary human fibroblasts in base pairs (bp)/PD as determined by flow-FISH. Telomere 
shortening for cell lines 425BR and 2BN were based on two measuring points only, all 
the others on minimum of 3 points. Zero point PD represents the first point at which we 
measured telomere length in the above cell lines since we received them. Real PD 
numbers can be obtained by adding PD values indicated in Table 2.1. 
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4.2.2 Telomere length analysis by Southern blot in human primary fibroblast cell lines 
In parallel with flow-FISH measurements we analysed telomere length in above 
cell lines using the classical Southern blot technique (Table 4.1). Representative 
examples of Southern blot results are shown in Figure 4.3. Based on these results we 
generated telomere shortening curves for all cell lines (Figure 4.4 A and B) and used 
the slopes of the telomere shortening curves to determine the rates of telomere 
shortening in each cell line (Table 4.1; Figure 4.4 C). This analysis revealed the rates 
of telomere shortening between 50 and 180 bp/PD (Table 4.1; Figure 4.4 C). 
4.2.3 Comparison of flow-FISH and Southern blot measurements 
To compare flow-FISH and Southern blot results we used two approaches. First, we 
simply performed a correlation analysis between flow-FISH and Southern blot results. 
This analysis revealed a relatively low correlation between these two methods in the 
case of above fibroblast cell lines used (R2=0.52) (Figure 4.5). However, there are 
some important differences between the methods that may not justify direct 
comparisons between them. For example, flow-FISH quantifies exclusively telomeric 
TTAGGG sequences whereas Southern hybridisation may also take account of 
telomeric sequences present in subtelomeric chromosome regions (Nakamura et al., 
1999; Freulet-Marriere et al., 2004). Individuals that have the same mean length of 
terminal hexamer repeat array may nevertheless have very different mean 
telomere/terminal restriction fragment (TRF) lengths, due to restriction site 
polymorphisms and/or length polymorphisms in the subtelomeric regions that 
determine the length of the subtelomeric portions of the TRF. Early studies showed that 
the mean length of this subtelomeric portion of the TRFs in unrelated individuals 
ranged from 2.5 to 6 kb (Levy et al., 1992). 
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Figure 4.3 Representative examples of Southern blot-based telomere length 
measurements in human primary fibroblast cell lines. MM: Molecular weight marker, P: 
passage number. The conversion of passages into PDs is described in Materials and 
Methods. 
113 
vooc ä- ääaääää 
00o rn c) moon In U) l') f, ) C) U) NN 
QI O) O) CO c0 (0 QQ 
OOOOOOOO 
U` U C7 Cý C7 UU0 C7 
*0 
ý- 
Chapter 4: Accelerated telomere shortening in radiosensitive cell lines 
A NFB 1 (GM 9503) 12 
" NFB 2 (GM 8399) 
0 NFB 3 (GM 4505) 
AT (AT1BR) 
AT variant (AT6BR) 
9A- FA (425BR) 
NBS (347BR) 
TRF (kbp) 
very 
iA 
6 _: " 
3 
0 10 20 30 40 
A 
POPULATION DOUBLINGS 
12 
9 
TRF (kbp) L4 
6 
3 
* NFB 1 (GM 9503) 
* NFB 2 (GM 8399) 
NFB 3 (GM 4505) 
=Artemis (CJ 179) 
- 2BN 
Ligase I (46BR) 
- Ligase IV (180BR) 
XP-C (XP14BR) 
A 
0 10 20 30 
POPULATION DOUBLINGS 
B 
0 40 80 120 160 200 
Telomere shortening (bp/PD) 
40 
Figure 4.4 A and B. Telomere shortening curves based on Southern hybridisation 
results in human primary fibroblast cell lines presented in Figure 4.3 and Table 4.1. 
Two separate panels are used to avoid significant curve overlaps. C. Rates of telomere 
shortening in primary human cell lines in base pairs (bp)/PD as determined by 
Southern blot analysis. 
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In addition, flow-FISH allows the selective exclusion of a specific cell population during 
the Go/G, phase of the cell cycle when measurements are performed, i. e. polyploid and 
apoptotic/necrotic cells. These cells were specifically excluded in flow-FISH analysis. 
Finally, we have already discussed the problem of auto-fluorescence observed in 
fibroblast cell lines after flow-FISH. 
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Figure 4.5 Comparison of telomere shortening rates (bp/PD) obtained by flow-FISH 
and Southern blot methods. All cell lines included from Table 2.1 were used except 
2BN, XP14BR, and GM04505. The rate of telomere shortening in the 2BN cell line was 
unusually high. The flow-FISH and Southern blot results of telomere length 
measurement for the XP14BR cell line were apparently different. The GM04505 cell 
line was not analysed by flow-FISH. 
Given the differences between the two methods when fibroblasts are used we 
decided to take an alternative approach to test if flow-FISH can detect biologically 
relevant differences between cell lines that can be detected by Southern blot. We 
divided our cell lines into three groups, namely the negative control group - cell lines 
from normal individuals, the positive control group - four cell lines from AT, NBS and 
FA patients shown earlier to have accelerated telomere shortening (Metcalfe et al., 
1996; Smilenov et al., 1997; Adelfalk et al., 2001; Hande et al., 2001; Ranganathan et 
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al., 2001; Tchirkov and Lansdorp, 2003) and the novel cell group - the five cell lines in 
which the rate of telomere shortening was not previously examined. The reasoning 
behind this approach is that if flow-FISH can reproduce differences between the 
negative control group and the positive control group that are now well documented 
largely based on Southern blot measurements (Metcalfe et al., 1996; Smilenov et al., 
1997; Adelfalk et al., 2001; Hande et al., 2001; Ranganathan et al., 2001; Tchirkov and 
Lansdorp, 2003) then we can argue that this method may be as good as Southern blot 
for calculating the rates of telomere shortening in primary fibroblast cell lines. If this is 
the case we can then make valid conclusions about the rate of telomere shortening in 
the novel cell group based on flow-FISH results. 
Statistical analysis of the rates of telomere shortening/PD is shown in Figure 
4.6. As expected, the difference in the rate of telomere shortening between the 
negative control group and the positive control group was statistically significant using 
Southern blot method (Figure 4.6 B) i. e. several previous studies largely based on 
Southern blot measurements revealed accelerated telomere shortening in AT, FA and 
NBS patients in comparison with control individuals (Metcalfe et al., 1996; Smilenov et 
al., 1997; Adelfalk et al., 2001; Hande et al., 2001; Ranganathan et al., 2001; Tchirkov 
and Lansdorp, 2003). Interestingly, we also observed a statistically significant 
difference in the rates of telomere shortening between the negative and the positive 
control groups using flow-FISH (Figure 4.6 A) suggesting that in spite of a relatively low 
correlation between Southern blot and flow-FISH results, when compared directly 
against each other, flow-FISH can detect biologically relevant differences between the 
cell lines. 
We then compared the rates of telomere shortening in the novel cell group 
using both methods. The rate of telomere shortening in the novel cell group was 
statistically significantly higher in comparison to the negative control group using the 
Southern blot method (Figure 4.6 B) in spite of the normal rate of telomere shortening 
in XP14BR cells (Figure 4.4 C). Similarly, comparison of the rates of telomere 
116 
Chapter 4: Accelerated telomere shortening in radiosensitive cell lines 
shortening between the negative control cell group and the novel cell group using flow- 
FISH revealed statistically significant differences (Figure 4.6 A). Therefore, this 
reinforces the view that flow-FISH can detect differences between the cell lines that are 
also detectable by Southern blot. 
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Figure 4.6 Statistical analysis (two-way t-test) of telomere shortening rates in bp / PD 
in the negative control group (GM09503, GM08399 and GM04505), the positive control 
group (AT1BR, AT6BR, 347BR and 425BR) and the novel cell group (46BR, CJ179, 
2BN, XP14BR and 180BR) as determined by flow-FISH (A) and Southern blot (B). 
Note that telomere shortening rates were taken from Figures 4.2 C and 4.4 C. 
Significantly higher than negative control (p<0.05 t-test). 
However, it is important to stress that discrepancies observed between 
Southern blot and flow-FISH measurements require further clarification perhaps by 
using alternative methods such as Q-FISH. For example, although in most cases the 
rates of telomere shortening were higher in radiosensitive cell lines than in normal cell 
lines as revealed by both methods we found one clear difference. In the case of 
XP14BR cells the rate of telomere shortening as measured by Southern blot was within 
the normal range whereas the rate measured by flow-FISH was within the range of the 
positive control group (Figures 4.2 C and 4.4 C). We also would like to point out that in 
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contrast to a previous study which indicated normal telomere length in /igase IV 
deficient 180BR cells, when compared with fibroblasts from an age matched normal 
individual as measured by Southern blot (d'Adda di Fagagna et al., 2001), our results 
indicate accelerated telomere shortening in this cell line in vitro (Figures 4.2 C and 4.4 
C). 
Taken together our results suggest that flow-FISH is sensitive enough to detect 
subtle differences in telomere length between fibroblasts cells in different passages 
and that in spite of a relatively low correlation between Southern blot and flow-FISH 
results, when compared directly with each other, flow-FISH can detect biologically 
relevant differences between most fibroblast cell lines that can be detected by 
Southern blot. Finally, our results suggest that cell lines sensitive to IR show 
accelerated telomere shortening in comparison with control cell lines. 
4.2.4 Analysis of telomere function in radiosensitive human cell lines 
Accelerated telomere shortening is a predisposing factor for premature loss of 
telomere capping function, which may lead to appearance of chromatin bridges in 
anaphase cells. Therefore, one way to verify that telomere length measurements in 
above cell lines were accurate would be to measure frequencies of anaphase bridges 
i. e. cells with higher rates of telomere shortening are expected to show higher 
frequencies of anaphase bridges than cells with lower rates of telomere shortening. To 
achieve this we decided to monitor frequencies of anaphase bridges in pre-senescent 
cells in at least two different passages between PDs 20 and 30 i. e. it is more likely that 
anaphase bridges will be detected in pre-senescent cells than in cells in early 
passages. For this we treated cells with cytochalasin B. Cytochalasin B inhibits 
cytokinesis and two nuclei remain preserved in a single cytoplasm after this treatment, 
which should make it easy to detect chromatin bridges arising as a result of inability of 
sister chromatids to separate in anaphase. However, contrary to our expectation this 
assay did not allow us to detect anaphase bridges clearly (Figure 4.7 A). We then used 
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a classical anaphase bridge assay without cytochalasin B treatment (Figure 4.7 B). 
Frequencies of anaphase bridges were low in all cell lines but nevertheless some 
differences were observed between radiosensitive and normal cell lines (Figure 4.8 A). 
The 2BN cell line showed a low mitotic index and complete lack of anaphase cells and 
as a result was excluded from the analysis. Statistical analysis revealed significantly 
higher frequencies of anaphase bridges in cells from the positive control group in 
comparison to cells from the negative control group (Figure 4.8 B). This is in line with 
previous studies reporting an increased incidence of telomeric fusions in cells from AT 
and FA patients (Metcalfe et al., 1996; Callen et al., 2002). Frequencies of anaphase 
bridges were also significantly higher in cell lines from the novel cell group in 
comparison to cell lines from the negative control group (Figure 4.8 B). 
y 
Figure 4.7 (A) Chromatin bridges detected in cytochalasin B treated bi-nucleated cells. 
In most cases these chromatin bridges were difficult to identify i. e. two observers could 
not agree whether these events were really chromatin bridges or artefacts caused by 
staining. (B) Anaphase bridges in human fibroblasts. In contrast to above chromatin 
bridges in bi-nucleated cells anaphase bridges were unambiguously identifiable. 
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Figure 4.8 (A). Analysis of anaphase bridges in 10 human fibroblast cell lines at 2-3 
different passages between PDs 20 and 30. For this purpose all cell lines have been 
synchronized to have similar PD numbers. In the case of some cell lines bars 
representing a passage number are missing. When this is the case that particular 
sample was not suitable for anaphase bridge analysis. A minimum of 50 anaphase 
cells / point were analysed (B). Comparison of anaphase bridge frequencies in 
radiosensitive fibroblasts. (*p<0.5, t-test) 
We also observed an increased incidence of chromosomes lacking detectable 
telomeric signals in all the DNA damage response deficient cells in comparison with 
cells from normal individuals (Figure 4.9). It is noteworthy that XP14BR cells showed 
higher frequencies of anaphase bridges (Figure 4.8 A) and chromosomes lacking 
detectable telomeric signals than normal cells (Figure 4.9 B) suggesting that the normal 
rate of telomere shortening observed in these cells by Southern blot analysis is not a 
good predictor of telomere function. However, metaphase end-to-end chromosome 
fusions were absent or rare in all cell lines (data not shown) and in contrast to earlier 
studies (Metcalfe et al., 1996; Callen et al., 2002), metaphase fusion events were not 
consistently observed either in AT or in FA cells. The fact that anaphase bridges were 
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observed reproducibly in all cell lines and metaphase end-to-end chromosome fusions 
rarely and irregularly may be explained by differences in the numbers of analysed 
anaphase cells (50/point) and metaphase cells (25/point). 
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Figure 4.9 (A). A metaphase cell hybridised with a telomeric PNA probe labelled with 
Cy-3 (see Material and Methods). Arrows indicate chromatids lacking signal. (B). 
Frequencies of CLTD (chromatids lacking detectable telomere) / cell in fibroblast cell 
lines as observed in 2-3 different passages between PDs 20 and 30 (i. e. presenescent 
cells). Missing bars indicate samples not suitable for analysis. (C). Comparison of 
chromatids lacking detectable telomere (CLDT) frequencies in human fibroblast cell 
lines. All bars represent the mean number of CLDT in a metaphase while the error bars 
represent the standard error of the mean (SEM). (*p<0.5, t-test) 
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We have also observed another unusual cytological phenomenon in 
radiosensitive cell lines: split telomeric signals. Examples of these split telomeric 
signals are shown in Figure 4.10 A. Frequencies of split telomeric signals were 
significantly higher in radiosensitive cell lines in comparison to control cell lines (Figure 
4.10 B and C). Split telomeric signals are remarkably similar to extra-chromosomal 
telomeric fragments observed previously in AT and FA cells (Hande et al., 2001; Callen 
et al., 2002) and we speculate that these may be manifestations of altered telomere 
metabolism (for details see discussion). 
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Figure 4.10 (A). A representative example of split telomeric signals (arrows) in 
chromosomes originating from a human fibroblast cell. (B). Chromatids with telomeric 
split (CTS) per cell in pre-senescent cells in 2-3 different passages between PDs 20 
and 30. Missing bars indicate samples not suitable for analysis. (C). Comparison of 
CTS/cell frequencies in human fibroblast cell lines. All bars represent the mean number 
of CTS in a metaphase while the error bars represent the standard error of the mean 
(SEM). (*p<0.5, t-test) 
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Taken together these results suggest that radiosensitive pre-senescent cells 
show altered telomere maintenance in comparison with control pre-senescent cells and 
it is likely that the observed accelerated telomere shortening in these cell lines as 
identified by flow-FISH and Southern blot is not an artefact. 
4.2.5 Telomere maintenance in mouse BRCA1 deficient cells 
To examine the association between radiosensitivity and telomere maintenance 
in non-human cells, mouse embryonic stem (ES) cells were used in which both copies 
of BRCA1 were disrupted by gene targeting (Snouwaert et al., 1999). BRCA1 
deficiency confers genomic instability and sensitivity to IR (Abbott et al., 1999; Foray et 
al., 1999). Mouse BRCA 1-ý- ES cells as well as BRCA 1+1+ ES cells, were grown for - 25 
PDs and their telomere lengths measured after each 3 PDs by flow-FISH. Southern 
blot cannot accurately estimate telomere length in mouse cells because this technique 
probably takes account of degenerate telomere-like sequences present in sub- 
telomeric regions of chromosomes thus masking real telomeric sequences and 
probably overestimating telomere length in mouse cells (Zijimans et al., 1997). Our 
analysis revealed that telomeres degrade more rapidly in BRCA1-1 cells than in 
BRCA 1+'+ cells (Figure 4.11 A). The level of apoptotic cells was similar in both cell lines 
and apoptotic cells were excluded from the analysis (data not shown). Using mouse 
lymphoma LY-R and LY-S cells with known telomere lengths (Mcllrath et al., 2001) as 
calibration standards for flow-FISH, telomere loss in BRCA1+'+ cells was calculated to 
be - 580 base pairs (bp) / PD. Telomere loss in BRCA1"1- cells was more pronounced 
and on average these cells were loosing - 1,000 bp / PD. Observation of telomere 
shortening in BRCA 1+'+ cells was somewhat surprising because mouse cells with 
normal telomerase activity are not expected to lose telomeric sequences. However, it is 
important to stress that BRCA1 proficient mouse embryonic stem cells used here might 
not be entirely normal i. e. this cell line has a mutation in the HPRT gene (Snouwaert et 
al., 1999) which could contribute to this phenotype. Also, our estimate of the rate of 
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telomere shortening in the above two mouse cell lines is unusually high in comparison 
with estimated rates of telomere shortening in human cell lines (see above). One 
possibility is that these cells were under physiological stress and we did observe 
changes in cell shape consistent with this possibility. ES cells require special media 
and supplements and the physiological stress could have been caused by our serum 
replacement (Knockout SR, Gibco) used instead of the standard foetal calf serum (see 
Materials and Methods). Another observation in line with a high level of physiological 
stress in these cells is increased levels of DSBs as detected with DSB-specific 
antibody (see below). Finally, in contrast to mouse ES cells the average telomere 
length was stable in human lymphoblastoid cells heterozygous for BRCA1 and BRCA2 
mutations (Figure 4.11 B) suggesting further potential presence of physiological stress 
in mouse ES cells. 
Next, we examined chromosome abnormalities in BRCA1-1- and BRCA1+'+ cells. 
We observed end-to-end chromosome fusions and chromosomes lacking detectable 
telomeric signals in BRCA 1-'- cells, whereas these events, indicative of telomere 
dysfunction, were absent in BRCA 1+'+ cells (Figure 4.12). Chromosome ends that lack 
a FISH signal preferentially participate in end-to-end fusions, providing a direct 
evidence for the link between short telomeres and end-to-end chromosome fusions 
(Hemann et al., 2001). Approximately 50% fusion events involved telomeric sequences 
at the fusion points. In addition, we observed elevated frequencies of extra- 
chromosomal telomeric fragments (ECTFs) in the form of double minute chromosomes 
in late passage BRCA1"'- cells in comparison with control BRCA1+'+ cells (Figure 4.12 B 
and C). These ECTFs could reflect a mechanism responsible for generating split 
telomeric signals observed in human fibroblast cell lines sensitive to IR (see above). 
Therefore, our cytogenetic analysis indicates that accelerated telomere shortening in 
BRCA 1-1- cells causes mild telomere dysfunction whereas telomeres remain functional 
in spite of their shortening in BRCA 1- + cells. 
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Figure 4.11 (A). Telomere length analysis by flow-FISH in mouse BRCA1t"+ and 
BRCA 1-'- embryonic stem cells. BRCA 1+ý+ cells were obtained at PD 35 and BRCA 1 '- 
cells at PD 23. (B). Telomere length analysis by flow-FISH in human lymphoblastoid 
cell lines established from carriers of BRCA 1+"- and BRCA27 - mutations as well as in 
lymphoblastoid cell lines from normal individuals (NLB). 
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Figure 4.12 A mouse BRCA 1ý mitotic cell showing end-to-end chromosome fusion 
lacking telomeric signal at the fusion point (arrow) (A). A mouse BRCA1-1- cell showing 
extra-chromosomal telomeric fragments (arrow) (B). Frequencies of end-to-end 
chromosomal fusions, chromatids lacking detectable telomere (CLDT) and extra- 
chromosomal telomeric fragments (ECTF) in mouse BRCA1+'+ and BRCA1 ' cells (C). 
4.2.6 DNA damage foci 
It has recently become possible to identify sites of DNA DSBs in mammalian 
cells by using antibodies against 'y-H2AX. Unphosphorylated H2AX is interspersed in 
chromatin throughout the genome, and following DNA damage one of the earliest 
events is the phosphorylation of Sen 39 of H2AX in large DNA domains encompassing 
a million base pairs. y-H2AX forms discrete foci within 10 minutes of DNA DSBs 
induction with BRCA1 detectable in these foci (Fernandez-Capetillo et al., 2004). In 
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human senescent cells or cells with dysfunctional telomeres y-H2AX co-localizes with 
telomeres suggesting that dysfunctional telomeres behave as DSBs (d'Adda di 
Fagagna et al., 2003; Takai et al., 2003). We have used an antibody against y-H2AX in 
our panel of novel human fibroblast cell lines sensitive to IR and in mouse ES cells 
(Figure 4.13). Human fibroblasts used for this purpose were in similar passages i. e. 
PDs 20-30 (pre-senescent) and mouse ES cells were in matching passages. We 
detected up to 5 positive foci per cell in fibroblasts cultures (Figure 4.13 A) whereas 
mouse embryonic stem cells showed a much higher number of foci positive for y-H2AX 
(Figure 4.13 B and 4.14 C) indicating that these cells were under physiological stress. 
Our analysis revealed significantly higher frequencies of y-H2AX positive foci in pre- 
senescent human fibroblasts from the novel cell group in comparison with the cell line 
from a normal individual (Figure 4.14 A and B) indicating a higher level of DSBs 
possibly including those at telomeres. Our attempt to detect simultaneously y-H2AX 
and telomeres did not work because commercially available antibodies specific for 
TRF1 and TRF2 used in immunocytochemistry experiments did not yield sufficiently 
strong signal to allow co-localization. An alternative for this is an immuno-FISH 
technique (immunocytochemistry combined with FISH). We have been able to use 
immuno-FISH only recently (for details see Chapter 5) but immuno-FISH analysis of 
human fibroblast was not sufficiently complete to be included in this thesis. High 
frequencies of y-H2AX positive foci in both human radiosensitive fibroblast cell lines 
from the novel cell group and mouse BRCA1 deficient cells indicate that the level of 
spontaneous DNA damage is higher in these cells than in normal control cells. 
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Figure 4.13 Representative examples of nuclei stained with -y-H2AX antibody (FITC) 
and counterstained with DAPI in a radiosensitive fibroblast cell line (A) and in a BRCA 1 
deficient mouse embryonic stem cell (B). The type of intense nuclear staining with y- 
H2AX antibody shown in panel B can rarely be found in radiosensitive fibroblasts. 
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Figure 4.14 Percentages of radiosensitive fibroblasts positive for y-H2AX staining (i. e. 
a cell with at least one focus was considered positive) (A) and statistical analysis (B). 
Percentages of y-H2AX positive cells in mouse embryonic stem cells (C). (*p<0.5, t- 
test) 
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4.3 Discussion 
4.3.1 Use of flow-FISH to measure telomere length in human fibroblasts 
So far, flow-FISH has been used to measure telomere fluorescence intensity, 
which is proportional to telomere length, mainly in human peripheral blood lymphocytes 
(Martens et al., 2002; Brummendorf et al., 2002; Baerlocher and Lansdorp, 2003) or 
other cells of hematopoietic origin i. e. human lymphoblastoid cell lines or mouse 
lymphoma cell lines (Scheding et al., 2003; Van Ziffle et al., 2003; Rigolin et al., 2004; 
and see Chapter 3). Cells of hematopoietic origin are particularly suitable for flow- 
cytometry analysis because of their intrinsic properties including cell shape, natural 
separation from other cells and low auto-fluorescence values. Our preliminary attempts 
to measure telomere length in human fibroblast cell lines with the purpose of 
determining if subpopulations of cells with different telomere lengths exist within these 
cell lines were successful (see Chapter 3). We have also been able to use flow-FISH to 
measure telomere length in human ALT cell lines (see Chapter 3). However, from 
these results we could not conclude if flow-FISH can be used to, for example, 
determine the rate of telomere shortening during the replicative senescence of human 
fibroblasts. If this is possible, it would be extremely useful i. e. flow-FISH is a much 
faster method in comparison with other telomere length measurement methods and it 
does not require large number of cells as Southern blot or mitotic cells as Q-FISH. The 
present study was designed to test for the above possibility. Our results suggest that 
flow-FISH method is sensitive enough to determine subtle differences in telomere 
length (i. e. differences of several hundred bp) arising as a result of replicative 
senescence in human fibroblasts. Moreover, our results suggest that flow-FISH can 
detect biologically relevant differences in the rates of telomere shortening between 
different fibroblast cell lines. For example, we observed accelerated telomere 
shortening in AT, NBS and FA cell lines in comparison with normal cell lines by flow- 
FISH. This is in line with published results (Metcalfe et al., 1996; Smilenov et al.. 1997; 
Hande et al., 2001; Ranganathan et al., 2001; Tchirkov and Lansdorp, 2003) and we 
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have also confirmed this using Southern blot analysis. Furthermore, similar results 
were obtained with Southern blot and flow-FISH in the novel cell group in which 
telomere length was not measured before. 
However, direct comparison between flow-FISH and Southern blot results 
revealed a relatively low correlation between these two techniques. We have already 
provided arguments for the possibility that these two techniques may differ in the 
sense, which DNA sequences are measured (i. e. discrepancy between telomeric and 
sub-telomeric sequences in the case of Southern blot) or which cells are taken into 
account for measurements (specific exclusion of some cells in flow-FISH) (see above). 
However, we cannot rule out the possibility that our method for telomere length 
measurement by flow-FISH in human fibroblast requires further optimisation to improve 
its correlation with Southern blot. Usually, a good correlation exists between Southern 
blot and flow-FISH when using human lymphocytes (Rufer et al., 1998). Similarly we 
obtained a good correlation between telomere length measurement by Southern blot 
and flow-FISH in a group of six human lymphoblastoid cell lines (see Chapter 3). One 
way to further optimise our method would be to treat fibroblasts with detergents, which 
will specifically remove the cytoplasm. Auto-fluorescence seems to be generated by 
the fibroblast cytoplasm to a larger degree than by the nucleus and stripping the 
cytoplasm from the cell could eliminate the problem of auto-fluorescence mentioned 
above (see Figure 4.1). We believe that further optimisation steps will improve the 
resolution of flow-FISH and make it suitable for telomere analysis in all cell types. 
4.3.2 Accelerated telomere shortening in radiosensitive cell lines 
We have shown previously, using peripheral blood lymphocytes from a group of 
29 breast cancer patients, that there is a correlation between chromosomal 
radiosensitivity and short telomeres (Mcllrath et al., 2001). This observation was 
recently confirmed by an American study in which lymphocytes from a much larger 
group of head & neck, lung, bladder and kidney cancer patients and equal number of 
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healthy individuals were used (Wu et al., 2003). This study revealed a significant 
negative correlation between telomere maintenance and radiosensitivity i. e. the shorter 
the telomeres the higher the radiosensitivity. In line with these results it was 
demonstrated that senescent human fibroblasts with short telomeres are significantly 
more radiosensitive than the same fibroblast with long telomeres (Rubio et al., 2002). 
Taken together above results argue that the mechanisms conferring sensitivity 
to IR may be linked with telomere maintenance mechanisms and this prompted us to 
investigate telomere length in cell lines known to be sensitive to IR. Our telomere 
length analysis by flow-FISH and Southern hybridisation demonstrated that 
radiosensitive cells generally show higher rates of telomere shortening than cell lines 
from apparently normal individuals. Our measurements are in agreement with 
previously published studies, which revealed accelerated rates of telomere shortening 
in AT, NBS and FA patients (Metcalfe et al., 1996; Ranganathan et al., 2001; Adelfalk 
et al., 2001). Furthermore, our results indicate accelerated telomere shortening in cells 
defective in ligase I, ligase IV, Artemis and two more defects that have not been 
examined before. We have also examined telomere shortening rates in mouse ES cells 
deficient in BRCA1 by flow-FISH and found that although telomeres were, on average, 
initially longer in BRCA 1-'- cells, they degraded more rapidly than telomeres in 
BRCA 1+'+ cells (Figure 4.11). We found approximately a two-fold difference in the rate 
of telomere shortening between radiosensitive mouse BRCA1 deficient cells and 
matching control cells. 
In all cases accelerated telomere shortening was accompanied by signs of 
telomere dysfunction including anaphase bridges (human fibroblasts), end-to-end 
chromosome fusions (mouse ES cells), increased incidence of chromatids lacking 
telomeric signals and increased incidence of split telomeric signal (human fibroblasts) 
or extra-telomeric signal (mouse ES cells). We believe that the split telomeric signal 
may reflect detachment of a broken telomeric fragment from a chromosome. This 
possibility is supported by several lines of evidence. First, in all cases we observed an 
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actual physical separation of two telomeric signals on a single chromatid leading to at 
least 5 telomeric signals/chromosome instead of expected 4 (see Figure 4.10 A). This 
suggests that a DSB occurred within the telomeric sequence. In line with this possibility 
the size of two split signals on a single chromatid was usually equivalent to the size of 
a single signal at its sister chromatid (see Figure 4.10 A). Sister chromatids are exact 
replicas of each other and they should have the telomeres of exactly the same size. 
Secondly, the fact that we observed increased incidence of split telomeric signal in 
cells with increased incidence of y-H2AX stained foci (marker of DSBs) (Figure 4.14 A) 
suggests that some DSBs detected by y-H2AX staining may occur at telomeres. This 
possibility can be tested by measuring co-localization of y-H2AX with telomeres and 
these experiments will be carried out in the near future in our laboratory. Thirdly, split 
telomeric signals could be cytological manifestation of a recently discovered 
mechanism of extra-chromosomal telomeric circle formation (Cesare and Griffith, 2004; 
Wang et al., 2004). Since the incidence of split telomeric signal is significantly elevated 
in cells with accelerated telomere shortening it is possible that split telomeric signals 
could contribute to telomere shortening i. e. a detached signal will be lost in the next cell 
division. 
The mechanisms that cause accelerated telomere shortening in radiosensitive 
cell lines are not known and further research is required to identify these mechanisms. 
The range of cell lines in our panel and the inclusion of defects in proteins that are not 
known to be located at telomeres (e. g. Artemis, DNA ligase IV), suggests that telomere 
shortening may be a consequence of defective DNA repair rather than a dual function 
of all the defective proteins. However, other mechanisms not directly related to DNA 
repair defects could also operate. The reduction of telomere length could be a 
consequence of breakage near or within the telomeres where the chromosome end 
associations are not resolved while chromosomes move in opposite directions. Extra- 
chromosomal telomeric DNA was indeed detected in fibroblasts from AT patients and 
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may represent fragmented telomeres or by-products of defective replication of 
telomeric DNA (Hande et al., 2001). As indicated above it was recently demonstrated 
that t-loop deletion by homologous recombination might contribute to extra- 
chromosomal telomeric fragments (Wang et al., 2004). These fragments were also 
observed in human ALT cell lines GM847 and WI-38 VA13 (Cesare and Griffith, 2004). 
We were able to detect higher incidence of extra-chromosomal telomeric fragments in 
late passage BRCA1 deficient mouse cells in comparison with control cells (see 
above). These extra chromosomal telomeric fragments in mouse cells had a form of 
double minute chromosomes and were similar to those recently reported in cells from 
ERCC1/XPF deficient mice (Zhu et al., 2003). This suggests that BRCA1 might play a 
similar role at telomeres as ERCC1/XPF in repressing the formation of extra 
chromosomal telomeric fragments. 
Another phenomenon that could be responsible for the accelerated telomere 
shortening in radiosensitive cells is oxidative stress. Since telomeres are highly 
sensitive to oxidative stress (von Zglinicki, 2002) it is possible that accelerated 
telomere shortening observed here could be caused by abnormalities in oxidative 
metabolism in the above cell lines i. e. a large proportion of IR induced damage arises 
via oxidative damage. The primary cause of accelerated telomere shortening in ATM 
deficient cells is oxidative stress (Tchirkov and Lansdorp, 2003). 
At the end we would like to mention a discrepancy between our results for the 
ligase IV deficient cell line 180BR and earlier results. d'Adda di Fagagna et al. (2001) 
found no difference in telomere length between this cell line and an age matched 
control cell line but no rate of telomere shortening for this cell line was determined. This 
result was interpreted to mean that ligase IV defect does not affect telomere length. 
However, our results revealed accelerated telomere shortening in vitro in this cell line 
(Figures 4.2 C and 4.4 C). To exclude the possibility that our results are due to 
artefacts we have recently obtained a cell line from another ligase IV'- patient (411 BR) 
and compared the rate of telomere shortening in this cell line with that of a cell line 
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established from a heterozygous parent of the 411 BR patient. We have been able to 
show accelerated telomere shortening in 411 BR cells in comparison with its 
heterozygotic counterparts (Slijepcevic, unpublished results). 
In conclusion, our findings suggest that multiple genetic defects that confer 
radiosensitivity and /or genomic instability also confer telomere shortening. It is worth 
noting that the converse is not necessarily true, e. g. telomerase deficient mice show an 
increase in genomic instability at later generations but not at early generations although 
their rate of telomere shortening is essentially the same (Goytisolo et al., 2000). 
4.4 Summary 
Telomere maintenance was examined in 9 primary fibroblast cell lines with 
different genetic defects that confer sensitivity to IR. These included cell lines derived 
from patients with ataxia telangiectasia, Nijmegen breakage syndrome, Fanconi 
anemia, defective Artemis, DNA ligase I and DNA ligase IV, an immunodeficient patient 
with a defect in DNA double strand break repair and a patient diagnosed with 
xeroderma pigmentosum who, in addition, showed severe clinical sensitivity to ionising 
radiation. The results from this study, based on flow-FISH and Southern hybridisation 
measurements, revealed an accelerated rate of telomere shortening in most cell lines 
derived from the above patients in comparison with cell lines from normal individuals. 
This accelerated telomere shortening was accompanied by the formation of chromatin 
bridges in anaphase cells, indicative of the early loss of telomere capping function. 
Telomere maintenance was also analysed in mouse embryonic stem cells deficient in 
BRCA 1, another defect conferring radiosensitivity. Similarly, these cells showed 
accelerated telomere shortening and mild telomere dysfunction in comparison to 
control cells. These results suggest that mechanisms that confer sensitivity to IR may 
be linked with mechanisms that cause telomere dysfunction. 
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CHAPTER 5 
ASSESSMENTS OF BRCA1 ROLE IN TELOMERE MAINTENANCE IN MAMMARY 
EPITHELIAL CELLS AND TELOMERE FUNCTION IN ALT CELLS 
5.1 Introduction 
Results presented in the previous chapter indicate that BRCA1 deficient cells 
may have a telomere dysfunction phenotype. BRCA1 deficiency is known to induce 
genomic instability and sensitivity to ionising radiation (IR) (Abbott et al., 1999; Foray et 
al., 1999). Similarly, a number of defects that confer sensitivity to IR appear to be 
associated with accelerated telomere shortening (see previous chapter). These results 
together with a number of published studies (Metcalfe et al., 1996; Pandita and Dhar, 
2000; Adelfalk et al., 2001; Hande et al., 2001; Ranganathan et al., 2001; Tchirkov and 
Lansdorp, 2003) argue that defective DNA damage responses are frequently 
accompanied by some form of telomere dysfunction. In this chapter we will explore 
further a potential involvement of BRCA1 in telomere maintenance and also examine 
the status of telomere function in ALT positive cell lines. 
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When telomeres become dysfunctional, either through the loss of telomeric 
sequences due to cell senescence or inactivation of key telomere binding proteins, this 
induces cellular DNA damage response similar to that activated after induction of DNA 
double strand breaks (DSBs) (d'Adda di Fagagna et al., 2003; Takai et al., 2003). It has 
been known for several years that key proteins involved in DSB repair e. g. Ku70/Ku86 
and DNA-PKcs are involved in telomere maintenance (Bailey et al., 1999; Samper et 
al., 2000; Goytisolo et al., 2001; Bailey et al., 2004). For example, the absence of Ku70 
or Ku86 promotes chromosome end-to-end fusion as a mechanism to repair 
dysfunctional telomeres. In the absence of chromosome fusions, dysfunctional 
telomeres may be recognised as DSBs (Espejel et al., 2002). 
Several examples of genetic mutations that cause chromosome instability and 
telomere dysfunction, not necessarily through defective DSB repair, have been 
documented. For example, chromosome instability and telomere dysfunction can be 
induced by mutations in specific genes that cause cancer-predisposition syndromes, 
including Fanconi anemia (FA), Nijmegen breakage syndrome (NBS) and ataxia 
telangiectasia (AT) (Metcalfe et al., 1996; Pandita and Dhar, 2000; Adelfalk et al., 
2001; Hande et al., 2001; Ranganathan et al., 2001; Tchirkov and Lansdorp, 2003). 
Our results point to the possibility that BRCA1 deficiency may cause accelerated 
telomere shortening and also telomere dysfunction (see Chapter 4). This opens an 
interesting possibility that two tumour suppressor mechanisms (i. e. BRCA1 is a tumour 
suppressor gene and functional telomeres constitute a powerful tumour suppressor 
mechanism) could actually converge to accelerate appearance of a malignant 
phenotype. 
BRCA 1-1- cells are hypersensitive to IR (Shen et al., 1998; Foray et al., 1999) 
suggesting its role in DNA repair. Indeed, cells lacking BRCA1 are particularly deficient 
in transcription-coupled repair whereby DNA repair is linked to the transcriptional 
machinery such that the transcribed strand is preferentially repaired. Cells lacking 
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BRCA1 are also deficient in homology-directed DNA repair, which uses the 
homologous sister chromatid as the repair template (Gowen et al., 1998; Abbott et al.. 
1999). The role of BRCA1 in DNA damage repair is further suggested by its association 
with other proteins involved in DNA repair including ATM, 53BP1, MDC1, RAD51, and 
the MRE11-RAD50-NBS1 (MRN) complex (reviewed in Deng and Brodie, 2000; Deng 
and Wang, 2003). In ALT (alternative lengthening of telomeres) cells, the MRN 
complex is localised with APB (ALT associated PML) bodies during late S-G2 phase, 
suggesting its involvement in telomere length maintenance (Grobelny et al., 2000; Wu 
et al., 2000). Given that the MRN complex is known to associate with BRCA1 and with 
telomeres and telomere binding proteins, Herbert et al. (2001) suggested that BRCA1 
might also play a role in telomere structure and function. Indeed, BRCA1 has been 
found to associate with APB bodies in tumour cells, which maintain telomeres by the 
ALT pathway (Wu et al., 2003), and thus with telomeres. APBs are nuclear subdomains 
that recruit and locally accumulate a large number of proteins, many of which are key 
regulators of various processes. They contain PML, telomeric DNA, and the telomere- 
binding proteins TRF1 and TRF2. NBS1 foci co-localise with the APBs during late S to 
G2 phase in ALT cells (Wu et al., 2000). PML bodies themselves recruit a variety of 
other proteins, including Sp100, SUMO-1, Daxx, pRB, p53, and BLM, suggesting roles 
in DNA replication and repair, cell cycle control, RNA transport and apoptosis (Seeler 
and Dejean, 1999; Ruggero et al., 2000). The fact that BRCA1 participates in the ALT 
pathway is consistent with its role in homology-directed DNA repair. 
The recruitment of the DNA damage signalling and repair proteins to sites of 
genomic damage constitutes a primary event triggered by DNA damage. The 
association of BRCA1 with the MRN complex is critical for this DNA damage response 
(Wu et al., 2003). Many components of the DNA damage response, including BRCA1, 
RAD51, and the MRN complex form foci that co-localise with phosphorylated histone 
H2AX (-y-H2AX) (Paull et al., 2000). These nuclear domains are thought to contain 
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hundreds to thousands of molecules that accumulate in the vicinity of a DSB. The 
formation of y-H2AX foci is a very early event after induction of DSBs and has been 
proposed to function in recruiting downstream DNA repair factors, including BRCA1, to 
DNA damage sites (Paull et al., 2000). BRCA1 is thus an early migrant to sites of 
H2AX phosphorylation (Paull et al., 2000), consistent with a role in the events that 
follow at the site of breakage. BRCA1 and y-H2AX detect double strand breaks (Paull 
et al., 2000; Celeste et al., 2003) and this may thus include breaks at telomeres. 
The present study was undertaken to determine the significance of BRCA1 in 
telomere maintenance in mammary epithelial cells using RNAi and 
immunocytochemistry. We have also applied immunocytochemistry methods to assess 
telomere function and BRCA1 co-localisation with DNA damage foci in ALT positive 
cells. 
5.2 Results 
5.2.1 Assessment of BRCA1 role in telomere maintenance using mammary epithelial cells 
5.2.1.1 siRNA depletion of BRCA1 in mammary epithelial cells 
To assess whether BRCA1 plays a role in telomere maintenance we used a 
siRNA approach. The ability of a siRNA oligonucleotide specific for BRCA1 (see 
Materials and Methods) to knockdown BRCA1 protein expression was tested in the 
breast epithelial cell line MCF10A and breast carcinoma cell line MCF7. MCF10A cells 
express lower levels of BRCA1 mRNA in comparison with MCF7 cells (Gudas et al., 
1996; Blagosklonny et al., 1999). We also planned to include in this analysis the Bre-80 
cell line, which is a normal breast epithelial cell line immortalized by ectopic expression 
of hTERT (Huschtscha et al., 1998). However, this cell line showed a high percentage 
of anaphase bridges, slow growth and expression of truncated BRCA1 (deletion of 
exon 11) as revealed by Western blotting (not shown) and therefore was excluded from 
the analysis. 
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BRCA1 is a molecule located in nuclear foci of all cell types, as was confirmed 
by Wilson et al. (1999), and despite the cell cycle dependence of BRCA1 mRNA 
expression, BRCA1 protein level does not change during the cell cycle (Aprelikova et 
al., 1996). Following a single transfection with siRNA-BRCA1 (for details of sequence 
see Material and Methods), BRCA1 protein levels, as assessed by 
immunocytochemistry (Figure 5.1 A), had fallen dramatically (up to 70%) by 24 h after 
transfection in MCF1 OA cells and remained at this level in most cells for at least further 
4 days (Figure 5.1 B). From day 6 onwards, a slow and non-uniform return to levels of 
expression before transfection with siRNA oligonucleotides was observed (Figure 5.1 
B). This time course is consistent with published reports for knock down of the BRCA1 
gene (Bruun et al., 2003; Xiong et al., 2003). Inhibition of BRCA1 expression in MCF7 
cells was less efficient than in MCF10A cells but nevertheless we observed a 
significant reduction in frequencies of nuclei stained with BRCA1 antibodies in 
comparison with control cells (Figure 5.1 C). There are two possible explanations for 
this. MCF7 cells show an unusual growth pattern with cells growing in two layers and 
this could affect efficiency of transfection. Alternatively, MCF7 cells express 
constitutively higher levels of BRCA1 levels compared with MCF10A cells 
(Blagoskionny et al., 1999) and this could be responsible for the observed difference. 
The mRNA expression of BRCA1 was also evaluated by semi-quantitative RT- 
PCR assays (Figure 5.2). A profile of temporary decrease in BRCA1 expression similar 
to that observed by immunofluorescence analysis was seen in MCF10A (Figure 5.2 A 
and B) and to a lesser extent in MCF7 cells (Figure 5.2 C and D). Although an earlier 
study indicated that MCF7 cells express a higher amount of BRCA1 mRNA than 
MCF10A cells (Blagosklonny et al., 1999) we could not see differences in BRCA1 
mRNA expression levels between the two cell lines. The RT-PCR results were 
corroborated by Western blot analyses, which clearly indicated reduced levels of 
BRCA1 expression following transfection with siRNA (Figures 5.3 and 5.4). 
139 
Chapter 5. Role of BRCA 1 in telomere maintenance 
Interestingly, it was revealed in a previous study that an exogenous BRCA1 
gene strongly inhibited telomerase enzyme activity in human prostate and breast 
cancer cell lines (Xiong et al., 2003). It was also shown in co-transfection experiments 
that a wtBRCA1 plasmid inhibited hTERT gene expression in human ovarian cancer 
(Zhou and Liu, 2003). Therefore, we decided to analyse hTERT expression in both 
MCF cell lines during BRCA1 depletion. However, no increase of hTERT gene by RT- 
PCR (Figure 5.2) and protein expression by Western blotting (Figures 5.3 and 5.4) was 
observed in either MCF cell lines. 
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Figure 5.1 Immunofluorescence detection of BRCA1 in MCF10A cell cultures before 
and after BRCA1-siRNA transfection (A). Histograms showing frequencies of BRCA1 
positive cells (100 cells counted) during BRCA1 depletion by siRNAs in MCF10A cells 
(B) and in MCF7 cells (C). 
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Figure 5.2 Expression of BRCA1 mRNAs as detected by RT-PCR in MCF10A cells (A) 
and in MCF7 cells (C). Subconfluent proliferating cultures were harvested for RNA 
isolation and semi-quantitative RT-PCR assays using primer sets shown in Table 2.4. 
Each amplified cDNA band was quantified by densitometry and expressed relative to ß- 
actin as a control in MCF10A (B) and MCF7 cells (D) 
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Figure 5.3 Expression of BRCA1 protein levels as detected by Western blotting in 
BRCA1-siRNA transfected (A) and mock-transfected MCF1 OA cells (B). Equal aliquots 
of total cell protein (50 pg/lane) were electrophoresed and the protein bands were 
detected by enhanced chemiluminescence. Histograms showing BRCA1 protein 
expression/ß-actin ratio levels in Western blots of MCF10A cells (C). 
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Figure 5.4 Expression of BRCA1 protein levels as detected by Western blotting in 
BRCA1 -siRNA transfected (A) and mock-transfected MCF7 cells (B). Equal aliquots of 
total cell protein (50 pg/lane) were electrophoresed and the protein bands were 
detected by enhanced chemiluminescence. Histograms showing BRCA1 protein 
expression/ß-actin ratio levels in Western blots of MCF7 cells (C). 
5.2.1.2 The effect of BRCA1 depletion on telomere maintenance 
To assess the effect of BRCA1 depletion on telomere maintenance, we 
analysed telomere function in MCF10A and MCF7 cells by scoring chromatin bridges in 
anaphase cells. The presence of anaphase bridges in cells is usually a sign of telomere 
dysfunction (see Chapter 4). The overall levels of anaphase bridge frequencies were 
low in both cell lines but nevertheless a slight increase was detected during partial 
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depletion of BRCA1 in comparison with mock-transfected cells (Figure 5.5). In the case 
of MCF10A cells this increase was statistically significant suggesting that BRCA1 
deficiency may affect telomere maintenance. 
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Figure 5.5 Effect of transient BRCA1 depletion on anaphase bridge formation in 
MCF10A (A) and MCF7 cells (B). (*p<0.05, t-test) 
To test this possibility more stringently we performed experiments to detect the 
DNA damage sensor, 7-H2AX, at telomeres in MCF10A and MCF7 cells. The presence 
of y-H2AX at telomeres is consistent with telomere dysfunction. We started this 
analysis by combining antibodies against 7-H2AX with antibodies against either TRF1 
or TRF2. The antibody specific for TRF1 (C-19, Santa Cruz, USA) did not generate any 
signal. An antibody specific for TRF2 (N-20, Santa Cruz, USA) produced some signal 
but this was not sufficient to identify efficiently co-localisation of , I-H2AX with telomeres. 
Telomere length measurements revealed extremely short telomeres in both cell lines 
(see below) a possibility consistent with weak TRF2 signals due to short telomeres. We 
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then performed FISH analysis of telomeres in interphase MCF10A and MCF7 cells and 
found that these are clearly visible under the fluorescence microscope (Figure 5.6). 
Therefore, we applied immuno-FISH, a technique combining immunofluorescence 
(antibody against y H2AX) with FISH (telomeric PNA probe). This approach generated 
much stronger telomeric signal than staining with anti TRF2 antibodies (Figure 5.6 A). 
However, the analysis was not completed before submission of this thesis and we hope 
that our ongoing experiments will show more definitely whether depletion of BRCA1 
causes telomere dysfunction in mammalian cells. Interestingly, we observed higher 
levels of 7y H2AX foci in BRCA1 depleted cells in comparison with mock-transfected 
cells (Figure 5.7). This further supports the notion that BRCA1 is involved in cellular 
DNA damage response. 
In parallel with the above experiments we have also performed telomere length 
analysis in MCF10A and MCF7 cells using flow-FISH. However, this analysis did not 
reveal any difference in telomere length between transfected and non-transfected cells 
(Figure 5.8). 
Figure 5.6 A representative example showing telomeres (yellow) (A) co-localised with 
y-H2AX proteins (green) (C) in a MCF10A nuclei by using a combined 
immunofluorescence with FISH technique counterstained with DAPI (B and D). 
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Figure 5.8 Telomere length analysis by flow-FISH in MCF cell lines. 
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5.2.2 Assessment of telomere function in human ALT cell lines 
5.2.2.1 Determination of ALT features 
ALT cell lines are characterized by a heterogeneous telomere length with some 
chromosomes showing long telomeres as detected by strong telomere fluorescence 
after FISH and some chromosomes completely lacking telomeric signal (Cerone et al., 
2001; Scheel et al., 2001; Scheel and Poremba, 2002). In this study, so far, we 
analysed many non-ALT human cell lines (28 in total) and found lack of telomeric 
signal in individual chromosomes only in late passage primary fibroblast from 
radiosensitive individuals (Chapter 4). We have also shown that this lack of telomeric 
signal is associated with telomere dysfunction i. e. increased incidence of anaphase 
bridges (see Chapter 4). 
This prompted us to investigate telomere function in ALT cells i. e. we reasoned 
that chromosomes lacking telomeric signal are likely to have dysfunctional telomeres. 
Initially we used an ALT positive cell line WI-38 VA13/2RA (Henson et al., 2002). 
Analysis of the cytogenetic profile of this cell line revealed that approximately 10 % of 
chromosomes lacked telomeric signal (Figure 5.9 A). We also noticed the presence of 
end-to-end chromosome fusions, with telomeric FISH signal present at the point of 
fusion, in approximately one third of WI-38 VA13/2RA cells (not shown) a possibility 
consistent with ongoing telomere instability. In addition, we found dicentric 
chromosomes in this cell line (Figure 5.9 A). Theoretically these dicentric 
chromosomes could result from end-to-end fusion of two chromosomes lacking 
telomeric signal. Another cytogenetic indicator of telomere dysfunction is the presence 
of mini chromosomes showing strong telomeric signals or extra-chromosomal telomeric 
fragments (ECTFs) in affected cells (Zhu et al., 2003). Extra-chromosomal telomeric 
DNA circles were observed in ALT cells by electron microscopy and confirmed by two 
dimensional pulsed-field gel electrophoresis (Cesare and Griffith, 2004). T-loop 
deletion by homologous recombination might contribute to ECTFs (Wang et al., 2004). 
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We found a large number of these indicators of telomere dysfunction in WI-38 
VA13/2RA cells (Figure 5.9 A, Table 5.1). Therefore, analysis of cytogenetic profile of 
the WI-38 VA13/2RA cell line revealed the presence of cytological indicators of 
telomere dysfunction. 
This prompted us to analyse more ALT positive cell lines by cytogenetic 
methods. For this purpose we used another lung adenocarcinoma cell line, SK-LU1 
(Figure 5.9 B) and two osteosarcoma cell lines, U2-OS and G-292 (Figure 5.9 C and 
D), previously shown to be ALT positive (Henson et al., 2002). Similarly to WI-38 
VA13/2RA cells, we found strong evidence of telomere dysfunction in these cell lines 
as summarized in Table 5.1. Collectively, these results argue that ALT positive cell 
lines show cytological evidence of telomere dysfunction. Examination of immortalized 
non-ALT human cell lines (e. g. six human lymphoblastoid cell lines described in 
Chapter 3) indicated complete lack of above indicators of genomic instability. 
Table 5.1 Percentages of cells with at least one chromosome fusion or dicentric 
chromosome, and with at least one extra-chromosomal fragment (ECTF) in four 
different ALT cell lines. 
Cell Line Chromosome fusions Dicentric chromosomes ECTF 
WI-38 VA13/2RA 29.4 17.6 70 
SK-LU 1 37.5 0 71 
U2-OS 21.5 7 
G-292 67 20 
100 
100 
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Figure 5.9 Representative examples of metaphases in ALT cells. Chromosomes 
showing lack of telomeric signal or heterogeneous telomere lengths. Closed arrows 
indicate either chromosome fusions or dicentric chromosomes and open arrows 
indicate extra-chromosomal telomeric fragments (ECTFs) in WI-38 VA13/2RA (A), SK- 
LU1 (B), U2-OS (C), and in G-292 (D) cells. 
5.2.2.2 Telomere length analyses by flow-FISH in ALT cells 
We also evaluated telomere length of ALT cells over time by flow-FISH. As 
expected, ALT cell telomeres were characterised by a much longer average size than 
the telomeres of non-ALT cells (Figure 5.10). The telomere length distribution in ALT 
cells was found to be dynamic, with frequent fluctuations in telomere size i. e. a pattern 
of erosion and rapid increase in length of telomeric DNA tracts was observed (Figure 
5.10). This finding is compatible with recent demonstration of rapid losses and 
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increases in telomere length of ALT cell lines via recombination (Cesare and Griffith, 
2004; Wang et al., 2004). Telomere length in the WI-38 VA13/2RA cell line varied 
between 17.6 and 31.9 kb (Figure 5.10 B) while in the parental cell line (non ALT W138 
fibroblast cell line) telomere length was on average shorter (13.8 kb) and stable during 
approximately 5 PDs (Figure 5.10 A). Telomere length in the other ALT cells varied 
between 21.6 and 33.1 kb in SK-LU1 cells (Figure 5.10 C), and between 15.8 and 21.6 
in G-292 (Figures 5.10 D). As shown in Chapter 3, the U2-OS cell line contained 3 
subpopulations of cells with different telomere length with average telomere length 
values 23.7,39.8 and 64.3 kb (Figure 3.18 B). 
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5.2.2.3 Immunocytochemical analysis in ALT cells 
5.2.2.3.1 Detection of APBs in ALT cell lines 
Since above results indicate telomere dysfunction at the chromosome level, this 
prompted us to investigate whether ALT cell lines will show telomere dysfunction by 
immunocytochemistry methods. We first performed immunocytochemistry experiments 
to detect APBs, ALT associated PML bodies which represent markers of ALT. APBs 
are defined by the co-localisation of PML with TRF1 /TRF2 proteins and/or telomeric 
DNA in ALT cells (Yeager et al., 1999) and are specific for ALT cells that maintain 
telomeres by recombination. The Santa Cruz antibody against TRF2 gave the best 
results and was used in subsequent co-localisation experiments. ALT cells with 
unusually long telomeres are also able to form t-loops (Cesare and Griffith, 2004) and, 
as TRF2 is involved in the t-loop establishment (Griffith et al., 1999), TRF2 should 
equally be detectable at telomeres in ALT cells. We found higher amounts of TRF2 
proteins in these cells compared with mammary epithelial cells having shorter 
telomeres (see above). 
APBs (PML- and TRF2 double positive nuclear foci) were observed in all four 
ALT cell lines in unusually high frequencies but were undetectable in the WI-38 cell 
line, which was used as a non-ALT control (Figure 5.11; Table 5.2). These percentages 
of cells with APBs were higher then previously reported (Yeager et al., 1999; Nabetani 
et al., 2004). In contrast, in non-ALT, telomerase-positive cell lines these telomeric 
proteins and the PML nuclear bodies occupy distinct and separate subnuclear domains 
(Yeager et al., 1999; Grobelny et al., 2000; Nabetani et al., 2004). The WI-38 
VA1 3/2RA and the U2-OS cells contained smaller nuclear aggregates than the other 2 
ALT lines and we are currently investigating reasons for this. 
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Figure 5.11 Detection of APBs by immunofluorescence in ALT cell lines. PML co- 
localises with TRF2 in the cell line WI-38 VA13/2RA (A), SK-LU1 (B), US-OS (C) and 
G-292 (D). Interphase cells were permeabilised and stained with anti-PML (green) and 
anti-TRF2 (red) antibodies. Nuclei were counterstained with DAPI. 
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5.2.2.3.2 Telomerase activity in ALT cells 
The absence of telomerase activity from ALT cells correlates with lack of 
expression of hTERT and sometimes hTR (Bryan et al., 1997; Henson et al., 2002). 
We evaluated all four ALT cell lines for hTERT expression and two ALT cell lines for 
telomerase activity. Surprisingly, however, RT-PCR detected hTERT mRNAs in U2-OS 
cell line (Figure 5.12 A) in contrast to a previous report (Scheel et al., 2001). Also, 
RTQ-TRAP assays revealed high telomerase activity levels in early passages of the 
U2-OS and WI-38 VA13/2RA cell lines (Figure 5.12 B). Equally Saos-2, another ALT 
cell line (Henson et al., 2002), showed telomerase activity (Scheel et al., 2001; Scheel 
and Poremba, 2002) suggesting that ALT cell lines do not necessarily lack this enzyme 
activity. 
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Figure 5.12 Detection of hTERT mRNA expression in ALT cell lines. 1: WI-38 
VA12/2RA; 2: SK-LU1; 3: U2-OS; 4: G-292. M: molecular weight marker, PC: human 
mammary epithelial Bre-80 cells as a positive control (A). Telomerase activity levels 
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5.2.2.3.3 Association of BRCA1 with telomeres in ALT cells 
Next, we examined the co-localisation of endogenous BRCA1 with TRF2 in the 
non-ALT WI-38 cells and in four ALT cell lines by fluorescent immunostaining using 
mouse anti-BRCA1 antibody. The analysis of a two-colour fluorescence 
immunostaining demonstrated that BRCA1 foci were overlaid with nuclear dots of 
TRF2 (Figure 5.13) in ALT cells but not in the non-ALT WI-38 cells. These results 
indicate that BRCA1 proteins co-localise with TRF2 and telomeres in ALT cell lines. 
Frequencies of co-localised spots ranged from 14 to 41 % in ALT cell lines (Table 5.2). 
5.2.2.3.4 Association of yH2AX with telomeres of ALT cells 
We next examined the co-localisation of endogenous phosphorylated histone 
H2AX and TRF2 foci in the non-ALT WI-38 and in four ALT cell lines by fluorescent 
immunostaining using mouse anti-y-H2AX. y-H2AX is one of the molecular signals that 
accumulate at damaged sites in the earliest time course of DSB repair (Paull et al., 
2000). 
The percentage of interphase cells possessing at least one y-H2AX nuclear 
focus ranged from 39 to 71% in ALT cells (Table 5.2). Interestingly, it was found that 
fractions of y-H2AX nuclear foci in ALT cells co-localised with TRF2 (Figure 5.14 and 
Table 5.2) indicating presence of DSBs at telomeres. Frequencies ranged from 32 to 
67 % (Table 5.2). In contrast, co-localisation of y-H2AX with telomeres as determined 
by immunofluorescence was absent in non-ALT W138 cells (Table 5.2). 
y-H2AX also associated with PML bodies in ALT cells (Figure 5.15). The PML 
bodies co-localised with y-H2AX are probably APBs, thus corroborating results from 
recently published studies (Nabetani et al., 2004) that , 1-H2AX is a constitutive 
component of APBs in ALT cells. 
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Figure 5.13 Detection of BRCA1 by immunofluorescence in ALT-positive cell lines. The 
visible BRCA1 foci are likely to represent aggregates of hundreds or more molecules. 
BRCA1 co-localises with TRF2 in the cell line WI-38 VA13/2RA (A), SK-LU1 (B). US- 
OS (C) and G-292 (D). Interphase cells were permeabilised and stained with anti- 
BRCA1 (green) and anti-TRF2 (red) antibodies. Nuclei were counterstained with DAPI. 
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Figure 5.14 Detection of y-H2AX by immunofluorescence in ALT cell lines. y-H2AX co- 
localises with TRF2 in the cell line WI-38 VA13/2RA (A), SK-LU1 (B), US-OS (C) and 
G-292 (D). Interphase cells were permeabilised and stained with anti-7 H2AX (green) 
and anti-TRF2 (red) antibodies. Nuclei were counterstained with DAPI. 
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Figure 5.15 A representative example of PML (green) co-localisation with y-H2AX (red) 
in a SK-LU1 nuclei. 
5.3 Discussion 
5.3.1 BRCA1 and telomere maintenance 
Telomere dysfunction induces a DNA damage response in mammalian cells. 
The MRE1 1 -RAD50-NBS1 (MRN) complex, which is implicated in DNA DSB repair, 
was found to interact with TRF2 and to localise at telomeres (Zhu et al., 2000). Other 
DNA damage response factors, such as y-H2AX, 53BP1, RAD1 7, RAD51 D, and ATM 
were discovered to become associated with dysfunctional, uncapped telomeres (Takai 
et al., 2003; d'Adda di Fagagna et al., 2004; Herbig et al., 2004; Tarsounas et al., 
2004). It was also reported that BRCA1 interacts and co-localises with the MRN 
complex following DNA damage (Zhong et al., 1999; Wang et al., 2000; Wu et al., 
2003) suggesting that BRCA1 could also associate with telomeres. 
Support for the notion that the BRCA 1 gene suppresses genome instability 
comes from several sources. Embryonic tissue lacking wild type BRCA1 revealed IR 
hypersensitivity, consistent with a defect in DSB repair (Sharan et al., 1997; Deng et 
al., 2000). BRCA1 homozygous mutant mouse embryo fibroblasts undergo 
spontaneous chromosome breakage accompanied by checkpoint-mediated growth 
arrest (Deng et al., 2000). Alterations in the BRCA1 gene affect multiple pathways 
including DNA repair through homologous recombination, transcription coupled repair, 
chromatin remodelling, centrosome duplication, apoptosis and cell cycle checkpoint 
158 
Chapter 5. Role of BRCA 1 in telomere maintenance 
control (reviewed in Venkitaraman, 2002). Accelerated shortening of telomeres in 
BRCA1 deficient mouse embryonic stem cells was demonstrated in Chapter 4, 
indicating that lack of BRCA1 may affect telomere function. Consistent with this 
possibility mouse cells with targeted truncation in exon 11 of BRCA 1 showed dicentric 
chromosomes (Xu et al., 1999; Weaver et al., 2002) some of which may result from 
end-to-end chromosome fusions, which represent signatures of telomere dysfunction. 
The most recent study revealed dramatically elevated levels of end-to-end 
chromosome fusions in BRCA1 l p53-ß mouse T-cells in comparison with cells from 
p53 mice (McPherson et al., 2004). A recently demonstrated ability of BRCA1 to 
suppress telomerase may contribute to its tumour suppressor activity (Xiong et al., 
2003). 
By depleting BRCA1 in two MCF cell lines, we wished to assess its effect on 
telomere maintenance. This part of our research is still in progress but initial results 
show that a transient decrease in BRCA1, as was determined by three independent 
techniques, immunofluorescence, RT-PCR and Western blotting, causes accumulation 
of DNA damage. Elevated levels of DNA damage were demonstrated by an increase in 
histone H2AX phosphorylation (y-H2AX) indices. We have also observed moderate 
telomere dysfunction levels in MCF10A cells possessing significantly higher levels of 
anaphase bridges than control mock-transfected cells. Telomere length was not 
affected during depletion of BRCA1 mRNA, possibly because lower levels of BRCA1 
protein lasted only 2-4 days. These results are consistent with the fact that BRCA1 
deficient cells suffer from both DSB repair and chromosomal instability (Wang et al., 
2001). 
Human telomerase reverse transcriptase (hTERT), the catalytic subunit of 
human telomerase, is responsible for the synthesis and maintenance of the telomeric 
repeats at the ends of human chromosomes. Previous studies have shown that c-Myc 
stimulates hTERT transcription through the binding sites located on the hTERT 
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promoter (Zhou and Liu, 2003). Recently, evidence has been provided that BRCA1 
protein binds to the c-Myc protein, turns off the transcription of hTERT, and prevents 
incidental cellular immortalisation (Li et al., 2002; Zhou and Liu, 2003; Xiong et al., 
2003). Xiong et al (2003) demonstrated that an exogenous BRCA 1 gene strongly 
inhibited telomerase enzyme activity in human prostate and breast cancer cell lines. It 
was also shown in co-transfection experiments that a wtBRCA1 plasmid inhibited 
hTERT gene expression in human ovarian cancer (Zhou and Liu, 2003). Therefore, we 
expected to observe changes in hTERT expression in both MCF cell lines during 
transient BRCA1 mRNA depletion. Surprisingly, however, no changes in hTERT 
expression were observed by RT-PCR and Western blotting. One possible explanation 
could be that the depletion of BRCA1 protein lasted too short to affect expression of 
hTERT in our cell lines. Alternatively, different cell lines may use different mechanisms 
of regulating hTERT i. e. we used genetically highly abnormal cell lines, which may 
show differences in either genetic content or gene expression in comparison with lines 
used in the study by Xiong et al. (2003). 
5.3.2 Analysis of telomere function in ALT cell lines 
One of the research aims in our laboratory is to identify the extent to which 
dysfunctional telomeres contribute to genomic instability. For this reason we decided to 
analyse telomere function in human ALT cell lines. As mentioned earlier these cell lines 
show highly heterogeneous telomeres with many chromosomes lacking telomeric 
signals as detected by PNA-FISH (Cerone et al., 2001; Scheel et al., 2001; Scheel and 
Poremba, 2002). Telomere function in ALT cells can be assessed by a novel method 
based on immunnocytochemical co-localisation of DSBs and telomeres (d'Adda di 
Fagagna et al., 2003; Takai et al., 2003). Using this method we assessed telomere 
function in four human ALT cell lines. In addition we assessed telomere function in ALT 
cells based on cytogenetic parameters i. e. cytologically apparent indicator of telomere 
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dysfunction such as dicentric chromosomes, end-to-end chromosome fusions and 
small telomere positive extrachromosomal fragments. Both methods revealed clear 
telomere dysfunction in ALT cell lines. 
Like BRCA1, histone H2AX is a target for ATM- or ATR-mediated 
phosphorylation and participates in transmission of the DNA damage signal to 
downstream molecules such as Chk1 and Chk2 (Motoyama and Naka, 2004). The 
molecular mechanism of the sensing of DNA damage, however, is still not clearly 
defined. Although phosphorylation of histone H2AX, y-H2AX, is dispensable for the 
initial recognition of DNA damage, -y-H2AX is essential for the recruitment of BRCA1 
and other DNA-repair and damage-response factors like 53BP1, MDC1, and the MRN 
complex to the site of DNA damage (Fernandez-Capetillo et al., 2002; Stewart et al., 
2003). The appearance of y-H2AX foci before these repair factors, and the dependence 
of all these foci on the prior phosphorylation of H2AX, suggests that phosphorylation of 
H2AX and focus formation is a necessary first step in the organisation of repair factor 
foci (Paull et al., 2000). Sites of DNA damage are marked within minutes by the 
phosphorylation of H2AX, which spreads over a region spanning thousands of bases 
around the lesion, suggesting that chromatin remodelling may occur to facilitate access 
of the repair machinery. As phosphorylation of H2AX is specific to DSBs (Bassing et 
al., 2002), this very likely indicates a high level of DSBs present in the cell all the time, 
which was especially observed in mouse ES cells (see Chapter 4). It is not yet clear 
whether these foci represent many DSBs being made with a high turnover of repair, or 
whether there are relatively few DSBs that persist in the cells for a longer time without 
being repaired. Interestingly, H2AX deficiency causes a dramatic decrease in BRCA1 
focus formation after IR (Bassing et al., 2002). 
We observed co-localisation of y-H2AX with the telomere binding protein TRF2 
in all four ALT cell lines analysed. In each of the four analysed ALT cell lines we found 
approximately 50% of cells positive for yy-H2AX foci, of which nearly all showed at least 
161 
Chapter 5. Role of BRCA 1 in telomere maintenance 
one y-H2AX focus co-localising with TRF2, demonstrating DNA repair response at 
telomeres i. e. the presence of DSBs at telomeres. This clearly suggests that telomeres 
in ALT cell lines are dysfunctional. To check whether this telomere dysfunction has any 
effect on cell survival we are currently irradiating ALT cell lines and monitoring their 
survival rates after IR relative to the non-ALT W138 cell line. We are also further 
examining the unexpected detection of telomerase activity (at least in early passages) 
in ALT cell lines. However, it has been shown that telomerase and ALT can co-exist in 
the same cell line (Cerone et al., 2001) and that some ALT cell lines have detectable 
telomerase activity (Scheel et al., 2001; Scheel and Poremba, 2002). 
One of the features of ALT is an accumulation of ALT associated PML bodies 
(APBs) (Yeager et al., 1999), which consist of DNA repair proteins that specifically 
coalesce, presumably, at telomeres (as judged by co-localisation in 
immunofluorescence experiments with telomeric DNA and the foci of TRF proteins). 
Proteins found associated with APBs include BRCA1, NBS1, RAD51, BLM, and others. 
These foci of repair proteins are generally considered to be hallmarks of active 
complexes, and possibly of active recombination at telomere ends. It was also 
demonstrated by incorporation of BrdU into the nucleus that DNA synthesis occurs at 
APBs (Grobelny et al., 2000; Nabetani et al., 2004), indicating a role for APBs in 
telomere elongation. In line with above results we found high percentages of APBs in 
all four ALT cell lines analysed. However, these percentages were much higher then 
previously reported by Yeager et al (1999) and Nabetani et al (2004). Yeager et al. 
(1999) detected APBs in only a subset (--5%) of interphase nuclei. Their lower 
percentages of cells with APBs can be explained by using paraffin embedded tissues 
and the antigen retrieval method, which suffers, depending on the antibody used, from 
a lower detection resolution (personal observation). 
Similarly to the study by Wu et al. (2003) we found that BRCA1 co-localises with 
telomeric protein TRF2 in all ALT cell lines. On average, 20% of cells in all four ALT 
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cell lines showed co-localisation of BRCA1 with TRF2 (Table 5.2). This, however, does 
not implicitly suggest that BRCA1 targets telomeric DNA since BRCA1 associates also 
with APBs, specifically during late S-G2 phase of the cell cycle phase (Wu et al., 2003), 
which contains TRF2 proteins. The focal location of BRCA1 in nuclear dots reflects 
possibly only a fraction of the cellular pool, perhaps that which is bound to particular 
nuclear structures. Nevertheless, we observed higher percentages of cells positive for 
BRCA1 in ALT cell lines compared to human non-ALT fibroblast cell lines. These 
results, therefore, are inconsistent with suggestions that long telomeres may provide a 
protective effect against genomic insults. Also mouse scid (severe combined 
immunodeficiency) cells have elongated telomeres and yet show telomere dysfunction 
(Slijepcevic et al., 1997; Bailey et al., 1999; Hande et al., 1999) suggesting that longer 
telomeres do not necessarily provide protection to chromosome ends. A similar 
conclusion was also drawn by a study on mouse leukaemia cells (Finnon et al., 2001). 
In conclusion, results presented in this chapter indicate clear telomere 
dysfunction in ALT cells and point to the possibility that BRCA1 could also affect 
telomere maintenance. Future work is required to conclusively demonstrate the role of 
BRCA1 at telomeres and such experiments are currently under way in our laboratory. 
5.4 Summary 
We examined the role of BRCA1 in telomere maintenance in two mammary 
epithelial MCF cell lines. BRCA1 was transiently depleted for 1-5 days to assess its 
effect on telomere function. This work is still in progress but preliminary results show 
that a transient decrease in BRCA1, as was determined by three independent 
techniques, immunofluorescence, RT-PCR and Western blotting, increased the number 
of histone H2AX phosphorylation ('y-H2AX), indicating elevated levels of DNA damage 
repair. Moderate telomere dysfunction may also be seen in MCF10A cells possessing 
slightly more anaphase bridges. Telomere length was not affected during depletion of 
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BRCA1 mRNA, possibly because lower levels of BRCA1 protein lasted only for a few 
days. These results are consistent with the fact that BRCA1 deficient cells suffer from 
both DSB repair and chromosomal instability. 
We also assessed telomere function in four human ALT positive cell lines. 
Using cytogenetic and immunocytochemistry methods we observed telomere 
dysfunction in ALT positive cell lines. We observed unexpectedly high frequencies of 
APBs in ALT cells. Not only BRCA1, also y-H2AX was used as a novel marker in 
detecting telomere dysfunction. We demonstrated that these early DNA damage 
response factors associate at telomeres in ALT cells. We are still investigating whether 
BRCA1 at telomeres aid in maintaining telomere end protection and in the repair of 
double strand breaks. 
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CHAPTER 6 
TELOMERASE ACTIVITY AND ALTERNATIVE SPLICING OF THE TELOMERASE 
REVERSE TRANSCRIPTASE (hTERT) TRANSCRIPT IN BRAIN TUMOURS 
6.1 Introduction 
In the previous chapters we have shown that fibroblasts with defects in DNA 
damage response and human ALT cells show dysfunctional telomeres. We argued that 
these phenotypes, at least in the case of human fibroblast cell lines defective in DNA 
damage response, may be the consequence of radiosensitivity. Cells that are 
radiosensitive usually show chromosomal instability. A typical example is cells from 
ataxia telangiectasia (AT) patients, which display a high degree of spontaneous or 
induced chromosomal instability (Metcalfe et al., 1996; Pandita and Dhar, 2000; Hande 
et al., 2001; Tchirkov and Lansdorp, 2003). It is likely that dysfunctional telomeres 
contribute to chromosomal instability in AT cells (e. g. Hande et al., 2001). 
Brain tumours exhibit considerable chromosomal instability (EI-Zein et al., 1999; 
Hui et al., 2001; Sawyer et al., 2003). Given that chromosomal instability is usually a 
consequence of altered DNA damage response (see above) this suggests that 
alterations in DNA damage response mechanisms, some of which may involve 
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telomeres, could be responsible for tumorigenesis in brain cells. The presence of 
dicentric chromosomes in telomerase negative meningiomas (Carroll et al., 1999; 
Sawyer et al., 2003), for example, could indicate abnormal telomere function. 
There is relatively little information about the role of telomeres/telomerase in brain 
tumorigenesis and in this chapter we were interested to assess telomerase activity in 
brain tumours, particularly in meningiomas. Previous studies of meningiomas showed 
contradicting results with regard to telomerase activity as revealed by the classical 
telomere repeat amplification protocol (TRAP) (DeMasters et al., 1997; Hiraga et al., 
1998; Langford et al., 1997; Sano et al., 1998; Carroll et al., 1999; Falchetti et al., 1999; 
Simon et al., 2000; Boldrini et al., 2003). However, when we started this study 
expression levels of the telomerase components in meningiomas and in other brain 
tumours were not known. We reasoned that by employing RT-PCR we would be able 
to monitor expression levels of telomerase components in brain tumours and thus 
resolve above contradicting reports. This is particularly important because the 
presence or absence of telomerase in meningiomas and other brain tumours may be 
used to predict the clinical outcome (Boldrini et al., 2003). In addition, the mRNA 
splicing variants of the telomerase reverse transcriptase component (hTERT) inhibit 
telomerase (see below) and this could explain the absence of telomerase activity not 
only in meningiomas but also in other brain tumours. Therefore, we analysed the role of 
hTERT mRNA and their splice variants in telomerase positive and negative brain 
tumours. 
Several publications deal with telomere length in brain tumours, more specifically 
in meningioma (Hiraga et al., 1998; Chen et al., 2000), glioblastoma (Hiraga et al., 
1998; Falchetti et al., 2000; Hakin-Smith et al., 2003), oligodendroglial brain tumours 
(Hiraga et al., 1998; Chong et al., 2000), and in ependymal tumours (Chong et al., 
2000). The method of choice for telomere length measurement in brain tumours was 
Southern hybridisation. The telomere restriction fragment (TRF) length in brain tumours 
was considered normal if it ranged between 8.5 and 14 kb or abnormally elongated if 
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longer than 14 kb (Hiraga et al., 1998; Chen et al., 2000; Chong et al., 2000; Hakin- 
Smith et al., 2003). Chen et al (2000) found that the mean TRF of brain tumours with 
telomerase activity was significantly shorter than that of the tumours with undetectable 
telomerase activity. In addition, Hiraga et al. (1998) and Morii et al. (1997) reported that 
telomerase-negative gliomas had longer telomeres when compared with telomerase- 
positive gliomas. It seems likely that ALT (alternative lengthening of telomeres) was 
present in one case of malignant meningioma (case 30) showing no telomerase activity 
and telomere length greater than 25 kb although this was not specifically mentioned by 
the authors (Chen et al., 2000). On the other hand, no statistical differences were found 
between the mean telomere length in telomerase-positive and telomerase-negative 
tumours (Chong et al., 2000) although a slightly shorter length was observed in 
telomerase-positive oligodendroglial tumours. In addition, Falchetti et al. (2000) 
showed that there is no significant difference in telomere length pattern between 
TRAP-positive and TRAP-negative glioblastoma multiforme (GBM) tumours. Basically, 
they found normal or elongated telomeres in all samples. They concluded that, 
because they could not find any difference in TRF pattern between GBM samples with 
or without telomerase activity as detected by TRAP, all GBM tumours could have 
telomerase activity, which may not always be detectable by the standard TRAP assay. 
However, in this study only one restriction enzyme, Dpnll, was used for TRF 
measurement instead of a combination of two enzymes (Hinft and Rsal), which are 
more commonly used and give better results. Therefore, the conclusion made in this 
study regarding the lengths of TRFs may not be entirely accurate. In spite of lack of 
clarity in the above results, the possibility cannot be excluded that ALT mechanisms 
could operate in brain tumours as shown by the presence of relatively long telomeres in 
many of them in spite of telomerase absence. ALT has been detected in a variety of 
human tumours. These include bone and soft tissue sarcomas, carcinomas of the lung, 
kidney, adrenal gland, breast, and ovary (Mehle et al.. 1996; Bryan et al., 1997). 
Recently, Hakin-Smith et al. (2003) discovered that some patients had GBM tumours 
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with the ALT phenotype and that ALT can be considered as a prognostic indicator for 
patients with these malignant tumours. 
A limited number of studies have also been performed on telomerase activity in 
brain tumours, particularly in meningiomas, which represent a common neoplasm 
arising from the meninges (Kleihues and Cavenee, 2000) (see section 1.9; Figure 1.5). 
To date, it is generally accepted that high telomerase activity levels characterise high- 
grade gliomas (Le et al., 1998; Falchetti et al., 1999; Huang et at., 1999; Harada et al., 
2000; Sugita et al., 2000) but the picture for meningiomas is less clear with some 
tumours shown to be telomerase positive and some telomerase negative. The 
hypothesis that reactivation of telomerase is required to maintain tumour growth (Kim 
and Wu, 1997) or may play a critical role in the progression or maintenance of the 
malignant phenotype (Rhyu, 1995), are in conflict with findings in meningiomas. 
Several previous studies performed on single specimens of intracranial tumours have 
reported that telomerase activity is present in the vast majority of malignant brain 
tumours while enzyme activity could not be detected in benign meningiomas 
(DeMasters et al., 1996; Hiraga et al., 1998; Sano et al., 1998; Carroll et al., 1999; 
Falchetti et al., 1999). However, up to 21 % of single specimens of benign meningiomas 
had telomerase activity (Langford et al., 1997; Simon et al., 2000). The difference 
between intrinsically benign and more aggressive meningioma variants is of great 
importance: whereas typical meningiomas can frequently be cured by complete 
resection, atypical and anaplastic meningiomas are characterised by a substantially 
increased risk of tumour recurrence (Hiraga et al., 1998; Simon et al., 2000), with a 
clearly documented bad prognosis. Telomerase activity and its hTERT mRNA 
expression tended to increase as the histological grading of intracranial meningiomas 
increased, suggesting a role for telomerase reactivation in the progression of these 
tumours (Boidrini et al., 2003). 
These findings prompted us to investigate whether undetectable telomerase activity 
in meningiomas is also reflected in the absence of hTERT mRNA expression. 
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Second, intratumoral differences in tumour tissues may have resulted in a false-high 
proportion of telomerase-negative tumours. Benign meningiomas were therefore 
evaluated for telomerase activity and telomerase gene expression in multiple 
specimens of a single tumour. 
Third, because hTERT spliced variants are believed to be a limiting factor for the 
expression of telomerase activity (Kilian et al., 1997; Wick et al., 1999), we examined 
whether these were limiting components for the expression of telomerase activity in 
benign meningiomas. We therefore used primers to amplify a sequence located 
upstream and a sequence within the reverse transcriptase domains A and B', including 
two potential splice sites (Figure 6.1), to determine hTERT mRNA expression. Hence, 
we amplified both functional and non-functional spliced variants. 
Finally, we investigated the tumour growth rate mainly by use of Ki-67 which is a 
nuclear protein detected in proliferating cells in all phases of the cell division cycle and 
is widely used as a proliferation marker. 
a. (36bp) (3(1 82bp) 
DO 
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1500bp 
PCR product 
of 145bp 
3000bp 
PCR products of 457, 
421,275 and 239bp 
Figure 6.1 Schematic diagram of hTERT mRNA with telomerase-specific T-motif and 
1,2, A and B' conserved reverse transcriptase motifs highlighted. Deletion a which 
occurs within the A motif (lacking 36 nucleotides at the beginning of exon 6), and 
deletion ß (lacking 182 nucleotides corresponding to exons 7 and 8), situated between 
motif A and B', of hTERT cause 4 spliced products. First set of PCR primers (hTERT- 
1784S and hTERT-1928A) amplifies a 145-base region upstream of the reverse 
transcriptase domain. Second set of PCR primers (hTERT-21645 and hTERT-2620A) 
amplifies a region within the reverse transcriptase domain, which includes both a and ß 
splices sites. 
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6.2 Results 
6.2.1 Telomerase activity in brain tumour samples 
Telomerase activity was examined in 49 specimens of brain tumours from 32 
patients (Figure 6.2, Table 6.1). The presence of telomerase activity was tested only 
once in a previously frozen protein lysate (liquid nitrogen) because a rapid sample 
degradation occurs after two or more cycles of cell thawing. A total of 7 out of 32 
examined tumours (22%) contained detectable telomerase activity. The glioblastomas 
in lanes 13,24,32 and the medulloblastoma in lane 11 expressed high telomerase 
activity (Figure 6.2). The atypical meningiomas in lanes 17 and 27, and the 
ependymoma in lane 14 displayed reduced telomerase activity (Figure 6.2). 
Telomerase activity was undetectable in all (18) benign meningiomas at both 0.7 µI and 
2.0 µI protein content per PCR reaction mixture (data not shown). Two of the three 
locally recurring tumours (case 12,23, and 27) failed to display telomerase activity 
(Figure 6.2). 
The glioblastomas demonstrated focal differences for telomerase activity in that a 
TRAP-positive cancer region and a TRAP-negative cancer region were found within a 
given tumour. Individual variation in the amount of the protein was found in multiple 
samples of the glioblastomas (Figure 6.3). Brain tissue, dura mater and arachnoid 
tissue did not reveal telomerase activity (data not shown). Telomerase activity could be 
assigned to a higher cellular density as a histomorphological feature in histological 
sections adjacent to telomerase-positive samples. 
To rule out false-negative results due to the presence of tissue-specific inhibitors, 
all extracts with no detectable telomerase activity were re-evaluated. Small amounts of 
protein extracts of Molt-4 cells with known telomerase activity were mixed with 
telomerase-negative extracts (1: 4) and the TRAP assay was repeated. In all re- 
evaluated cases, a similar telomerase-specific 6 nt repeat ladder was obtained, 
indicating that these tissues did not contain telomerase inhibitors (data not shown). 
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Telomerase activity could not be detected in in vitro cultures of some 
meningiomas and glioblastomas (data not shown). However, in vitro telomerase activity 
is not necessarily synonymous with in vivo enzyme activity. 
6.2.2 Expression of hTERT in brain tumours 
hTERT transcripts were initially detected by RT-PCR using a set of primers 
(hTERT-1784S and hTERT-1928A) that amplify a region within the T-motif of hTERT 
mRNA giving a product of 145 bp (Figure 6.1; Figure 6.4A). The 145 bp hTERT cDNA 
was present in 20 of 32 (63%) intracranial tumours (Table 6.1). Whereas hTERT 
mRNA was consistently low or absent in meningiomas, brain tumours with telomerase 
activity exhibited elevated levels (Figure 6.4A; Table 6.1). In 13 cases (40.6 %), 
detectable hTERT mRNA was demonstrated in the absence of telomerase activity 
(Table 6.1). Different samples from the same tumour showed individual variation in 
hTERT mRNA expression, e. g. case 24 (Figure 6.4A; Table 6.1). We were unable to 
detect hTERT mRNA expression in the confluent cell cultures of meningiomas (cases 
5,7,9,17, and 20). hTERT could not be detected in cell cultures, derived from the 
arachnoid or from the dura mater. 
6.2.3 Expression of hTERC in brain tumours 
The expression of telomerase RNA component (hTERC) in brain tumours was 
determined by RT-PCR. Since hTERC transcript of approximately 450 bases is not 
polyadenylated, first-strand cDNA was reverse transcribed using random 
hexanucleotides and cDNA fragments were amplified by PCR. PCR bands of the 
predicted size were generated from all brain tumour specimens (Figure 6.4B) and also 
from normal brain and meninges (data not shown). 
Although we were unable to detect hTERT mRNA expression in the confluent cell 
cultures of meningiomas, all cultures expressed the hTERC mRNA. 
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NC M12345678 
36 bp IC 
36 bp IC 
36 bp IC 
36 bp IC 
Figure 6.2 Telomerase activity in intracranial tumours, as measured by TRAP assay. 
The presence of a 6-base incremental ladder is evidence for telomerase activity in a 
given sample. NC: cDNA was replaced by lysis buffer as negative control. M: Molt-4 
positive control. IC: 36 bp internal control. 
36 bp IC 
Figure 6.3 Telomerase activity in 3 different samples of a glioblastoma, case 24. PCR 
cycles were 27,30 and 33 in lane 1,2 and 3, respectively. M: Molt-4 with 33 PCR 
cycles; IC: 36 bp internal control. 
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6.2.4 Alternative splicing of hTERT in brain tumours 
Reverse transcription-FOR using primers within the reverse transcriptase domain 
A and B' of hTERT amplified a region including two potential splice sites (Figure 6.1). 
The a splice site causes a 36 bp deletion in the conserved reverse transcriptase motif 
A, which is required for an active reverse transcriptase. The ß splice site results in a 
182 bp deletion causing a non-sense mutation that truncates the protein, which also 
results in a non-functional reverse transcriptase. PCR performed using primers hTERT- 
2164S and hTERT-2620A revealed the presence of 4 spliced messages (Figure 6.4C, 
Table 6.1). These 4 transcripts represent the full-length hTERT transcript (457 bp), the 
a deletion transcript (421 bp), the ß deletion transcript (275 bp), and the a and ß 
deletion transcript (239 bp). Every tumour sample that expressed the 457 bp hTERT 
transcript with complete A and B' motif also expressed one or more spliced variants of 
hTERT mRNA. However, all 4 spliced transcripts were detected simultaneously only in 
tumours with marked telomerase activity and in Molt-4 positive control cells. The two 
different sets of primers could not detect any of the hTERT PCR fragments in 7 of 18 
benign meningiomas. Among the intracranial tumours, the full-length hTERT message 
was found also in the TRAP-negative tissues (3,5,10,12, and 29), although some of 
them only showed low levels. Telomerase activity was observed in the absence of 
detectable 457 bp hTERT transcript in only one tumour (case 17). Eight of 13 TRAP- 
negative tumours (cases 6,8,9,15,16,25,26, and 28) with no detectable 457 bp 
hTERT, but positive for 145 bp hTERT, showed spliced hTERT transcripts. The 
frequency of the 275 bp cDNA product was highest (21 of 32,66%). The 457,421 and 
239 bp transcripts were significantly less frequent (Figure 6.4C, Table 6.1). The 
presence of only the 457 bp DNA band was never detected, although in case 10, a 
pituitary adenoma, its intensity was greater than the 275 bp band. The relative amount, 
deduced from the band intensity in the gel, of each of the four spliced fragments was 
not the same between tumour samples, e. g. the 275 bp DNA was relatively more or 
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less present in comparison with the 457 bp DNA. Analysis of a rapidly growing cell 
culture from a glioblastoma (U251), not being part of the brain tumours under study, 
showed all hTERT spliced products in vitro. 
6.2.5 Immunohistochemical analysis of brain tumour proliferation 
Immunohistochemical analysis of tumour proliferation has been accomplished 
with the Ki-67 monoclonal antibody, which recognizes a nuclear antigen expressed 
during late G1, S, G2 and M phases of the cell cycle. The Ki-67 labelling indices (LI) 
were determined in randomly chosen areas and calculated as a percentage of the 
positively stained nuclei over the total number of tumour cell nuclei counted. The mean 
percentage of proliferating cells in the 32 intracranial tumours is given in Table 6.1. We 
observed relatively homogenous staining in all samples (Figure 6.5), but in some 
malignant tumours a heterogeneous distribution was evident. Cases 15,16 and 23 
were excluded because most of the paraffin blocks contained partially or completely 
oedematous brain tissue. In benign meningiomas, the mean proliferation index was 
1.2% (sd=1.0), in atypical meningiomas 3.4% (sd=0.4), and in the remaining malignant 
brain tumours 13.6% (sd=9.0), revealing a highly significant difference between benign 
and malignant tumours. The mean proliferation index was 1.9% (sd=1.8) for TRAP- 
negative tumours, 6.1% (sd=4.7) for low telomerase activity tumours, and 17.5% 
(sd=10.5) for high telomerase activity tumours. A significant correlation between 
telomerase activity scores and mean Ki-67 LI was found in intracranial tumours 
(y=7.8x-7.1, rp=0.71 Spearman rank correlation, Figure 6.6), as well as between Ki-67 
LI and the degree of the 145 bp hTERT expression (y=7.7x+2.9, rp=0.74 Spearman 
rank correlation, Figure 6.7). 
We studied a large array of other proliferation related markers in all samples of 
brain tumours in vivo (tissues embedded in paraffin) as well as in vitro (cells grown on 
thermanox coverslips or fixed and dropped on slides). The rate of ribosome biogenesis 
is closely related with cell growth and cell cycle progression of the cell. Therefore 
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AgNORs, which associate with transcriptionally active sites of ribosomal DNA and 
nucleolin, which regulates the rate of pre-ribosome production were chosen as 
alternative proliferation markers (Tuteja and Tuteja, 1998; Sirri et al., 2000; Derenzini et 
al., 2004). They can be considered as markers for protein synthesis and thus the 
proliferation rate of a given cell. Also of interest is that telomerase RNA accumulates in 
nucleoli (Filipowicz and Pogacic, 2002). A representative overview of applied 
proliferation markers is shown in Figure 6.8. Higher percentages of AgNORs and 
nucleolin dots showed a positive correlation with malignant brain tumours (data not 
shown). The use of PCNA antibodies proved not to be useful as a proliferation marker 
in brain tumours (data not shown). 
ýý =ý 
ý . ;- ý- 
Figure 6.5 Detection of proliferating cells by Ki-67 immunostaining in meningioma (A) 
and in glioblastoma (B). Malignant brain tumours, like this glioblastoma in B showed a 
much higher percentage of proliferating cells than their benign counterparts as 
meningioma in A. 
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Figure 6.6 Correlation between Ki-67 labelling index (%) and negative, low and high 
telomerase activity in intracranial tumours as determined by immunohistochemistry and 
TRAP assay, respectively. 
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Figure 6.7 Correlation between Ki-67 labelling index (%) and hTERT mRNA 
expression levels (145 bp hTERT transcripts) in intracranial tumours as determined by 
immunohistochemistry and RT-PCR, respectively. 
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Figure 6.8 Representative examples of proliferation markers AgNOR and nucleolin in 
brain tumours. Immunofluorescence staining of nucleolin (A) and AgNOR silver 
staining (B) in meningioma. Immunofluorescence staining of nucleolin (C) and AgNOR 
silver staining (D) in glioblastoma. Glioblastomas and other malignant brain tumours 
showed higher amounts of nucleolin and AgNOR proteins per cell. 
6.2.6 TUNEL apoptotic cell detection 
Brain tumour samples for RT-PCR and TRAP assays (see previous sections) 
were taken from viable brain tumour tissues. Therefore, tumour samples were analysed 
for apoptotic/necrotic tissues by the TUNEL apoptotic cell detection assay. For the 
detection of apoptosis only fields of vision containing immunostained nuclei were 
accepted for the calculation. The apoptotic index (Al) was calculated as a percentage 
of TUNEL stained nuclei divided by the total number of tumour cell nuclei counted. 
Regions of apoptotic/necrotic brain tumour tissues were only found in highly malignant 
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glioblastomas (data not shown) and were discarded for hTERT and telomerase activity 
analysis. 
6.2.7 Double immunocytochemical detection of hTERT and cell cycle-related Ki- 
67 in brain tumour cells in vitro 
Brain tumours analysed by hTERT RT-PCR and the TRAP assay demonstrated a 
correlation between hTERT/telomerase activity with the Ki-67 antigen. However, the 
level of telomerase activity in brain tumours composed of telomerase-competent cells 
may depend on the fraction of proliferating cells. Therefore, we assessed the position 
of hTERT and Ki-67 protein in the cell. hTERT is found throughout the nucleus and is 
also concentrated in nucleoli (Etheridge et al., 2002; Wong et al., 2002; Yang et al., 
2002) and in Cajal bodies (Zhu et al., 2004). 
We investigated hTERT and Ki-67 by different immunocytochemical techniques 
in 21 primary cell cultures of brain tumours. Hela cells were used as a positive control 
and monocytes and quiescent lymphocytes were used as a negative control. hTERT 
was detected strongly in Hela cells but was absent in the mononuclear blood cells 
(Figure 6.9 A-B). Overall, meningiomas showed less hTERT in their nuclei compared 
with malignant brain tumours (Figure 6.9 C-E). Interestingly, detection of hTERT in the 
nuclei failed after a week suggesting that hTERT disapears from the nucleus within a 
few days in cell culture (Figure 6.9 E-F). This could explain the reason why these 
primary cell cultures were TRAP negative. Similarly, cell culture growth reduction by 
contact inhibition, as shown by a lower Ki-67 labelling index, revealed also the 
presence of much less hTERT antigen. 
Surprisingly, double staining of hTERT and Ki-67 revealed no positive correlation 
(Figure 6.10). hTERT antigen is present in proliferating cells in vitro but it can also be 
detected in Ki-67 negative brain tumour cells. This study implies that the hTERT L-20 
antigen cannot be used as a proliferation marker in brain tumours in vitro. 
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Figure 6.9 Immunocytochemistry of hTERT. Monocytes were used as a negative 
control (A) and Hela cells as a positive control (B). hTERT expression in meningioma 
cells stained with DAB and counterstained with Haematoxylin (C); hTERT in 
meningioma cells stained with Texas Red and counterstained with DAPI (D). 
Glioblastoma cells stained with DAB and counterstained with Haematoxylin (E) and 
after 4 days in culture (F). 
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Figure 6.10 Double immunodetection of hTERT and Ki-67 in glioblastoma cells. Cell 
cultures were grown on thermanox coverslips and stained with anti-TERT L-20 
simultaneously either indirectly with a polyclonal anti-Ki-67 (A) or directly with a 
monoclonal anti-Ki-67 (green) (B). Arrows point to a nucleus with both hTERT and Ki- 
67 proteins present. Other nuclei contain only Ki-67 signals. 
6.3 Discussion 
6.3.1 Telomerase activity in brain tumours 
Telomerase activity was undetectable in benign intracranial tumours (20 in total), 
the majority of which were meningiomas (18 in total) (Table 6.1). It is important to 
determine whether these results of the TRAP assay are truly negative or positive, since 
the presence of inhibitors of either the polymerase used in PCR or the telomerase 
enzyme have been reported to be a potential problem in the analysis of a total protein 
extract (Wright et al., 1995; Sugino et al., 1997). All meningiomas in our study were 
attached to the dura and their histological sections, stained with Masson trichrome, 
mostly showed the presence of connective tissue. Proteins may be present in this 
connective tissue that inhibit Taq polymerase activity and prevent amplification of 
telomerase products (Bachor et al., 1999). However, we do not think that telomerase 
activity in the specimens of meningiomas was suppressed by inhibitors. For example, 
the amplified 36 bp internal control in each TRAP assay was always present (Figure 
6.2) suggesting the absence of PCR inhibitors. In addition, telomerase activity of Molt-4 
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positive control cells was not inhibited when mixed with the TRAP-negative sample 
extracts (data not shown). 
Although the TRAP assay relies on internal controls to detect PCR inhibitors and 
spurious telomerase activity, it cannot assess the enzyme inactivation with time. We 
found that tissue preservation was important for the detection of telomerase activity. 
Some malignant tumours with a negative or reduced telomerase activity were frozen in 
liquid nitrogen 2-4 hours after tumour resection. Protein degradation might have 
occurred in these tissues. We tested this assumption on other tissue samples that had 
previously been shown to have telomerase activity. We found that telomerase activity 
was undetectable or showed decreased TRAP products in tissues that had not been 
frozen immediately (data not shown). Time that elapsed between tumour resection and 
freezing is apparently important in detecting telomerase enzyme activity. Although 
telomerase is thought to be detectable even when 100 positive cells are present, small 
biopsy sizes were excluded because they are far more susceptible to enzyme 
degradation. 
Benign meningiomas, which lacked telomerase activity in multiple regions, 
showed uniformity of tissue samples in terms of tumour density and cell type. On the 
other hand, histological sections of malignant tumours invariably consisted of mixtures 
of tumour cells, necrotic tissues, and remnants of normal brain tissues. It is likely that 
different regions of glioblastomas may show variation in telomerase activity (Figure 
6.3). This finding is supported by in situ hybridisation experiments of hTERT, which 
showed a focal pattern in both TRAP-positive and TRAP-negative glioblastomas 
(Faichetti et al., 2000). Thus, the classification of a glioblastoma as telomerase- 
positive, however, seems limited as demonstrated by the markedly intratumoral 
variation in telomerase activity. This means that a single tumour sample, which was 
assayed for telomerase activity, can hardly be regarded as representative for a given 
glioblastoma, limiting the diagnostic value of the telomerase activity assays on 
glioblastoma cancer biopsies. Intratumoral variations in telomerase activity have also 
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been documented in high-grade astrocytomas (Kleinschmidt-DeMasters et al., 1998) 
and in prostate cancer (Wullich et al., 1997). In other studies on telomerase activity. 
tissue heterogeneity is mostly not taken into account. Histological sections of cases 15, 
16 and 23 contained considerable amounts of oedematous brain tissue, which might 
explain why these malignant tumours were telomerase negative in the specimens used 
for the TRAP assay. 
The absence of telomerase activity suggests that telomerase activity is not an 
essential prerequisite for meningioma development. Similar observations were made 
for retinoblastoma (Gupta et al., 1996), renal cell carcinoma (Mehle et al., 1996) and 
pheochromocytoma (Kubota et al., 1998) as well as for soft tissue tumours (Yan et al., 
1999). The absence of telomerase activity in benign meningiomas might correspond to 
the short telomeres found in these tumours (Chen et al., 2000). Also, the presence of 
dicentric chromosomes in telomerase negative meningiomas (Carroll et al., 1999; 
Sawyer et al., 2003), which are absent in glioblastomas (Magnani et al., 1994), might 
represent abnormal telomere function due to absence of telomerase. Langford et al. 
(1997) and Simon et al. (2000) observed, however, telomerase activity in five of 30, 
and in seven of 34 benign meningiomas, respectively. These authors have used the 
downstream primer CX in the TRAP assay, which can form primer-dimer products and 
thus lead to false-positive results. We used the alternative downstream primer ACX, 
which results in a significant reduction of primer-dimer PCR artefact formation (Kim et 
al., 1994). 
6.3.2 Telomerase mRNA expression in brain tumours 
The human telomerase catalytic subunit (hTERT) is regarded as the core 
component of the enzyme telomerase (Wick et al., 1999). hTERT expression has been 
demonstrated in association with telomerase activity, although it may also be present in 
the absence of telomerase activity (Kyo et al., 1999; Liu et al., 1999; Wu et al., 1999; 
Yan et al., 1999: Falchetti et al., 2000; Simon et al., 2000; Ulaner et al., 2000). To date, 
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hTERT regulation in relation to absence or presence of telomerase activity is not fully 
understood. It is considered to take place at the transcriptional level (Greenberg et al.. 
1999), post-transcriptional level (Li et al., 1998), or at the post-transcriptional level 
through alternative splicing (Ulaner et al., 1998; 2000). 
In this study, the relative expression of hTERT was assessed by densitometric 
analysis of the PCR products obtained by a duplex PCR protocol that allowed the 
simultaneous amplification of hTERT and the housekeeping gene transcripts. 
Messenger RNA, encoding the reverse transcriptase of telomerase, was present in 20 
of 32 (63%) intracranial tumours, whereas telomerase could be detected in only 7 
(22%) intracranial tumours (Figure 6.4; Table 6.1). The detection of hTERT mRNA may 
be a more sensitive indicator of enzyme activity than TRAP due to its insensitivity to 
proteases or protein inhibitors. RT-PCR has the added advantage of being far more 
tolerant in amplifying fragments of partially degraded RNA than the TRAP assay in 
detecting enzyme activity. This scenario seems plausible in case 29, a glioblastoma 
which was frozen in liquid nitrogen 2.5 hours after surgery, where hTERT mRNA is 
expressed in the absence of an expected telomerase activity (Figures 6.2 and 6.4). 
Previous studies have shown that the expression of hTERT mRNA correlates 
with telomerase activity (Kilian et al., 1997; Nakayama et al., 1998; Nakamura et al., 
1999; Ulaner et al., 1998; 2000; Chong et al., 2000; Yan et al., 2001; Boldrini et al., 
2003) and may be used as an alternative tumour marker (Kyo et al., 1999; Park et al., 
1999; Wu et al., 1999). However, hTERT mRNA expression did not coincide perfectly 
with telomerase activity in cancers of various tissues e. g. glioblastomas (Faichetti et al., 
2000), endometrial cancers (Kyo et al., 1999), lymphocytes (Liu et al., 1999), 
meningiomas (Simon et al., 2000), Ieiomyomas (Ulaner et al., 2000), skin tumours (Wu 
et al., 1999) and sarcomas (Yan et al., 1999). Intracranial tumours in our series of 
samples expressed hTERT independently of the presence or absence of detectable 
telomerase activity. Thirteen cases were found with hTERT mRNA expression and 
lacking telomerase activity, but with mostly lower levels of hTERT mRNA expression 
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than those in TRAP-positive cases. Our results suggest a lack of a strongly positive 
correlation between hTERT mRNA expression and measurable telomerase activity. 
Although the extracts used for TRAP assay and RT-PCR were obtained from different 
portions of the same tumour, these discordances cannot be fully explained by 
heterogeneity of the tumour cells contained in the specimens or by poor sample 
preparation for the TRAP assay. Indeed, if telomerase was present in an active or 
inactive form in the TRAP-negative tumours, a marked expression of hTERT mRNA as 
in the TRAP-positive tumours would be expected. The lack of telomerase activity in 13 
hTERT mRNA-positive meningiomas could indicate that in addition to up-regulation of 
hTERT expression, further events are required for the expression of functional 
telomerase, which might lead to proliferation. 
To determine whether telomerase activity is regulated at the transcriptional level, 
the expression of the telomerase RNA component was analysed in telomerase-positive 
and negative brain tumours. In all brain tumours and normal brain samples examined, 
the presence of hTERC did not indicate the presence of telomerase activity (Figure 6.4 
B). These results are in accordance with recent reports that the presence of telomerase 
RNA component in the absence of detectable telomerase activity is observed in a 
number of normal tissues and in some tumours (Feng et al., 1995; Kyo et al., 1999; Wu 
et al., 1999; Yan et al., 2001). 
6.3.3 Alternative hTERT splicing in brain tumours 
Like BRCA1, which has 4 different splicing variants (Miki et al., 1994), the hTERT 
transcript has been shown to have at least six alternative splicing sites (four insertion 
sites and two deletion sites), and variants containing both or either of the deletion sites 
are present (Kilian et al., 1997; Wick et al., 1999). The a deletion (lacking 36 
nucleotides in the beginning of exon 6), the ß deletion (lacking 182 nucleotides 
corresponding to exon 7 and 8) and the a+ß deletions (lacking both sites) have been 
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studied in various tissues relatively frequently (Kilian et al., 1997; Ulaner et al.. 1998; 
2000; 2001; Wick et al., 1999; Yi et al., 2001) but not in brain tumours. Only the full- 
length hTERT transcript is considered to be functional in activating telomerase, while 
the a deletion has been shown to act as an endogenous negative telomerase regulator 
(Colgin et al., 2000; Yi et al., 2000). The a-form of hTERT inhibits telomerase activities 
in telomerase-positive cells, which results in telomere shortening and chromosome 
end-to-end fusions (Colgin et al., 2000). These results suggest a possible role for 
hTERT splice variants in the regulation of telomerase activity. The function of the 
remaining splice variants of hTERT is still unclear; it is generally accepted that these 
cannot play a role in the activation of telomerase, since they lack key reverse 
transcriptase or C-terminal sequences as a result of open reading frame shifts and 
premature stop codons (Wick et al., 1999). 
Many of the brain tumours in our study had spliced variants of the two conserved 
hTERT motifs: motif A contained a 36 bp deletion, resulting in the 421 bp band, 
whereas the 275 bp PCR product contained a 182 bp deletion between motif A and 
motif B' of telomerase RT protein (Figure 6.1). Certain tumours, cell lines, foetal tissues 
and normal tissues, show similar spliced variants (Kilian et al., 1997; Brenner et al., 
1999; Ulaner et al., 1998; 2000). All four spliced products were detected 
simultaneously only in samples with marked telomerase activity (Figures 6.2 and 6.4 
C). Thirteen hTERT-positive tumours (hTERT full length transcripts and spliced 
variants) did not express enzyme activity. Alternately spliced hTERT transcripts could 
account for enzyme inactivity in the absence of hTERT full-length transcripts in some of 
these tumours (cases 6,8,9,15,16,25,26, and 28) (Figure 6.4 C; Table 6.1). 
To explain the absence of telomerase activity in tumours despite absence of 
telomerase inhibitors and optimal tissue preservation, the existence of an ALT 
mechanism has been suggested (Bryan et al., 1997; Kim and Wu, 1997; Reddel et al., 
1997). Chen et al (2000) found that the mean TRF length of the tumours with 
telomerase activity was significantly shorter than that of the tumours with undetectable 
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telomerase activity for each tumour. However, the occurrence of these mechanisms 
may be ruled out in benign meningiomas because reduced telomere lengths were 
detected in these tumours (Chen et al., 2000) suggesting that telomere elongation did 
not occur. 
At present, undetectable hTERT mRNA in meningiomas cannot be explained by 
genetic alterations in hTERT. The hTERT gene is located on chromosome 5p and 
deletions in this region of meningiomas are not reported in literature so far (Sanson and 
Cornu, 2000; Lusis and Gutmann, 2004; Whittle et al., 2004). 
6.3.4 Brain tumour cell proliferation 
Telomerase activity was demonstrated in proliferating stem cells and in tissues 
during embryonic development (Wright et al., 1996; Ulaner and Guidice, 1997; Ulaner 
et al., 1998). Notably, all telomerase-positive tissues are permanently renewing 
epithelia or tissues that proliferate in regular cycles. It seems that telomerase activity 
can be detected also in brain tumours with a high proliferation index. Falchetti et al. 
(2000) demonstrated that TRAP-positive glioblastomas have a much higher 
proliferation index than TRAP-negative ones. In our study, benign meningiomas 
showed no or very low numbers of Ki-67 positive nuclei at the moment of observation, 
whereas malignant brain tumours with telomerase revealed high Ki-67 LI (Figure 6.5). 
Apparently, a slowly growing benign meningioma in which most of the cells are 
quiescent has no or very low levels of telomerase, whereas a rapidly dividing tumour 
such as a glioblastoma and medulloblastoma has high levels of telomerase. Although 
the number of TRAP-positive tumours in our series was low, it seems that we found a 
significant correlation between telomerase activity scores and Ki-67 proliferation index 
(Figure 6.6). A positive association was also found between Ki-67 proliferation index 
and the degree of hTERT mRNA expression (Figure 6.7). The correlation that we found 
between telomerase and in vivo cell proliferation is in line with data for lung cancer 
(Albanell et al., 1997: Fujiwara et al., 2000), melanoma (Miracco et al., 2000), 
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colorectal adenocarcinomas (Okayasu et al., 1998), and meningiomas (Simon et al., 
2000). 
6.4 Summary 
Telomerase activity was examined in intracranial tumours and compared with 
gene expression of the two core components of telomerase, the reverse transcriptase 
subunit (hTERT) and the RNA subunit (hTERC), and proliferative index. We 
investigated 32 tumours across 3-5 sampled regions (20 meningiomas, 1 acoustic 
schwannoma, 1 pituitary adenoma, 8 gliomas, and 2 medulloblastomas). 
Telomerase activity was demonstrated by the telomeric repeat amplification protocol 
(TRAP) assay in 7 (22 %) intracranial tumours (4 malignant brain tumours, 2 atypical 
meningiomas and 1 ependymoma) but could not be detected in the 18 (100 %) benign 
meningiomas. 
hTERT and hTERC mRNA were detected by RT-PCR. hTERT mRNA was 
present in 20 (63%) intracranial tumours. Whereas hTERT mRNA transcripts were 
consistently low or absent in meningiomas, malignant brain tumours exhibited elevated 
hTERT mRNA's. Multiple regions of glioblastomas showed differences in telomerase 
activity and in the presence of hTERT mRNA. 
RT-PCR analysis revealed, for the first time in intracranial tumours, the presence 
of hTERT mRNA spliced products, corresponding to full-length mRNA as well as 
spliced mRNA's with critical reverse transcriptase motifs deleted. Only tumours with 
marked telomerase activity showed all hTERT spliced messages simultaneously. The 
absence of a positive correlation between telomerase activity and hTERT mRNA could 
not be attributed to the presence of hTERT spliced variants. 
We found a significant correlation between telomerase activity scores and Ki-67 
proliferation index. A positive association was also seen between Ki-67 staining and 
the degree of hTERT mRNA expression. This shows that there seems to be a 
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relationship between telomerase activity or the degree of hTERT expression and 
proliferation rate in intracranial tumours. 
In summary, multiple specimens of benign meningiomas demonstrated no 
detectable telomerase activity and expressed no or low levels of hTERT mRNA. 
hTERT expression may therefore not be a marker for tumour diagnosis as such. 
Further experiments are needed to clarify whether hTERT splicing is a limiting factor for 
the expression of telomerase activity in brain tumours. High telomerase activity and 
hTERT mRNA expression were detected solely in glioblastoma and medulloblastoma, 
tumours with a high proliferation rate. 
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CHAPTER 7 
GENERAL DISCUSSION AND PROSPECTS FOR FUTURE RESEARCH 
In this thesis we assessed the role of telomeres/telomerase in cellular DNA 
damage response and in benign and malignant brain tumours. Our results revealed 
some previously unknown aspects of telomere maintenance or telomerase regulation 
and these are briefly summarized below. 
7.1 Telomere length measurement by flow-FISH 
To accurately assess telomere function it is frequently necessary to measure 
telomere length in cells under investigation. As discussed in Chapter 3 several 
methods are commonly used for telomere length measurements (Table 3.3) and we 
specifically focused on one of the most recent methods - flow-FISH. The key reason 
for this is that flow-FISH is much faster than other methods and results can be 
generated within several hours. In contrast, techniques such as Southern blot or Q- 
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FISH may require several days to obtain results. By analysing several human and 
mouse cell lines by flow-FISH we discovered a phenomenon that we termed 
TELEFLUCS (TElomere LEngth FLUctuations in Cell Subpopulations). Although we 
observed TELEFLUCS using Q-FISH and Southern blot, these methods are inferior to 
flow-FISH for detecting cell subpopulations with different telomere lengths within the 
same sample. For example, Southern blot and Q-FISH can detect TELEFLUCS only if 
subpopulations of cells with different telomere lengths comprise relatively large 
percentages of cells in a given sample. In contrast to flow-FISH neither method can 
provide accurate quantitative assessment of cell subpopulations i. e. the proportion of 
subpopulation x relatively to subpopulations y or z. In addition, based on our results we 
proposed that flow-FISH should be a method of choice for assessing the average 
telomere length in human lymphocytes. A typical sample of peripheral blood contains 
different subpopulations of lymphocytes and these have different telomere lengths 
(Rufer et al., 1998; 1999; Batliwalla et al., 2000; Brummendorf et al., 2000; Baerlocher 
and Lansdorp, 2003). By analysing peripheral blood samples using Southern blot, Q- 
FISH or quantitative PCR no laboratory was able to show existence of lymphocyte 
subpopulations with different telomere lengths (Poon et al., 1999; Martens et al., 2000; 
Terasaki et al., 2002; Wu et al., 2003) and this was only possible to demonstrate by 
flow-FISH (Rufer et al., 1998; 1999; Batliwalla et al., 2000; Brummendorf et al., 2000; 
Baerlocher and Lansdorp, 2003). Ability to detect subpopulations of lymphocytes with 
different telomere lengths is important. For example, the most recent study suggests 
that the "life-stress" can affect telomere length and that this can be used as a predictor 
of cell aging and therefore could be a useful indicator of patient general health (Epel et 
al., 2004). Epel et al. (2004) measured telomere length in peripheral blood lymphocytes 
by real-time PCR. By using flow-FISH in similar future studies the resolution of average 
telomere length measurement from any individual will be greatly improved through 
identifying telomere length in several subpopulations of lymphocytes as detected by 
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antibodies specific to these lymphocyte subpopulations, a technique known as multi- 
colour flow-FISH. The use of multi-colour flow-FISH on peripheral blood samples, 
therefore, may have important prognostic applications. 
We have also shown that we can use flow-FISH for telomere length 
measurements in human fibroblasts. To the best of our knowledge this is the first 
successful attempt to measure telomere length by flow-FISH in human fibroblasts. 
However, further improvements in our flow-FISH method are required to optimise 
telomere length measurements in fibroblasts. For example, we think that stripping 
fibroblasts from the cytoplasm can result in reduced auto-fluorescence, which is one of 
the problems associated with telomere length measurements in senescing human 
fibroblasts. 
7.2 Accelerated telomere shortening and telomere dysfunction in DNA damage 
response defective cells 
Accelerated telomere shortening has been conclusively demonstrated in several 
human syndromes characterized by defective DNA damage responses at cellular and 
molecular levels. These include ataxia telangiectasia (AT), Nijmegen breakage 
syndrome (NBS) and Fanconi anemia (FA) (Metcalfe et al., 1996; Pandita and Dhar, 
2000; Adelfalk et al., 2001; Hande et al., 2001; Ranganathan et al., 2001; Tchirkov and 
Lansdorp, 2003). We have previously been able to show association between short 
telomeres and alterations in DNA damage response as measured by chromosomal 
radiosensitivity in a group of breast cancer patients (Mcllrath et al., 2001) and our 
results have recently been confirmed in a much larger group of different cancer 
patients (Wu et al., 2003). Collectively, these results provide an intriguing clue i. e. that 
alterations in telomere maintenance could constitute a marker of defective DNA 
damage responses. If correct, this possibility would be enormously useful in, for 
example, detecting people at risk from cancer i. e. defective DNA damage response is a 
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cancer predisposing factor (Slijepcevic, 2004). To provide a theoretical framework for 
understanding these results from the perspective of cancer detection and treatment we 
have recently proposed that a group of genes in mammalian cells can, if affected. 
cause dual phenotypes, namely sensitivity to ionising radiation (IR) as one phenotype 
and telomere dysfunction as the other phenotype and this group of genes is termed 
TERAGENE (TElomeres and RAdiosensitivity GEne NEtwork) (Slijepcevic, 2004). The 
current number of genes that cause these phenotypes in mammalian cells stands at 10 
and they are summarized in Table 7.1. Therefore, the main implication of the 
TERAGENE hypothesis is that the two phenotypes, namely cellular/organismal 
sensitivity to IR and telomere dysfunction are in many cases linked. 
Results generated during the course of this project provide additional evidence 
for the possibility that IR sensitivity and telomere dysfunction may be linked. For 
example, in addition to being able to confirm accelerated telomere shortening in cells 
from AT, NBS and FA patients in comparison with cells from apparently normal 
individuals (Figures 4.2 A and 4.4 A), we have also detected accelerated telomere 
shortening in a panel of five novel cell lines originating from patients who over- 
responded to radiation therapy (Figures 4.2 B and 4.4 B). Radiosensitivity of these 
patients is caused by different genetic defects including defects in ligase I, ligase IV, 
Artemis, and two less well-defined defects. In the case of one patient (named 2BN) it is 
likely that a new, as yet unidentified, factor involved in DNA double strand break (DSB) 
repair may be involved (Dai et al., 2003). The remaining patient had xeroderma 
pigmentosum (complementation group XP-C) but in addition showed severe sensitivity 
to IR, a possibility consistent with an additional mutation in a gene responsible for IR 
response i. e. XP patients are not normally sensitive to IR (Rogers et al., 2000). In 
almost all cases these novel cell lines showed accelerated telomere shortening in 
comparison to control cell lines (Figure 4.6). 
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We also observed accelerated telomere shortening in murine BRCA1 deficient cells in 
comparison with a BRCA1 proficient cell line (Figure 4.11 A). We also transiently 
depleted BRCA1 by siRNAs in two human mammary epithelial cell lines (Figures 5.1; 
5.2; 5.3 and 5.4) but could not find changes in telomere length in comparison with 
control cells (Figure 5.8). 
Given that some genes from the TERAGENE family have not been shown to 
play a direct role in telomere maintenance in the sense that they do not localise at 
telomeres (e. g. ATM), and the fact that this also applies to the proteins defective in our 
novel cell group (e. g. ligase I, ligase IV, Artemis) one of the implications of the 
TERAGENE hypothesis is that accelerated telomere shortening may be a general 
consequence of radiosensitivity. A theoretical framework that can explain this 
possibility already exists. For example, IR exerts its effects on cells through causing 
oxidative stress and telomeres are exceptionally sensitive to oxidative stress (von 
Zglinicki, 2002). In line with this possibility it was recently shown that ATM defective 
cells show telomere dysfunction largely as a result of oxidative stress (Tchirkov and 
Lansdorp, 2003). 
Accelerated telomere shortening is usually associated with dysfunctional 
telomeres and these can be detected by several methods. For example, we have 
observed an increased incidence of chromosomes lacking detectable telomeric FISH 
signals in all the DNA damage response deficient cells in comparison to cells from 
normal individuals (Figure 4.9) a possibility which further suggests that telomeres 
shorten faster in DNA damage response defective cells. Chromosome ends that most 
frequently lack a FISH signal preferentially participate in end-to-end fusions, providing 
a direct link between short telomeres and end-to-end fusions (Hemann et al., 2001). 
Although we observed chromosomes lacking detectable telomere FISH signals in 
radiosensitive fibroblasts (Figure 4.9), chromosome end-to-end fusions were rare in 
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metaphase cells of radiosensitive fibroblast cell lines. In contrast, we observed 
elevated levels of anaphase bridges in these cells (Figure 4.8). Future work is required 
to explain these discrepancies. 
We have also observed cytological evidence of telomere dysfunction in mouse 
BRCA1 deficient cells. For example, elevated levels of end-to-end chromosome 
fusions, chromosomes lacking telomeric FISH signals and extra-chromosomal 
telomeric fragments were present in these cells in comparison with control cells (Figure 
4.12). Extra-chromosomal telomeric fragments had a form of double minute 
chromosomes (Figure 4.12 B) and were similar to those recently reported in cells from 
ERCC1/XPF deficient mice (Zhu et al., 2003) suggesting that BRCA1 might play a 
similar role at telomeres as ERCC1/XPF. This enzyme, a well-known DNA repair 
enzyme that cleaves away portions of DNA strands that have been damaged by 
ultraviolet light, is responsible for removing the 3' overhang strand from uncapped 
telomeres. In addition we identified a lymphoblastoid cell line from a BRCA1 carrier and 
a breast tumour cell line (HCC1937) with elevated levels of telomeric fusions (Al- 
Wahiby and Slijepcevic, in press). Thus overall, these cytogenetic analyses indicate 
that accelerated telomere shortening in mouse BRCA 1"'- cells causes telomere 
dysfunction whereas telomeres remain functional in control cell lines. By using siRNA 
oligonucleotides against human BRCA 1 we have been able to significantly reduce 
expression of this gene in two mammary epithelial cell lines (Figures 5.1; 5.2; 5.3 and 
5.4). We observed a significant increase in anaphase bridge frequency in one cell line 
compared with the mock-transfected counterpart (Figure 5.5 A). Future work is now 
required to examine in more detail whether mammary cells transfected with BRCA1 
siRNA oligonucleotides show telomere dysfunction and we are currently exploring other 
techniques to determine whether mammary epithelial cells with reduced BRCA1 levels 
show impaired telomere maintenance (Figure 5.6). 
Finally, we have been able to show that human ALT positive cell lines show 
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dysfunctional telomeres as detected by either the presence of DSBs at their telomeres 
or cytogenetic analysis. We believe that this is a particularly interesting observation 
from the perspective of cancer therapy. Anti-telomerase drugs have been suggested as 
a potentially promising anti-cancer therapeutic tool. However, cancer cells may use 
ALT mechanisms in the absence of telomerase (Henson et al., 2002). Our results 
suggest that ALT cells show dysfunctional telomeres and usually cells with 
dysfunctional telomeres are sensitive to IR (see above). If this is the case with human 
ALT cells than the problem of ALT activation as a result of exposing cancer cells to 
anti-telomerase drugs may be solved by exposing these cells to IR. 
In conclusion, evidence from this study supports the hypothesis that the 
phenotypes of telomere dysfunction and altered DNA damage responses as revealed 
by IR sensitivity are linked in many cases. However, more work needs to be done to 
verify mechanisms underlying this link. 
7.3 hTERT and telomerase activity in brain cancer 
Brain tumours exhibit considerable chromosome instability (EI-Zein et al., 1999; 
Hui et al., 2001; Sawyer et al., 2003), suggesting that DNA repair mechanisms may be 
impaired in these cells or that their genetic susceptibility may lead to defects in DNA 
damage response pathways. Since the development of the TRAP (telomeric repeat 
amplification protocol) assay, the number of reports investigating the association of 
telomerase activity with human cancer has increased exponentially. Nearly, all cancer 
types have been screened, and a strong association between the presence of 
telomerase and malignancy has been established. Importantly, high telomerase activity 
generally indicates aggressive potential, and frequently, but not always, high 
proliferation rates (reviewed in Dhaene et al., 2000). The latter observation inspired 
many researchers not only to regard telomerase as a new proliferation marker, but also 
to accept that cells are telomerase-negative only when TRAP results are negative after 
198 
Chapter 7. General discussions and future project 
excessive growth stimulation of cells (Greider, 1998; Wynford-Thomas, 1999). Since in 
most cancers and in stem cells of renewal tissues, telomerase activity levels generally 
correlate with the proliferation state of the cells (Greider, 1998), it seems appropriate to 
regard the enzyme's activity as a guarantee for indefinite cellular replicative capacity if 
there is a drive for proliferation and if nothing else arrests the cells. 
At the time when we started this project no hTERT assessments were available 
in the literature. Only the standard PCR based TRAP was applied to assess 
telomerase activity in brain tumours and, particularly in meningiomas, an unclear 
picture emerged as to whether or not these tumours have telomerase activity 
(DeMasters et al., 1996; Langford et al., 1997; Hiraga et al., 1998; Sano et al., 1998; 
Carroll et al., 1999; Falchetti et al., 1999; Simon et al., 2000; Boldrini et al., 2003; 
Pistolesi et al., 2004). Although meningiomas are generally benign, i. e. encapsulated 
by a connective tissue and thus cells do not metastasise, they can grow to large sizes 
within the brain, which can be life threatening. We hoped by employing RT-PCR and 
immunocytochemistry to get a more informative view on telomerase in brain tumours. 
Since the presence of mRNA splicing was first suggested (Chow et al., 1977), 
alternative splicing was found to be a very important level of gene regulation (Lopez, 
1998) and its existence is now predicted in one-third of the genes (Mironov et al., 
1999). hTERT spliced variants were discovered in various tissues (Kilian et al., 1997) 
and are believed to be a limiting factor for the expression of telomerase activity (Kilian 
et al., 1997; Brenner et al., 1999; Ulaner et al., 1998; 2000). Therefore, we examined 
whether hTERT splicing variants were limiting components for the expression of 
telomerase activity in brain tumours, particularly in meningiomas. 
Our results revealed for the first time hTERT mRNA and their spliced variants in 
brain tumours. hTERT mRNA was absent or expression levels were low in 
meningiomas and mostly high in malignant brain tumours, in agreement with 
telomerase activity in brain tumours. Although we found positive correlations between 
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telomerase activity, hTERT mRNA levels and proliferation (Figures 6.6 and 6.7), the 
presence of hTERT splice variants did not strictly correlate with the absence of 
telomerase activity (Figure 6.4; Table 6.1). We detected, in total, eight telomerase 
negative tumours (mainly meningiomas) out of 32 brain tumours with hTERT mRNA 
splicing variants and this opens up the possibility that hTERT splicing may contribute to 
activation of ALT mechanisms i. e. tumour cells need to maintain telomeres in the 
absence of telomerase activity. Elongated telomere lengths, for example, were 
detected in meningiomas with undetectable telomerase activity (Chen et al., 2000). We, 
therefore, speculate that alternative splicing of hTERT could be involved in telomerase 
and/or telomere length regulation in brain tumours. Furthermore, we detected the main 
component of telomerase, hTERT, by immunocytochemistry in TRAP-negative 
meningiomas in vitro. This suggests that low levels of telomerase activity, which are 
below detection of TRAP assay, might operate in meningiomas. 
7.4 Future research 
As discussed above, novel results generated by this thesis include: 
" Discovery of TELEFLUCS 
" Discovery of telomere dysfunction in ALT cells 
" Potential implication of BRCA1 in telomere maintenance 
" Demonstration of accelerated telomere shortening in 5 novel human 
radiosensitive cell lines 
" Discovery of splice variants of hTERT in brain tumours. 
To explore the significance of these results several lines of research are now 
being pursued in our laboratory. First, it is of interest to determine whether the 
observed telomere dysfunction phenotype in ALT cells has any effect on survival of 
these cells after, for example, treatment with IR. It is well documented that telomere 
dysfunction causes organismal and cellular sensitivity to IR (Goytisolo et al., 2000; 
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Wang et al., 2000; Mcllrath et al., 2001). If the same happens in ALT cells this may 
have significant clinical implications i. e. ALT cells, being sensitive to IR, should not be a 
problem in anti-telomerase cancer therapy as long as there is simultaneous exposure 
of these cells to IR during anti-telomerase treatment. Opposite results may also be 
important i. e. if ALT cells are not sensitive to IR this could mean that telomere 
dysfunction is a symptom of highly adaptable cells which simply use genomic 
rearrangements as a tool to survive and may therefore be the highest form of 
malignancy i. e. the most difficult cells to eradicate by any form of therapy. In this 
scenario functional telomeres would be an obstacle to cell survival. We have already 
irradiated an ALT cell line, its parental non-ALT cell line and the same ALT cell line 
transfected with hTERT with several doses of gamma rays to generate survival curves. 
Analysis of results is currently in progress and it is planned that several more ALT cell 
lines will be included in this analysis. 
Second, we wish to examine mechanisms through which accelerated telomere 
shortening occurs in radiosensitive cell lines. We are currently assessing the level of 
oxidative stress in the panel of novel radiosensitive cell lines in comparison with control 
cells and also developing methods that will specifically detect damage at telomeres due 
to oxidative stress. One interpretation of our results is that accelerated telomere 
shortening in IR sensitive cells is caused by oxidative stress (see above). It is 
interesting in this regard that IR can generate high levels of telomeric sister chromatid 
exchanges (T-SCE) (W. Wright, Texas, a talk presented at XV International 
Chromosome Conference held at Brunel in September 2004) in contrast to SCEs in the 
rest of the genome which remain unchanged after IR. T-SCEs can be detected by a 
technique called chromosome orientation FISH (CO-FISH) (Bailey and Eberle, 2001: 
Bailey et al., 2004). We have already assessed two novel radiosensitive cell lines 
(Artemis and Ligase IV) using CO-FISH and our preliminary evidence indicates 
elevated levels of T-SCEs after IR in an Artemis cell line. A larger study along the lines 
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described above is planned in the near future. 
Thirdly, to examine in more detail a potential role of BRCA1 in telomere 
function we are currently using immuno-FISH do detect the presence of DSBs at 
telomeres after BRCA1 depletion in two mammary epithelial cell lines. A pilot immuno- 
FISH experiment was successful (Figure 5.6). In addition, FISH slides are being 
analysed for chromosome aberrations in mammary epithelial cell lines. Although, we 
were successful in depleting BRCA1 by siRNA in mammary epithelial cells, the time 
duration of BRCA1 depletion is short and it may not be sufficient to detect effects of 
BRCA1 on telomeres if any. Therefore, we wish to incorporate our BRCA1 siRNAs into 
an appropriate plasmid and generate a vector that will prevent expression of BRCA1 in 
a more stable fashion. We also have access to BRCA 1-'- p53'- mice through 
collaboration with Dr. Beverly Koller (University of North Carolina at Chapel Hill) and 
wish to investigate telomere function in these mice. In a recent study BRCA1-1- p53'- 
mice generated by another group were reported to have high incidence of end-to-end 
chromosome fusions (McPherson et al., 2004). 
Finally, our analysis of hTERT expression and telomerase activity in brain 
tumours points to the possibility that hTERT splice variants may be involved in the 
regulation of telomerase enzyme activity. Therefore, further experiments are needed to 
clarify whether hTERT splicing is a limiting factor for the expression of telomerase 
activity in brain cancer or if it plays a role in telomere maintenance. Alternatively, lack 
of telomerase activity in some brain tumours may indicate active ALT mechanisms and 
this possibility could be examined in future experiments. 
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